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Abstract 
Mood disorders are amongst the most prevalent and disabling conditions 
worldwide. There is increasing evidence for the involvement of disrupted 
circadian rhythms in mood disorders. The mechanism of associations between 
circadian dysfunction and mood disorders are complex and not fully understood. 
This thesis explores the influence of genetic variation of circadian function on 
mood disorder-related phenotypes within two relatively large cohorts, ALSPAC 
(N=8,100) and UK Biobank (N=500,000). I investigated genetic variants associated 
with different features of circadian function and how genetic loading for these 
common variants was associated with risk of mood disorders and related traits. 
To my knowledge, this is the first application of circadian polygenic risk scores 
to investigate mood disorder risk. 
 Both a priori candidate gene profile risk scores (CACNA1C) and polygenic 
risk scores (PRS) were used to investigate the relationship between the genetics 
of circadian function and mood disorder-related phenotypes. A genome-wide 
association study (GWAS) was carried out to identify common variants associated 
with circadian rest/activity rhythmicity and to assess genetic correlation with 
mood disorders. Mendelian randomisation was used to assess the direction of the 
relationship between circadian dysfunction and mood disorders. 
 Chronotype polygenic risk scores (specifically ‘eveningness’ PRS) were 
associated with increased risk of bipolar disorder in UK Biobank and with 
hypomanic features in ALSPAC. The GWAS of low relative amplitude (a measure 
of circadian rest/activity rhythmicity) identified several associated variants and 
these variants were used to create a PRS for low relative amplitude. Increased 
PRS for low relative amplitude was associated with mood instability in UK 
Biobank.  
 There are limitations to the population cohorts used in these analyses. 
They may be under-representative of individuals with clinically-diagnosed mood 
disorders. Also, the mood phenotypes tested were based on self-report which 
could be vulnerable to response biases. The polygenic risk scores had small but 
significant effects on the mood disorder phenotypes investigated. 
 This work identified associations between genetic variation of circadian 
function and mood disorder-related phenotypes in both ALSPAC and UK Biobank. 
With expansion, development and replication, PRS of circadian function could 
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inform treatment stratification approaches for mood disorders. This thesis also 
suggests a need for further investigation of the underlying biology of circadian 
function and how this relates to the pathophysiology of mood disorders. 
 Strengths to this thesis include the large sample sizes of the cohorts. The 
actigraph data obtained from UK Biobank allowed for the largest GWAS of 
rest/activity rhythmicity to date. The extensive self-report and interview-based 
data available in UK Biobank also provide a breadth of mood disorder-related 
phenotypes to investigate. 
 As this is one of the first examples of using circadian polygenic risk scores 
to investigate the underlying pathophysiology of mood disorders this work 
requires replication in other population cohorts. It would also be of interest to 
test these risk scores within clinical populations and assess the extent to which 
they may support clinical management decisions. 
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Chapter 1 Introduction 
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Mood disorders are amongst the most common psychiatric conditions, with 
depression reported as one of the world’s leading causes of disability in adults 
and with increasing prevalence in adolescents (GBD 2016; Fabbri et al. 2018). It 
is widely accepted that an individual’s susceptibility to psychiatric disorders is 
influenced by a complex mix of genetic and environmental factors (Yoshimizu et 
al. 2015; Wray et al. 2018).  
 There have been many studies aiming to elucidate the underlying genetic 
architecture of mood disorders. This introductory chapter will consider the 
research to date on the genetic underpinnings of bipolar disorder (BD) and major 
depressive disorder (MDD) in particular. 
1.1 Introduction to Bipolar Disorder and Major 
Depressive Disorder 
BD and MDD are complex, chronic conditions reported as leading causes of 
disability worldwide; as such these disorders are important public health 
problems (Palagini et al. 2018; GBD 2016; Fabbri et al. 2018).  
BD and MDD are among the most prevalent conditions with lifetime prevalence 
of up to 4% and 15% in the general population, respectively (Merikangas et al. 
2011; Lépine & Briley 2011). As recurring conditions, the impact on public health 
represents a major concern for global disease burden in the context of disability 
adjusted life years (DALYs), morbidity and premature mortality (Palagini et al. 
2018; Ferrari et al. 2013). Due to the chronic disease course, BD and depression 
are among the leading causes of DALYs and are responsible for more DALYs lost 
than all forms of cancer and other major neurological conditions (BD and 
MDD=79,619, cancer=76,716, major neurological conditions=20,823) (World 
Health Organization 2002; Merikangas et al. 2011; Ferrari et al. 2013).  
1.2 Characteristics of BD and MDD 
BD is characterised by recurrent episodes of mania (hypomania) and depression, 
as well as euthymic phases (McCarthy et al. 2018a; Harrison 2016).  
BD is typically divided into subtypes: BD type 1 (BDI) is characterised by manic 
episodes and high rates of hospitalization (Tharp et al. 2016); BD type 2 (BDII) is 
characterised by less severe hypomanic episodes; and BD non-specified (BP-NOS) 
describes individuals with significant bipolar features which fall below the 
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threshold for BDI and BDII (O’Donovan et al. 2009).  
 Cognitive impairment is also a common feature of both BD and MDD, and 
has been shown to persist throughout mood states with patients displaying 
impaired processing speeds and memory (Cullen et al. 2015; Lépine & Briley 
2011).  BD patients can present with mixed mood states and chronic mood 
instability; these symptoms can also persist during periods of remission (Phillips 
& Kupfer 2013; Harrison et al. 2018; Bauer et al. 2018). Residual symptoms, 
including cognitive and social impairment, are also often reported during 
remission by individuals with MDD; these persistent symptoms could influence 
individuals quality of life (QOL) and increase the risk of relapse (Lépine & Briley 
2011; Bauer et al. 2018).  
Individuals with mood disorders usually have high comorbidity with other 
psychiatric and physical health conditions, with a life expectancy approximately 
10 years lower than the general population (Jawinski et al. 2015). Bipolar and 
depressed individuals also have an estimated 20 to 30-fold increased risk of 
death by suicide (Jawinski et al. 2015; Dong et al. 2018). 
 An estimated 50% of BD patients, observed in clinical populations, also 
experience psychotic features which are associated with greater severity of 
symptoms and long-term morbidity (Neves et al. 2016). Overall, the substantial 
morbidity seen in BD is due primarily to recurrent depressive episodes (Harrison 
et al. 2016).  
1.3 Diagnostic issues  
Diagnosis of mood disorders is dependent upon the presentation of clinical 
symptoms and the interpretation of those symptoms by the clinician. There are 
currently no biomarkers which have been identified to aid in the diagnosis of 
mood disorders (Baryshnikov et al. 2015; Watmuff et al. 2016). The clinical 
presentations of both BD and MDD are heterogeneous, with BD often referred to 
as a spectrum disorder (Wray et al. 2018; Smith et al. 2008). BD is thought to be 
widely under-recognized, often only recognized after a long delay, and is 
commonly misdiagnosed, as borderline personality disorder or depression 
(Baryshnikov et al. 2015). The misdiagnosis of BD can have negative effects on 
the individual and result in the prescription of inappropriate treatments; this 
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could result in more frequent recurrence of mood episodes, more severe 
cognitive impairments and an increased risk of suicide (Tseng et al. 2015).  
There is shared genetic architecture between psychiatric disorders which 
suggests that distinct clinical classifications may not be accurate (Cross-Disorder 
Group of the Psychiatric Genomics Consortium 2013; Forstner et al. 2017; Stahl 
et al. 2017). By relying solely on clinical classifications of disorders some of the 
underlying biology influencing disorder-related traits may not be identified 
(Phillips & Kupfer 2013).  
 Investigating transdiagnostic components may give a greater 
understanding of the pathophysiology of psychiatric conditions (Cuthbert & Insel 
2013), for example Research Domain Criteria (RDoC) traits, personality traits and 
circadian measures; the latter (circadian features) will be the main focus of the 
analyses in this thesis. 
1.4 Treatment of BD and MDD 
Mood disorders tend to manifest initially during late adolescence or early 
adulthood; many individuals then experience a chronic illness course which 
requires lifetime treatment (Watmuff et al. 2016). Currently, the main therapy 
for both BD and depression is pharmacological (lithium, antipsychotics, 
antidepressants and anticonvulsants) alongside psychological interventions 
(Geddes & Miklowitz 2013; Kupfer et al. 2012; Yatham et al. 2018). Many mood 
disorder patients are continuously symptomatic and experience relapses (Keers 
et al. 2009; Dunn et al. 2015). Many of the pharmaceutical therapies used result 
in adverse drug reactions and, therefore, cause negative consequences to an 
individual’s long-term physical health. Antipsychotics have also been reported to 
influence the cognitive impairment of patients which may lead to non-
compliance and the eventual deterioration of the patient’s mental health (Keers 
et al. 2009; Cullen et al. 2015). 
 This highlights the importance of the development of novel treatments 
and treatment approaches for BD and MDD. Unfortunately, there has been a lack 
of suitable therapeutics which have been successfully translated from animal 
models to patient use (Watmuff et al. 2016). New approaches to develop better 
therapeutic interventions for these disorders are required and are an important 
consideration in mood disorder research.  
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1.5 Current understanding of the genetics of BD and 
MDD 
The underlying genetic architecture of psychiatric disorders is polygenic (to an 
extent this is explained by the large accumulation of small additive genetic 
effects) and complex (Sklar et al. 2011). There are several methods by which the 
genetics of psychiatric disorders have been investigated.  
 Family, twin and adoption studies have demonstrated the relatively high 
heritability of mood disorders. Genetic epidemiology estimates were calculated 
from observational studies of large family pedigrees with mood disorders, 
hospital and population registry data. Evidence from these studies have reported 
a high heritability for BD of approximately 70-89% (Craddock & Sklar 2013; 
Jawinski et al. 2015; Starnawska et al. 2016) and a heritability of 35-40% for MDD 
(Sullivan et al. 2000; Shih et al. 2004). Linkage studies typically used to identify 
causative variants and genes in family pedigrees have been unable to robustly 
identify potential risk variants in BD and MDD (Visscher et al. 2012). 
Candidate gene studies have been undertaken in order to investigate the 
underlying aetiology of BD and MDD. These candidate gene studies are usually 
hypothesis-driven, based on suspected pathways and processes involved in the 
pathophysiology of BD and MDD. However, the results of these are usually based 
on small sample sizes and have not been replicated (Dunn et al. 2015). The 
overall value of candidate gene studies in this area is considered low. 
Another example of how the genetics of psychiatric disorders are studied is the 
use of genome-wide association studies (GWAS) in large cohorts to identify 
relatively common genetic variants (minor allele frequency (MAF) 0.01-0.05), 
referred to as single nucleotide polymorphisms (SNPs), which associate with the 
phenotypes of interest. There have been several GWAS of BD and MDD which 
have identified SNPs associated with the disorders; in the case of BD, several 
variants associated with BD have been replicated in further GWAS (Hou et al. 
2016; Stahl et al. 2017; Ferreira et al. 2008; Cross-Disorder Group of the 
Psychiatric Genomics Consortium 2013; Sklar et al. 2011; Wray et al. 2018). 
 One example of a replicated finding within BD GWAS is the CACNA1C 
gene; several polymorphisms within this gene have been associated with BD, and 
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with some evidence for association with MDD; this will be explored in more 
detail in Chapters 3 and 5. 
GWAS has demonstrated that many common variants, each with small effects, 
influence risk of BD and MDD (Sullivan et al. 2018). Even with the many variants 
identified, GWAS have been unable to explain the high heritability estimates 
reported by family and twin studies of BD and MDD (Breuer et al. 2018). It has 
been suggested that 25% and 30% of phenotypic heritability of MDD and BD, 
respectively, is attributed to common SNPs; however, most GWAS of mood 
disorders report much smaller SNP heritability (h2SNP) (Wray et al. 2018; Bulik-
Sullivan et al. 2015; Cross-Disorder Group of the Psychiatric Genomics 
Consortium et al. 2013; Stahl et al. 2017). It is thought that this ‘missing 
heritability’ is due to rare alleles (MAF<0.05), with small or intermediate effect 
sizes, and structural variation in the genome, such as deletions, insertions, 
inversions, translocations and copy number variations (repeats of cloned DNA 
fragments (Feuk et al. 2006)) which are often not included in GWAS (Harrison 
2016).  
Even though several variants have been identified by GWAS, the true causal 
variants or genes involved have not yet necessarily been identified (Starnawska 
et al. 2016; Harrison 2016). Due to linkage disequilibrium (LD) within the 
genome, it is difficult to reliably identify the causal variant within the loci 
highlighted by GWAS. It is often not known whether there are coding variants in 
LD with the risk SNPs which could result in the alteration of the gene product 
but it is likely that SNPs may influence gene expression (Starnawska et al. 2016).  
As mentioned previously, there appears to be shared genetics amongst 
psychiatric and mood disorders; some cross-disorder studies have identified risk 
loci which overlap between BD and other major psychiatric disorders (Cross-
Disorder Group of the Psychiatric Genomics Consortium 2013; Forstner et al. 
2017; Stahl et al. 2017). There is some overlap of loci with MDD but there is 
greater overlap with schizophrenia, and it has been suggested that BD and 
schizophrenia are a continuous spectrum disorder (Harrison 2016). Some variants 
have also been found to be associated with features of BD, including psychosis 
and suicidality (Harrison 2016). 
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1.6 Researching the pathophysiology of BD and MDD 
Although many risk variants associated with BD and MDD have been identified by 
GWAS there has been little progress in using these variants to aid our 
understanding of the underlying biological mechanisms of the disorder (Wray et 
al. 2007; Gratten et al. 2014). As BD is heterogeneous, the genetic variants 
linked to the disorder may influence multiple symptoms by affecting many 
different pathways (Jawinski et al. 2015). Using a combination of GWAS and 
gene expression data, there have been a range of pathways reported to have a 
potential association to BD, including calcium signalling, glutamatergic 
signalling, second messenger systems, hormone regulation, histone modification 
and immune pathways (Harrison 2016). 
Attempting to understand the effects these genetic variants have on the 
underlying biological mechanisms of BD and MDD has proved challenging. It is 
difficult to model the disorder using animals and recent studies have also 
reported species-specific differences in synaptic biology between animal models 
and human; the responses seen in humans to specific pathophysiological 
processes often show a poor correlation with the response displayed by the 
animal models used (Watmuff et al. 2016). 
One method which has been used to investigate the pathophysiological 
mechanisms of mood disorders is to study reprogrammed induced pluripotent 
stem cells (iPSCs) obtained from mood disorder patients and controls have been 
used to investigate differential gene expression and regulation (Madison et al. 
2015). iPSCs are cells derived from an individual, transformed by growth factors 
and signal pathway modifiers to produce a pluripotent cell line which can be 
induced to differentiate into other cell types – for example, neurons (Soliman et 
al. 2017). Induced neurons from BD patients displayed significant differences in 
their neuronal transcriptomes including the upregulation of transcripts for ion 
channels, membrane-bound receptors and transcripts involved in neuronal cell 
differentiation compared with controls (Yoshimizu et al. 2015).  
 At present, the study of MDD patient-derived iPSCs is not as developed as 
studies using BD patient cells. With the current methods used to generate iPSCs 
it is not feasible to carry out large scale patient-derived iPSC studies due to the 
labour intensive and often variable nature of cell line transformation (Soliman et 
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al. 2017); the findings of these studies are based on small sample sizes (N=20) 
and require replication (Yoshimizu et al. 2015). However, the small scale of 
molecular studies based on reprogrammed cells means they are likely to be 
underpowered to detect effects when investigating single candidate risk variants 
identified by GWAS. In the future, iPSCs may be a useful tool to model risk 
variants (highlighted by GWAS or those included in genetic risk scores) and their 
potential influence on molecular mechanisms. Currently these influences are 
unclear but with greater information on the genetic architecture of mood 
disorders and with future advances in iPSC generation, patient-derived cells 
could become a useful tool to expand on genetic findings and give a further 
understanding the biology of mood disorders. 
1.7 Circadian function in mood disorders 
One area of primary interest to this thesis is the potential involvement of 
dysregulation of circadian rhythmicity in the pathophysiology of BD and MDD. 
Circadian rhythms are fundamental to homeostasis and are described as 
variations in physiology and behaviour which occur over an approximate 24 hour 
period (McClung 2007). These rhythms influence a range of biological and 
behavioural features, including mood, and are crucial to influences on physical 
and mental wellbeing (Reppert & Weaver 2001; Merikanto et al. 2017). Circadian 
rhythmicity is complex and involves the interaction of many different inputs, 
including core and peripheral genes (described in greater detail in chapter 6) 
and environmental stimuli. As will be described further in several chapters of 
this thesis, there is growing evidence, both epidemiological and genetic, 
supporting the involvement of circadian function in various aspects of mood 
disorders. For example, both subjective and objective measures of circadian 
rhythmicity (such as self-reported chronotype and accelerometer-measured 
activity) have been investigated in mood disorders and disrupted rhythmicity has 
been associated with increased risk of mood disorders (Burton et al. 2013; 
Geoffroy et al. 2014; Wulff et al. 2010). However, the majority of investigations 
into circadian rhythmicity and mood disorders have been based on relatively 
small clinical populations looking at phenotypic associations. There have been 
very few genetic studies looking at this relationship with those studies focussed 
on specific core circadian clock genes (Landgraf et al. 2014; Moon et al. 2016). 
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The complete genetic architecture of circadian function is unclear and how this 
influences mood disorder pathophysiology requires further investigation. 
1.8 Key gaps in the literature 
1. There is currently a lack of understanding of the genetic architecture of 
mood disorders and mood disorder-related traits. Until very recently the 
majority of studies looking at mood disorder risk variants have been based 
on small sample sizes and were often not replicated. 
2. A relationship been circadian rhythmicity and mood disorders has been 
suggested but the genetic architecture of circadian rhythmicity is 
currently unclear. Also, the influence of circadian genetics on mood 
phenotypes has not been extensively investigated. 
3. Within mood disorders, investigations have used mostly subjective 
circadian measures to investigate circadian dysregulation in patients. 
4. Most studies focus specifically on small patient populations. There are 
relatively few studies investigating mood disorder genetics in large 
cohorts which may be more representative of the general population. 
1.9 How this thesis will contribute to new knowledge 
1. This study uses a relatively large amount of high-quality data to 
contribute to the current knowledge of mood disorder genetics. 
2. It investigates the relationship between disrupted circadian rhythmicity 
and mood disorders at a genetic level. 
3. It will contribute to an understanding of the genetic architecture of the 
circadian rest-activity cycle using large-scale objective data through 
GWAS. 
4. It uses recent GWAS findings to apply new polygenic risk scores (PRS) to 
large scale data to investigate associations between circadian measures 
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(both subjective and objective) and mood disorder-related phenotypes 
within two separate cohorts (Outline 1.1). 
5. This thesis also highlights areas of interest which could inform future 
clinical considerations (i.e. features of an individual’s phenotypic 
presentation which could be incorporated into a clinical assessment to 
inform a diagnosis) and potential treatment targets. 
1.10 Importance of thesis 
A greater understanding of the underlying mechanisms of mood disorders could 
aid in the identification of biomarkers or treatment targets (Neves et al. 2016). 
Of specific interest in this thesis is the relationship between circadian rest-
activity rhythm function and mood disorders. 
 As will be described in Chapter 4 and 6, epidemiological evidence has 
demonstrated associations between disrupted circadian function and mood 
disorders. This thesis will investigate a possible link between circadian 
rhythmicity and mood phenotypes at a genetic level. To my knowledge, this is 
the first example of using PRS for circadian features in the investigation of mood 
disorder-related traits. 
This evidence could inform future research and the development of targeted 
treatments for mood disorders based on an individual’s genotype. 
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Outline 1.1 Outline of analyses in context of the overall study (Chapter 2 (Methodology) and 
Chapter 8 (Conclusions) are not included). Diagram highlights the analyses undertaken in each 
chapter, including which genetic risk score was used, the phenotypes-of-interest and the cohorts 
investigated. Dotted line represents analyses using the UK Biobank cohort only.  
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Chapter 2 Dataset description and research 
methodology 
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2.1 Avon Longitudinal Study of Parents And Children 
(ALSPAC) 
2.1.1 Participants and ethical approval 
ALSPAC is a UK birth cohort recruited from the Avon area of England. Pregnant 
women with expected delivery dates between April 1991 and December 1992 
were recruited to the cohort. All participants provided informed written 
consent. Data from mothers, partners and children has been collected 
periodically from September 1990; data includes mother-completed and child-
completed questionnaires, interviews, environmental measures, mother and 
child biological samples, and genetic data.(Golding et al. 2001) The full details 
of the available data can be found at 
http://www.bristol.ac.uk/alspac/researchers/access/.  
2.1.2 Genotyping and imputation 
The Illumina HumanHap550 quad genome-wide SNP genotyping platform was 
used to genotype DNA samples obtained from 9,912 participants at age 7 
(approximately 70% of the sample (Jones et al. 2000)). Participants of ALSPAC 
who were genotyped were only included in the ALSPAC genotype database after 
meeting particular quality control criteria. Those individuals found to have >3% 
individual missingness, evidence of cryptic relatedness (>10% alleles identical by 
descent) insufficient sample replication and extremes of heterozygosity were 
excluded from the data. Individuals with gender mismatches and of non-
European ancestry were also excluded. Related individuals who passed these 
quality controls were retained for phasing and imputation, whereupon, further 
participants were removed due to SNP ID mismatching and violation of Hardy-
Weinberg equilibrium (HWE)  
(p value < 5x10-7). Imputation was performed using Impute V2.2.2 and the 1000 
genomes reference panel (Phase 1, Version 3) with 2,186 reference haplotypes; 
SNPs with a quality metric of <0.8, <95% call rate and MAF of <1% were 
excluded. The genetic data of 8,230 participants with 500,527 SNPs were 
available (Jones et al. 2016a). Only unrelated individuals were included in 
analyses in an attempt to prevent shared environmental factors influencing 
associations (Dudbridge 2016); a list of unrelated individuals (N=8,197; 96% of 
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the genotyped sample) was provided by ALSPAC. Individuals that were not 
recorded as Caucasian, or those with missing ethnic background data (N=1,112; 
13.08%), were also removed from analyses leaving N=7,390. 
2.1.3 Mood disorder phenotypes 
2.1.3.1 Hypomania 
To assess probable bipolarity in ALSPAC participants, answers given to the 32 
item Hypomania checklist-32 (HCL-32) questionnaire were converted into a 
categorical measure of hypomania. As per the recommendation of Court et al. 
2014, based on a Rasch analysis of unidimensionality, only 28 of the 32 items 
were included to produce Hypomania checklist-28 (HCL-28) and provide a HCL-28 
hypomania score (0-28) (Court et al. 2014). Individuals were assessed age 22-23 
and those who did not respond, or those with no data, for these 28 items 
(N=5,700; 69.54% of the whole sample) were coded as missing and were not 
included in any further analyses. The scores out of 28 were also combined with 
additional information regarding the duration of “high” states and how often 
individuals had experienced these “high” states, to produce a categorical 
measure of hypomanic features, as follows: individuals with a HCL-28 score of 
greater than 14; a duration of “high” states of “2-3 days” or longer and either 
“negative consequences” or “negative plus positive consequences” as a response 
to these “high” states, were designated as “hypomania”(Hayes et al. 2016). 
Individuals who did not meet these criteria were designated as “no hypomania”. 
Note that this categorical definition of hypomania was the primary outcome 
measure; the HCL-28 score was then used as a continuous outcome for secondary 
analyses to further investigate hypomania. 
2.1.3.2 Depressive features 
Depressive symptoms were assessed in the ALSPAC cohort during late childhood 
and adolescence using the Short Mood and Feelings Questionnaire (SMFQ) 
between the ages of 10 and 19. The SMFQ is a 13-item self-reported 
questionnaire assessing depressive symptoms over a 2 week period (Wiles et al. 
2012; Stringaris et al. 2014). Each item is scored 0, 1 or 2 depending on the 
whether the participant answered “not true”, “sometimes true” or “true”, 
respectively. This generated a categorical depression measure (binary 
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depression) based on a score of greater than 16, as well as an SMFQ score 
ranging from 0 to 26 (Wiles et al. 2012). As for hypomania, the categorical SMFQ 
measure was used as the primary outcome measure for depression and the SMFQ 
score was a secondary outcome. 
2.1.4 Sleep phenotypes 
Four measures of sleep problems, reported at two different ages, were used for 
analyses. Mothers responded to the following questions when their child was 
aged 10: “In the past month child found sleep hard” (kv7034) (referred to as 
Difficult sleeping-10); “In past month child slept too much” (kv7035) (Too much 
sleep), both questions were answered with “yes”, “no” or “don’t know”. At 
child age 13, mothers were again asked “Child had difficulty getting to sleep in 
past month” (tb7034) (Difficult sleeping-13) answering either “yes”, “no” or 
“don’t know”. Also at age 13, mothers were asked: “Degree to which child had 
problems sleeping during last month” (tb5538) (Difficult sleeping-scale) with 
responses of “not at all”=1, “a little”=2, “yes”=3 and “don’t know”=9, and 
“Frequency worrying interferes with child’s sleep” (tb6555) (Worried sleep) 
answering “not at all”=1, “yes not most days”=2, “yes most days”=3 and “don’t 
know”=9. Those who answered “don’t know” were coded as missing and were 
not included in analyses. 
The primary outcome measures for sleep in ALSPAC were the categorical 
variables “Difficulty sleeping-10” and “Difficulty sleeping-13”, which were 
tested for association with PRS using logistic regression. A secondary outcome 
measure “Too much sleep” was also tested using logistic regression, the 
remaining secondary measures (“Difficulty sleeping-scale” and “Worried sleep”) 
were tested using linear regression. 
2.2 UK Biobank 
2.2.1 Participants and ethical approval 
Over 502,000 UK residents aged 37-73 years (most aged 40-70) were recruited to 
the UK Biobank cohort from 2006-2010. At one of 22 assessment centres across 
the UK, participants completed a range of lifestyle, demographic, health, mood, 
cognitive and physical assessments and questionnaires, with DNA samples taken 
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at baseline assessment (Sudlow et al. 2015). UK Biobank obtained informed 
consent from all participants and this study was conducted under generic 
approval from the NHS National Research Ethics Service (approval letter dated 
13 May 2016, Ref 16/NW/0274) and under UK Biobank approvals for applications 
12761 (PI Cathy Wyse; accelerometer data for use in GWAS) and 6553 (PI Daniel 
Smith; genetic and phenotypic data). 
2.2.2 Genotyping and imputation 
UK Biobank released genotypic data for over 500,000 participants using two 
genotyping arrays specifically designed for UK Biobank with 95% shared marker 
content (Bycroft et al. 2017). Approximately 10% of these participants were 
genotyped using Applied Biosystems UK BiLEVE Axiom array by Affymetrix, with 
the remaining participants being genotyped using Applied Biosystems UK Biobank 
Axiom Array. Phasing on the autosomes was done using SHAPEIT3 using the 1000 
Genomes Phase 3 dataset as a reference panel. Imputation of SNP genotypes was 
carried out using IMPUTE4; the merged UK10K and 1000 Genomes Phase 3 
reference panel, as used for the UK Biobank interim genotype data release. 
Approximately 850,000 SNPs were directly genotyped with more than 90 million 
SNPs available after imputation. Stringent quality control was applied to the 
data, described in an open access document (Bycroft et al. 2017). 
2.2.3 Self-reported Bipolar Disorder and Depression 
All UK Biobank participants were given the opportunity to provide a self-report 
of bipolar and depression status (Data-Field 20002). These outcomes are referred 
to as SR Bipolar Disorder and SR Depression/Recurrent Depression. 
2.2.4 Probable Bipolar Disorder and Major Depressive Disorder 
Measures of probable BD and MDD were generated for 123,000 UK Biobank 
participants using questions based on Structured Clinical Interview for DSM-IV 
Axis I Disorders (SCID-I), items from the Patient Health Questionnaire (PHQ) and 
items on help-seeking for mental health. This was obtained during the final two 
years of recruitment (Smith et al. 2013a). These questions allowed for the 
distinction of single episode and recurrent depression. Those with single episode 
of depression were removed from further analyses. From this data, categorical 
Chapter 2  29 
measures of probable BD (probable BD) and probable depression (probable 
recurrent depression) were generated, and individuals who did not meet either 
criteria were classified as controls. 
2.2.5 Psychiatric diagnoses, neuroticism and mood instability 
2.2.5.1 Bipolar Disorder, Major Depressive Disorder and Generalised 
Anxiety Disorder  
A mental health questionnaire (MHQ) was developed by a UK Biobank mental 
health research reference group to collect additional mental health phenotype 
data and was administered during 2016-2017 (Davis et al. 2018). The MHQ was 
used to obtain information about individuals’ lifetime experiences of psychiatric 
disorders, as well as other risk factors for these disorders, such as anxiety, 
substance abuse and childhood trauma. The composite questionnaire consisted 
of 10 sections and was based on a modified Composite International Diagnostic 
Interview Short Form (CIDI-SF), PHQ-9, Generalised Anxiety Disorder 
Questionnaire (GAD-7) and questions devised by the mental health research 
reference group. Lifetime depression (referred to here as ‘lifetime MDD’), 
‘lifetime BD’ and lifetime generalised anxiety disorder (referred to as ‘lifetime 
GAD’) were evaluated based on answers provided by participants to the online 
MHQ. Therefore, as with the depression and bipolar disorder phenotypes 
described above, these assessments represent a likelihood of diagnosis, rather 
than a confirmed diagnoses (Davis et al. 2018). Individuals who had self-reported 
BD or MDD were excluded from the control groups. This resulted in variables 
generated for 157,366 UK Biobank participants. 
2.2.5.2 Neuroticism  
To define neuroticism a score was taken from the 12-item neuroticism scale of 
the Eysenck Personality Questionnaire-Revised Short Form (EPQ-R-S) (Eysenck et 
al. 1985; Smith et al. 2016). Individuals were given a score of 0 or 1 for a “no or 
yes” answer to each item, with total score from 0 to 12. Higher neuroticism has 
been associated with higher incidences of psychiatric disorders, therefore, it is 
linked to greater socioeconomic cost and premature mortality (Lahey 2009; 
Smith et al. 2016). 
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2.2.5.3 Mood instability 
A “mood instability” phenotype was also obtained from the EPQ-R-S 
questionnaire. One of these questions was “Does your mood often go up and 
down?” (answer options “yes”, “no”, “don’t know” or “prefer not to answer”) 
(Eysenck et al. 1985). Individuals who selected “don’t know” or “prefer not to 
answer” were coded as missing (very few participants); this allowed the 
generation of a categorical mood instability variable where those who answered 
“yes” were designated as cases and participants who answered “no” were 
controls, those answering “don’t know” and “prefer not to answer” were 
excluded (Ward et al. 2017). 
2.2.6 Chronotype phenotype 
Chronotype was derived from the participants’ responses to a question from the 
UK Biobank Morningness-Eveningness questionnaire (Taillard et al. 2003). The 
question consisted of “Do you consider yourself to be...” with response options 
“Definitely a “morning” person”, “More a “morning” than “evening” person”, 
“More an “evening” than “morning” person”, “Definitely an “evening” person”, 
“Do not know” and “Prefer not to answer”.  This chronotype assessment is a 
widely accepted measure and has previously been reported to explain the 
greatest variance in individual preference of sleep-wake timings (Taillard et al. 
2003). Categorical variables were then generated based upon the responses 
given, resulting in the generation of four separate chronotype variables 
(“Definite morning”, “Definite evening”, “Overall morning”, “Overall evening”). 
The primary outcome measures used for analysis were the “definite morning” 
and “definite evening” variables. Secondary outcome measures of “overall 
morning” and “overall evening” were also assessed. Individuals who answered 
either “don’t know” or “prefer not to answer” were coded as missing for each of 
the variables and excluded (22.8%) (Figure 2.1).  
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Figure 2.1 Case/control designation from SR Chronotype in UK Biobank 
2.2.7 Accelerometry data collection and pre-processing 
In 2013, 240,000 UK Biobank participants were invited to wear an accelerometer 
for seven days as part of a physical activity monitoring investigation (Doherty et 
al. 2017). Of these, 103,720 (43%) accepted and returned the accelerometer to 
UK Biobank after use. Participants received a wrist-worn Axivity AX3 triaxial 
accelerometer in the post and were asked to wear the device on their dominant 
wrist continuously for seven days, while continuing with their normal activities. 
At the end of the seven-day period, participants were instructed to return the 
accelerometer to UK Biobank using a prepaid envelope. Accelerometers were 
calibrated to local gravity. Devices recorded data at a sampling rate of 94-
104Hz, and data were resampled to 100Hz offline. Periods where no data were 
recorded for >1s were coded as missing, and machine noise was removed using a 
Butterworth low-pass filter (cut-off 20Hz). Raw activity intensity data were 
combined into five second epochs. Further details on data pre-processing are 
available from UK Biobank at 
http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=131600 (Doherty et al. 2017).  
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2.2.8 Circadian rest-activity rhythmicity (RA)  
From the summary five second epoch data, a measure of relative amplitude (RA) 
was calculated using Clocklab Version 6 (Actimetrics) by Dr. Cathy Wyse (Wyse et 
al. 2018, unpublished). This accelerometer-derived activity measure has 
demonstrated reliability and validity in associating with health measures (Sadeh 
2011; Lyall et al. 2018). RA is used commonly as a non-parametric measure of 
rest-activity rhythm amplitude. It is defined as the relative difference between 
the most active continuous 10-hour period (M10) and the least active continuous 
5-hour period (L5) in an average 24-hour period (Van Someren et al. 1996):  
𝑅𝐴 =
(M10 − L5)
(M10 + L5)
 
M10 is the mean activity during the continuous 10 hour period containing 
maximum activity in each 24 hour recording period (midnight to midnight). L5 is 
the mean activity for the corresponding 5 hour period containing the minimum 
activity within the same recording period. For each individual, the RA data point 
was the mean RA value across all included 24-hour periods (seven days). RA 
ranges from 0 to 1, with higher values indicating greater distinction between 
activity levels during the most and least active periods of the day.  
Participants who provided accelerometer data for less than 72 hours or who did 
not provide data for all one-hour periods within the 24-hour cycle were excluded 
from analyses. Over 10,000 participants were also excluded because their data 
was identified by UK Biobank as having poor calibration, poor wear compliance, 
or flagged by UK Biobank as unreliable (unexpectedly small or large size) and 
where participants whose wear-time overlapped with a daylight savings clock 
change (Lyall et al. 2018).  
2.3 Polygenic risk scores 
Weighted PRS were generated for all individuals with genotype data available in 
ALSPAC and UK Biobank using Plink 1.9 (Purcell et al. 2007). 
Only SNPs with a MAF of greater than 0.01 – here the minor allele is designated 
A1 – within the cohorts were considered for inclusion in the PRS calculation 
(generally most SNPs included). All SNPs were tested for HWE in both cohorts; 
SNPs with HWE p value of less than 0.001 were excluded from further analysis. 
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All statistical analyses (i.e. logistic and linear regressions) were carried out using 
the statistical software package Stata Student Edition 13 for Windows; the 
standard nominal p value significance cut-off value of p<0.05 was used for all 
analyses. Changes in the weighted PRS scores are small due to the use of the log 
of O.R; to provide a more comprehensive interpretation of the analyses, the 
weighted scores were standardised to their z values. 
Most of the association analyses used logistic regression assuming an additive 
allelic (0/1/2) effect model. For ALSPAC, potential confounders, sex and 
socioeconomic status were included in the models. For UK Biobank, the adjusted 
analysis included age, sex, socioeconomic status (measured using the Townsend 
deprivation score), 8 UK Biobank genetic principal components, assessment 
centre, genotyping chip and batch as covariates. 
Methodology specific to each analyses is detailed in the appropriate chapters. 
2.3.1 Power calculation 
As the effect sizes reported for polygenic risk scores are often relatively small a 
large sample size was required for each analysis (Dudbridge 2013). To determine 
the sample sizes required to detect the effects of genetic risk scores on the 
various phenotypes in ALSPAC and UK Biobank to significance post-hoc power 
calculations were undertaken using GPower software (Version 3.1). The 
estimated effect size and desired power (95% power) were inputted and the 
required minimum sample size was calculated based on a logistical regression 
model (Faul et al. 2009; Faul et al. 2007). As described in the limitations of each 
analysis, some investigations were underpowered to detect effects to 
significance due to the relatively small number of cases available in the 
categorical mood-related phenotypes.
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Chapter 3 Investigating the effect of Calcium 
Voltage-Gated Channel Subunit Alpha 1 C 
(CACNA1C) single nucleotide polymorphisms 
on mood disorder phenotypes within two 
population cohorts 
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Outline 3.1 Chapter in context of overall study 
 
3.1 Introduction 
This chapter will investigate the potential associations of CACNA1C SNPs with 
mood disorder-related traits in ALSPAC and UK Biobank using a GPRS approach. 
In GWAS, several SNPs within the Calcium Voltage-Gated Channel Subunit Alpha 
1 C (CACNA1C) gene have been associated with neuropsychiatric disorders, 
including BD, schizophrenia and MDD (Bigos et al. 2010; Sklar et al. 2011; 
Smoller 2013; Heilbronner et al. 2015; Stahl et al. 2017). This association 
appears to be strongest for BD, the genome-wide significant allelic associations 
localize within intron 3 of CACNA1C (p<2x10-8) (Fiorentino et al. 2014).  
Most genetic variants associated with common neuropsychiatric disorders are 
relatively common (typically MAF>5%) in the general population (Bigos et al. 
2010). For example, the CACNA1C minor allele rs1006737 SNP – which is a 
replicated finding and has been of considerable interest in previous studies 
(Green et al. 2013; Ferreira et al. 2008; Bigos et al. 2010) – is found in 
approximately one third of individuals of European ancestry and is a common 
variant in other populations (see Table 3.2) (NCBI 2018). These genetic variants 
may also highlight pathways which could lead to the development of more 
targeted pharmaceutical therapies (Dunn et al. 2015; Harrison et al. 2018). 
3.1.1 The CACNA1C gene 
The CACNA1C gene encodes the alpha subunit of the L-type voltage-gated 
calcium channel (L-VGCC) Cav1.2 (Erk et al. 2014a). The CACNA1C locus is 
Chapter 3  36 
located on the short arm of chromosome 12, spanning a genomic region of 
approximately 740kb (Soldatov 1994). The gene contains approximately 55 exons 
and several splice variants have been detected, however the exact range of 
transcripts and protein isoforms produced is unknown (Soldatov 1994; Harrison 
2016). The majority of risk variants associated with psychiatric disorders, 
including BD, identified through GWAS are found within introns and 5’ and 3’ 
untranslated regions (Fiorentino et al. 2014; Kabir et al. 2017). A particular area 
of interest is CACNA1C intron 3; this intronic region is highly conserved in 
mammals, suggesting a fundamental functional importance for the region 
(Fiorentino et al. 2014). Variation in this region may have an effect on 
regulatory elements within the large intronic region with several possible 
outcomes, including altered expression of CACNA1C transcripts, altered 
expression of CACNA1C splice variants and differential expression during 
development (Yoshimizu et al. 2015). 
3.1.2 Potential pathways of pathophysiology 
Functional studies have suggested that risk SNPs lie within regions of tight 
transcriptional control: gene expression may become altered through the 
differential binding of regulatory nuclear proteins or by altering interactions 
between intronic enhancers and promoters (Kabir et al. 2017). One study, 
undertaken in BD patients, suggests that risk variants affect the genome 
architecture and, therefore, influences interactions with transcription start sites 
and altering gene expression (Starnawska et al. 2016). Several studies have 
reported expression changes of the CACNA1C gene associated with risk SNPs in 
various tissues using both post-mortem samples and induced neurons derived 
from BD patients (Harrison 2016). 
 DNA methylation is also a potential mechanism by which non-coding 
variants can result in the phenotype variability seen in BD. Altered methylation 
is linked to abnormal gene expression, differential splicing and the use of 
alternate gene promoters. Overall, hypermethylation has been reported in BD 
patients (N=582) and the rs1006737 CACNA1C risk SNP has been found to be 
associated with the hypermethylation of CpG island 3 (found within intron 3) of 
the CACNA1C gene in BD subjects compared to controls (Starnawska et al. 2016). 
It is therefore possible that the CACNA1C risk SNPs influence the underlying 
mechanisms of BD via altered DNA methylation patterns (Starnawska et al. 
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2016).  
 It is also possible that non-coding risk variants influence the 
pathophysiology of BD by affecting non-coding RNAs or antisense transcripts 
influencing other regulatory elements or genes (Harrison 2016). 
3.1.3 The Cav1.2 channel  
The protein encoded by CACNA1C, the alpha subunit of L-VGCC Cav1.2, is the 
only component of the channel which forms the transmembrane pore vital for 
allowing action potentials on the cell membrane to be converted to calcium 
influx (Erk et al. 2014a; Catterall 2011). This transduction of electric excitability 
is critical to the physiological roles of many organs (Liao & Soong 2010). Cav1.2 
channels are expressed by a variety of cell types, including neurons, 
lymphocytes, smooth muscle cells, pancreatic beta cells, and cardiomyocytes 
(Moosmang et al. 2005; Cabral et al. 2010; Liao & Soong 2010; Bidaud & Lory 
2011), and are involved in many processes, summarised in Figure 3.1, such as 
excitation-contraction coupling, hormone regulation and secretion, integration 
of synaptic input, cell survival and neurotransmitter release (Tabuchi et al. 
2000; Gomez-Ospina et al. 2006; Kolarow et al. 2007; Liao & Soong 2010; Bidaud 
& Lory 2011; Catterall 2011; Erk et al. 2014b; VT et al. 2015).  
 The influx of calcium ions via Cav1.2 channels activates several pathways 
within neurons (Soeiro-De-Souza et al. 2017) including the subsequent activation 
of a series of calmodulin-dependent protein kinases leading to the transduction 
of molecular cascades and gene expression, via cAMP response element binding 
proteins (CREB) (Kabir et al. 2017). CREB-activated genes are critically involved 
in synaptic and neuronal plasticity (Kabir et al. 2017). It has been reported that 
CACNA1C risk SNPs are associated with higher intracellular calcium ion 
concentrations in neurons of BD individuals compared to healthy controls; these 
risk SNPs may therefore influence BD through greater activity of calcium-
dependent cascades. It is of note this study was undertaken using a small case 
sample (N=50) (Soeiro-De-Souza et al. 2017). 
3.1.4 Possible influence of CACNA1C in the brain 
Several studies have reported that carriers of CACNA1C risk variants show 
altered activity and connectivity in various regions of the brain, and some 
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evidence of structural differences in areas such as the hippocampus, perigenual 
anterior cingulate (pgACC) and amygdala (Erk et al. 2010; Tesli et al. 2013; Erk 
et al. 2014b; Jakobsson et al. 2015; Kamali et al. 2015). However, as mentioned 
previously, these studies were based on relatively small sample sizes and are 
likely to be underpowered. CACNA1C may influence brain structure via its roles 
in neuronal plasticity and dendritic retraction (Soeiro-De-Souza et al. 2017).  
 Evidence of CACNA1C involvement in brain activity has been 
demonstrated in both BD patients and unaffected first degree relatives who 
carry the risk variants. Examples of this include reduced activity in the pgACC 
during stress and mood-related responses (Erk et al. 2014b), altered activity 
during emotional processing (Heyes et al. 2015), reduced activity in the 
hippocampus, and dysfunction in the amygdala (Tesli et al. 2013; Erk et al. 
2014b) (see Figure 3.1). The CACNA1C variant rs1006737 has been previously 
associated with increased anxiety and depression scores in individuals carrying 
the SNP relative to those who do not; this has been demonstrated in both 
individuals with BD and unaffected first degree relatives (heterozygous risk 
variant carriers: N=119, mean 0.16 vs homozygous wild-type: N=141, mean 0.09, 
p 0.02) (Erk et al. 2014a). 
3.1.5 Potential as a therapeutic target for mood disorders 
L-VGCCs are known to be highly sensitive to calcium channel antagonists (Bidaud 
& Lory 2011). The alpha subunit of Cav1.2, encoded by CACNA1C, is the main 
binding site for antagonists such as dihydropyridines (DHPs), benzothiazepines 
and phenylalkylamines (Bidaud & Lory 2011). Mice exposed to L-VGCC agonists 
displayed severe neurobehavioral symptoms and prolonged depressive symptoms; 
these symptoms were reversed after treatment with a DHP drug (Keers et al. 
2009). The calcium channel blockers verapamil and nimodipine may have 
efficacy in the mood stabilisation of BD, making Cav1.2 a possible target for 
therapeutic treatment (Keers et al. 2009; Bidaud & Lory 2011; Erk et al. 2014b).  
Overall, it is reasonable to conclude that common variants at the CACNA1C locus 
may have an important role in the pathophysiology of mood disorders, 
particularly BD, and that CACNA1C potential as a therapeutic target. 
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Figure 3.1 Various Cav1.2 channel functions and potential pathophysiological influences 
3.2 Rationale  
Previous investigations into the effects of CACNA1C SNPs have focussed only on 
single variants in relatively small samples and are likely to be underpowered 
(Bigos et al. 2010; Heilbronner et al. 2015; Dao et al. 2010; Strohmaier et al. 
2013). Generating a weighted score using several risk SNPs may allow for the 
detection of small effects within our cohorts. As this risk score is calculated 
using SNPs from only one gene locus this risk score is referred to as the genetic 
profile risk score (GPRS) for the CACNA1C gene, as opposed to a PRS which uses 
variants from many gene loci. The preliminary analyses make use of very large 
samples from the first release of genetic data from UK Biobank sample 
(N=152,000), and all available genetic data in ALSPAC (N=8,365) and, therefore, 
are likely to be sufficiently powered to find low effect sizes (greater than 90% 
power to detect low effects). 
Previous studies investigating the influence of CACNA1C in the context of 
psychiatric disorders have suggested that risk alleles may have a greater effect 
on one sex compared to the other (Dao et al. 2010; Strohmaier et al. 2013; 
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Heilbronner et al. 2015; Starnawska et al. 2016). The analyses were also 
undertaken upon separating the samples by sex. 
 The subsequent release of genetic data for the remaining UK Biobank 
sample and further phenotype data allows the UK Biobank to act as a replication 
cohort. These analyses were carried out to test the robustness of the findings 
from the primary analyses. 
3.3 Hypotheses to be tested 
In this chapter, the primary hypothesis being tested was: is there an association 
between greater genetic loading of CACNA1C variants and the clinical expression 
of several mood disorder phenotypes within two population cohorts (ALSPAC and 
UK Biobank)?  These phenotypes included: hypomania and depressive features 
within ALSPAC; and mood instability, neuroticism, BD status and MDD status 
within the UK Biobank cohort.  
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3.4 Methods  
3.4.1 GPRS analysis 
A weighted GPRS was generated for all individuals with genotype data available 
in ALSPAC and UK Biobank using Plink 1.9 (Purcell et al. 2009). To provide 
weighting for the CACNA1C SNPs, the log of the odds ratios provided by BD GWAS 
and meta-analyses were used (Kloiber et al. 2012; Green et al. 2013; Fiorentino 
et al. 2014; Heilbronner et al. 2015). Only SNPs with a MAF of greater than 0.01 – 
here the minor allele is designated A1 – within the cohorts were considered for 
inclusion in the GPRS calculation. All SNPs were tested in both cohorts for LD 
and HWE; SNPs with a HWE p value of less than 0.001 were excluded from 
further analysis (see Table 3.2).  
For the analyses using the ALSPAC cohort only, individuals genotyped at all 19 
SNPs-of-interest were included. In the case of UK Biobank, analyses were run 
using individuals genotyped for all 15 SNPs found to be in HWE. 
Changes in the weighted GPR scores are small due to the use of the log of O.R; 
to provide a more comprehensive interpretation of the analyses, the weighted 
scores were standardised to z values (i.e. per standard deviation). 
All O.R and coefficients reported are per SD of GPRS. 
3.4.2 ALPSAC 
Details of recruitment to the cohort and genotyping are described in Chapter 2. 
Only unrelated individuals were included in these analyses to prevent shared 
environmental factors influencing associations (Dudbridge 2016); a list of 
unrelated individuals (N=8,197; 98% of the whole sample) was provided by 
ALSPAC. Individuals not recorded as Caucasian, or those with missing ethnic 
background data (N=973; 11.87%), were also removed from analyses leaving 
N=7,224. 
3.4.2.1 Hypomania 
To test associations between CACNA1C GPRS and features of BD in ALSPAC, 
categorical and continuous measures of hypomania were used. The full details of 
how these measures are generated using HCL-28 can be found in Chapter 2. HCL-
28 score is used as the continuous measure of hypomania and represents an 
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individual’s score out of 28 using the checklist. The categorical measure of 
hypomania (binary hypomania) combines the HCL-28 score with additional 
information regarding the duration of “high” states and how often individuals 
had experienced these “high” states. The categorical definition of hypomania 
was the primary outcome measure and the HCL-28 score was a secondary 
outcome. 
3.4.2.2 Depressive features 
Depressive symptoms were assessed in the ALSPAC cohort during late childhood 
and adolescence using the SMFQ. This generates an SMFQ score ranging from 0 to 
26 (Wiles et al. 2012), as well as a categorical depression measure (binary 
depression) based on a score of greater than 16. The categorical SMFQ measure 
was used as the primary outcome measure and the SMFQ score was the 
secondary outcome. 
These primary outcome measures of hypomania and depression were tested for 
association with CACNA1C GPRS using logistic regression assuming an additive 
allelic effect model. The dimensional secondary outcome measures (HCL-28 
score and SMFQ score) were analysed using linear regression. 
3.4.3 UK Biobank cohort 
Individuals were filtered from the initial cohort of N=152,000 based upon several 
quality control criteria, including relatedness, ancestry (Non-Caucasian 
individuals), gender mismatch and quality control failure in the UK BiLEVE study. 
This left N=119,953 (78.9% of the cohort). Individuals missing genotype 
information for any of the 15 chosen SNPs were also excluded from analyses, 
leaving N=95,073. 
3.4.3.1 BD and MDD 
Individuals with BD and recurrent MDD were identified according to the criteria 
previously used by Smith and colleagues (Smith et al. 2013a) and as described 
within Chapter 2. These data were only available on approximately one third of 
the UK Biobank cohort because specific questions on manic features were only 
introduced towards the end of the recruitment period. BD and MDD defined in 
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this way were the primary outcomes of interest.  
However, at initial recruitment all UK Biobank participants were given the 
opportunity to provide a self-report of bipolar and depression status. These were 
used as secondary outcomes in the current analyses and are referred to as SR 
Bipolar Disorder and SR Recurrent Depression. 
3.4.3.2 Neuroticism 
To define neuroticism a score taken from the 12 item neuroticism scale of the 
Eysenck Personality Questionnaire-Revised Short Form (EPQ-R-S) (Eysenck et al. 
1985). Individuals were given a score of 0 or 1 for a “no or yes” answer, 
respectively, for each item and given a total neuroticism score ranging from 0 to 
12. As described in Chapter 2. 
3.4.3.3 Mood instability 
As described in Chapter 2, a “mood instability” outcome measure was also 
obtained from the EPQ-R-S questionnaire: participants were asked “Does your 
mood often go up and down?” and given the option to answer “yes”, “no”, 
“don’t know” or “prefer not to answer”. Individuals who selected “don’t know” 
or “prefer not to answer” were coded as missing (<5%); this allowed the 
generation of a categorical mood instability variable where those who answered 
“yes” were designated as cases and participants who answered “no” were 
included as controls.  
3.4.3.4 Mental Health Questionnaire phenotypes 
A MHQ was developed by a UK Biobank mental health research reference group 
to collect additional mental health phenotype data and was administered during 
2016-2017. Lifetime BD and lifetime MDD variables were generated for 157,366 
UK Biobank participants. Further details for these variables have been described 
in Chapter 2. 
Most of the association analysis carried out used logistic regression assuming an 
additive allelic effect model (the association analysis using neuroticism score 
used a linear regression). The adjusted analysis included age, sex, 
socioeconomic status (assessed using the Townsend deprivation score), 10 UK 
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Biobank genetic principal components, assessment centre, batch and array as 
covariates. The association analyses were also performed separately for males 
and females, both unadjusted and adjusted, with age, deprivation index, 8 UK 
Biobank genetic principal components, assessment centre, batch and array 
included as covariates.  
  
Chapter 3  45 
3.5 Results 
Table 3.1 Demographics of cohorts 
 
 ALSPAC 
N total = 8,197 
UK Biobank 
N total = 119,953 
Sex  
Female, N (%) 3,525 (48.8) 63,088 (52.6) 
Age  
Mean (SD) 24.497 (0.5) 56.867 (7.93) 
Deprivation  
Mean (SD) 2.831 (1.33) -1.466 (2.99) 
Range 3 -2.278 
 
As the two population cohorts capture participants of different age groups, and 
parents were excluded from ALSPAC analysis (the ALSPAC table above refers to 
child participants only), it is unlikely that there is any overlap between the 
samples (Table 3.1). It is of note, in ALSPAC, DNA was obtained at age 7 with the 
hypomanic and depressive data used below collected between ages 22-23 and 
10-19, respectively. UK Biobank DNA samples and self-report mood phenotypes 
were obtained at baseline assessment. The deprivation data in ALSPAC was 
obtained from the maternal socioeconomic status and Townsend score was used 
in UK Biobank. 
As described in the methodology above, many CACNA1C SNPs-of-interest (listed 
in Table 3.2) were selected to generate GPR scores for genotyped individuals in 
ALSPAC and UK Biobank (LD structure of SNPs displayed in Supplemental Figure 
3.1).  
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Table 3.2 SNP-of-interest information (ALSPAC/UK Biobank) 
SNP ID Position A1 A2 MAF O.R (for BD) HWE p value 
rs2007044 2344960 G A 0.393/0.395 1.198 0.371/0.002 
rs1006737 2345295 A G 0.337/0.332 1.198 0.147/0.069 
rs2159100 2346393 T C 0.337/0.333 1.198 0.134/0.074 
rs1024582* 2402246 A G 0.348/0.338 1.19 0.286/0.000 
rs4765913 2419896 A T 0.216/0.217 1.14 0.622/0.833 
rs4765914 2420377 T C 0.212/0.206 1.14 0.646/0.495 
rs3819532 2436837 T C 0.395/0.401 1.32 0.963/0.721 
rs3819534 2436868 A G 0.395/0.394 1.32 1/0.825 
rs2238065 2442631 A G 0.264/0.268 1.06 0.497/0.252 
rs2238066 2445399 G A 0.293/0.294 1.02 0.651/0.161 
rs2283302 2452619 A G 0.289/0.289 1.35 1/0.53 
rs2238070 2456115 G T 0.437/0.448 1.33 0.874/0.005 
rs2238071* 2456416 A G 0.427/0.431 1.34 0.839/0.000 
rs2239073 2538500 C T 0.433/0.431 0.83 0.369/0.509 
rs4765681 2557196 T C 0.43/0.434 0.82 0.835/0.919 
rs4765937 2570535 C T 0.419/0.432 0.92 0.856/0.004 
rs16929470 2601742 T C 0.039/0.04 0.65 0.558/0.007 
rs11062247* 2616128 G A 0.169/0.167 0.79 0.781/1.62x10-7 
rs11062248* 2616188 T A 0.169/0.168 0.78 0.812/2.23x10-7 
The effect alleles used to calculate the risk scores are indicated in bold. Those excluded from 
analysis in UK Biobank are indicated by *. The MAF given is for Allele 1(A1). All SNPs found within 
intron 3 of CACNA1C. 
 
3.5.1 ALSPAC cohort 
The primary outcome used to investigate hypomanic features in ALSPAC was the 
categorical hypomania measure (based on the answers given to HCL-28 at age 
22-23). An unadjusted logistic regression was conducted to establish the 
potential for association between increasing GPRS and a designation of 
“hypomania”. Although genotypic data was available for 7,224 Caucasian 
individuals in ALSPAC, not all individuals genotyped for the 19 risk SNPs-of-
interest have HCL or SMFQ scores.  
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Table 3.3 Primary hypomania and depression outcome measures 
ALSPAC Cases Controls 
Hypomania, N (%) 181 (7.25) 2,316 (92.75) 
Depression, N (%) 33(0.58) 5,689 (99.42) 
 
A logistic regression was carried out on the 2,072 individuals genotyped for all 19 
SNPs-of-interest available, using the primary outcome measure – hypomania 
status – as the response variable and GPR score as the explanatory variable: no 
association was seen (Table 3.4). A linear regression was also carried out using 
the secondary outcome measure (Supplemental Figure 3.2) and GPR score. 
Again, no association between hypomania and CACNA1C risk scores was apparent 
(Table 3.4). 
Table 3.4 Regressions of primary and secondary outcomes and GPRS 
Phenotype  O.R S.E p value 95% CI r2 
Binary Hypomania 0.983 0.085 0.843 0.831/1.164 0.0000 
Binary Depression 1.311 0.247 0.151 0.906/1.897 0.0065 
 Coefficient  
HCL score -0.163 0.132 0.217 -0.422/0.096 0.0008 
SMFQ score 0.057 0.05 0.254 -0.041/0.156 0.0003 
Unadjusted model 
 
A similar strategy was used to investigate depressive features: the influence of 
CACNA1C GPR scores on the primary depression outcome (binary depression, 
generated from SMFQ score which was assessed between the ages of 10 and 19) 
was investigated using an unadjusted logistic regression (4,638 observations). 
The largest effect seen was for binary depression (O.R 1.311), however, this was 
not significant (p<0.05). When linear regression was applied to the secondary 
outcome measure, SMFQ score, the association was not significant. 
Table 3.5 Primary hypomania and depression outcomes separated by sex 
ALSPAC Female  
 Cases Controls 
Hypomania, N (%) 99(54.7) 1,500(64.8) 
Depression, N (%) 13(39.4) 2,823(49.6) 
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In order to investigate the potential of a sex effect, the sample was stratified. 
The above analyses were then repeated separately for males and females. 
Splitting the sample according to sex resulted in an uneven distribution of 
observations: only 746 males had both HCL-28 scores and were genotyped for all 
19 SNPs-of-interest, whereas, 1,326 females were included in the hypomania 
analyses. 
Table 3.6 Regressions of primary and secondary outcomes and GPRS separated by sex 
Phenotype  O.R S.E p value 95% CI r2 
Hypomania  
Female 0.862 0.102 0.21 0.683/1.088 0.0027 
Male 1.135 0.143 0.317 0.886/1.453 0.0023 
Depression  
Female 1.737 0.554 0.083 0.93/3.245 0.0003 
Male 1.13 0.269 0.607 0.709/1.801 0.0013 
HCL score Coefficient  
Female -0.332 0.167 0.046 -0.659/-0.005 0.0032 
Male 0.088 0.215 0.681 -0.333/0.51 0.0002 
SMFQ score  
Female 0.147 0.069 0.033 0.012/0.283 0.0022 
Male -0.036 0.073 0.622 -0.18/0.108 0.0001 
Unadjusted model 
 
The primary outcome measures for both hypomania and depression had no 
significant association to an increasing GPRS in either sex groups. However, 
increasing HCL score had a negative association to GPRS (coefficient -0.332) that 
was nominally significant (p 0.046). It is however worth noting that no 
association was found for the primary hypomania variable. A separate 
association was also seen in females for SMFQ score (coefficient 0.147, p 0.033) 
(Table 3.6). Again, no association was identified for the primary depressive 
outcome measure. In males, there were no significant associations for the 
primary or secondary outcome measures. 
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3.5.2 UK Biobank 
To investigate the effect of CACNA1C GPRS on the mood disorder phenotypes 
logistic regression assuming an additive allelic model was used. The primary 
outcomes of interest were BD and recurrent MDD (Table 3.7). A logistic 
regression was carried out using the GPRS of individuals who were genotyped for 
all 15 SNPs-of-interest (which passed HWE testing). 
Table 3.7 Mood phenotypes in UK Biobank 
UK Biobank Cases Controls 
Probable BD, N (%) 354(1.12) 31,386(98.88) 
Probable Recurrent Depression, N (%) 5,687(15.79) 30,325(84.21) 
SR Bipolar Disorder, N (%) 332(0.28) 119,621(99.72) 
SR Recurrent Depression, N (%) 7,384(6.16) 112,569(93.84) 
Neuroticism, N (%)  49,692(50.84) 48,045(49.16) 
Mood Instability, N (%) 53,271(45.47) 63,898(54.53) 
 
As was the case for ALSPAC, not all individuals with mood disorder data were 
genotyped for the chosen SNPs, resulting in 25,187 available observations for BD 
and 28,536 for Recurrent MDD. The logistic regression yielded no significant 
effects for the standardised GPRS on BD or Recurrent MDD (Table 3.8). In 
secondary analyses, the outcome measures of SR Bipolar Disorder and SR 
Recurrent MDD were assessed. However, no significant effects were found. Both 
unadjusted and adjusted logistic regressions were conducted. The adjusted 
analyses included age, sex and deprivation as well as the principal components 
and the quality control steps described above as potential confounders. Again, 
no significant associations between CACNA1C GPRS and BD or depression were 
identified. 
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Table 3.8 Regressions of mood phenotypes and GPRS 
Phenotype  O.R S.E p value 95% CI r2 
Probable BD 1.086 (1.09) 0.063 (0.063) 0.153 (0.138) 0.97/1.217 
(0.973/1.222) 
0.0007 
(0.0228) 
Probable 
Recurrent 
Depression 
1.008 (1.01) 0.016 (0.016) 0.611 (0.543) 0.977/1.04 
(0.979/1.042) 
0.0000 
(0.0218) 
SR Bipolar 
Disorder 
1.01 (1.014) 0.06 (0.061) 0.874 (0.821) 0.898/1.135 
(0.901/1.14) 
0.0000 
(0.0254) 
SR Recurrent 
Depression 
0.984 (0.986) 0.013 (0.013) 0.216 (0.303) 0.959/1.01 
(0.961/1.012) 
0.0000 
(0.0216) 
Mood 
Instability 
1.003 (1.005) 0.006 (0.007) 0.613 (0.425) 0.991/1.016 
(0.992/1.018) 
0.0000 
(0.0185) 
 
Coefficient      
Neuroticism 
score 
0.011 (0.011) 0.011 (0.011) 0.349 (0.307) -0.012/0.033  
(-0.011/0.33) 
0.0000 
(0.0411) 
Unadjusted model (adjusted model) 
 
Analyses were then carried out on the other mood disorder phenotypes of 
interest. Associations between the binary “mood instability” outcome variable 
and the GPRS were tested using logistic regression. As above, an unadjusted 
regression was first completed and then repeated with adjustment for potential 
confounders. There were no significant associations found between mood 
instability and CACNA1C risk score for either the unadjusted or adjusted 
regressions. 
A standardized linear regression was used to test the continuous neuroticism 
score, also adjusted for potential confounders, but no evidence of association 
was found. 
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Table 3.9 Mood phenotypes in UK Biobank separated by sex 
UK Biobank Female 
 Cases Controls 
Probable BD, N(%) 163(46.04) 15,548(49.54) 
Probable Recurrent Depression, N(%) 3,598(63.27) 14,826(41.17) 
SR Bipolar Disorder, N(%) 179(53.91) 62,909(52.44) 
SR Recurrent Depression, N(%) 4,780(64.73) 58,308(51.8) 
Mood Instability, N(%) 29,528(55.43) 32,127(50.29) 
 
The sample was then stratified to test for a potential sex effect of CACNA1C 
variants. Logistic regressions were used to investigate the effect of the CACNA1C 
GPR scores on both the primary and secondary BD/Recurrent Depression 
outcome measures and mood instability. As above, a linear regression was used 
to test the association between risk scores and the continuous neuroticism 
measure. 
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Table 3.10 Regressions of mood phenotypes and GPRS separated by sex.  
Phenotype  O.R  S.E p value 95% CI r2 
Prob BD  
Female 1.194 
(1.199) 
0.098 
(0.099) 
0.031 (0.027) 1.021/1.409 
(1.015/1.406) 
0.0031 
(0.0347) 
Male 0.99 (0.99) 0.082 
(0.082) 
0.901 (0.904) 0.842/1.16 
(0.841/1.165) 
0.0000 
(0.0198) 
Prob Rec Depression  
Female 0.996 
(0.999) 
0.02 
(0.021) 
0.841 (0.982) 0.957/1.037 
(0.96/1.041) 
0.0000 
(0.0108) 
Male 1.025 
(1.026) 
0.026 
(0.026) 
0.34 (0.32) 0.975/1.077 
(0.976/1.079) 
0.0001 
(0.0084) 
SR BD  
Female 1.053 
(1.056) 
0.085 
(0.085) 
0.525 (0.503) 0.899/1.233 
(0.901/1.237) 
0.0002 
(0.0219) 
Male 0.961 
(0.966) 
0.085 
(0.086) 
0.65 (0.695) 0.808/1.143 
(0.811/1.15) 
0.0001 
(0.0383) 
SR Rec Depression  
Female  0.973 
(0.978) 
0.016 
(0.016) 
0.103 (0.187) 0.942/1.005 
(0.947/1.011) 
0.0001 
(0.0141) 
Male 0.999 
(1.001) 
0.022 
(0.022) 
0.949 (0.95) 0.957/1.042 
(0.959/1.046) 
0.0000 
(0.0144) 
Mood Instability      
Female 1.003 
(1.007) 
0.009 
(0.009) 
0.757 (0.45) 0.986/1.02 
(0.989/1.025) 
0.0000 
(0.0193) 
Male 1.002 
(1.004) 
0.009 
(0.01) 
0.773 (0.694) 0.984/1.021 
(0.985/1.023) 
0.0000 
(0.0151) 
Neuroticism score Coefficient  
Female 0.011 
(0.016) 
0.016 
(0.016) 
0.499 (0.31) -0.02/0.042  
(-0.015/0.047) 
0.0000 
(0.0152) 
Male 0.006 
(0.006) 
0.016 
(0.016) 
0.717 (0.69) -0.026/0.374  
(-0.249/0.038) 
0.0000 
(0.0222) 
Unadjusted model (adjusted model) 
 
For males, there was no association between any of the outcome measures and 
CACNA1C GPR score (Table 3.10). However, for females, a small effect was 
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found for the primary BD outcome measure: both the unadjusted (p 0.031) and 
the adjusted (p 0.027) regressions suggested that CACNA1C GPRS may have a 
(small) positive effect on the risk of BD. However, this association was not found 
for the secondary BD outcome measure (SR Bipolar Disorder) and no other 
associations were seen in females for the other mood disorder phenotypes. 
3.5.3 Replication in UK Biobank 
The preliminary analyses above were undertaken using the first release of 
genetic data from UK Biobank (N=152,000). The more recent collection of data 
using the MHQ is potentially a more reliable assessment of BD and MDD status. 
The CACNA1C GPRS were then tested for association with lifetime BD and MDD 
status. However, there were no associations found using these MHQ-defined 
phenotypes (Table 3.11). 
The associations between CACNA1C GPRS and neuroticism, and mood instability 
were also tested in the larger UK Biobank cohort but no associations were 
identified (Table 3.11). 
Table 3.11 Regressions of MHQ mood phenotypes and GPRS 
Phenotype  O.R  S.E p value 95% CI r2 
Lifetime BD 0.994 
(0.994) 
0.026 
(0.026) 
0.834 
(0.815) 
0.945/1.047 
(0.994/1.046) 
0.000 
(0.018) 
Lifetime MDD 1.005 
(1.004) 
0.007 
(0.007) 
0.422 
(0.532) 
0.993/1.018 
(0.944/1.046) 
0.000 
(0.043) 
Mood 
Instability 
1.001 
(1.001) 
0.003 
(0.003) 
0.72 
(0.66) 
0.995/1.007 
(0.995/1.008) 
0.000 
(0.017) 
 Coefficient  
Neuroticism 
score 
0.003 
(0.003) 
0.005 
(0.005) 
0.55 
(0.552) 
-0.007/0.014 
(-0.007/0.014) 
0.000 
(0.02) 
Unadjusted model (adjusted model) 
 
Consistent with the preliminary analyses above, UK Biobank participants with 
MHQ data were stratified by sex to assess potential associations between 
CACNA1C GPRS and the MHQ mood disorder measures, neuroticism, and mood 
instability. However, no significant associations between the GPRS and these 
mood phenotypes were found in males or females (Table 3.12). 
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Table 3.12 Regressions of mood phenotypes and GPRS separated by sex 
Phenotype  O.R S.E p value 95% CI r2 
Lifetime BD  
Female 0.962 
(0.961) 
0.003 
(0.029) 
0.209 (0.198) 0.906/1.022 
(0.905/1.021) 
0.0031 
(0.0347) 
Male 1.004 
(1.002) 
0.003 
(0.003) 
0.896 (0.957) 0.942/1.071 
(0.939/1.068) 
0.0000 
(0.0198) 
Lifetime MDD  
Female 0.998 (1) 0.008 
(0.008) 
0.787 (0.968) 0.982/1.014 
(0.984/1.016) 
0.0000 
(0.0108) 
Male 1.012 
(1.009) 
0.011 
(0.011) 
0.282 (0.411) 0.99/1.034 
(0.987/1.031) 
0.0001 
(0.0084) 
Mood Instability      
Female 0.997 
(0.998) 
0.004 
(0.004) 
0.48 (0.7) 0.989/1.005 
(0.99/1.007) 
0.0000 
(0.0193) 
Male 1.005 
(1.005) 
0.005 
(0.008) 
0.26 (0.27) 0.996/1.014 
(0.996/1.014) 
0.0000 
(0.0151) 
Neuroticism score Coefficient  
Female -0.001 
(0.001) 
0.007 
(0.007) 
0.846 (0.31) -0.015/0.014  
(-0.013/0.016) 
0.0000 
(0.0152) 
Male 0.005 
(0.005) 
0.008 
(0.008) 
0.52 (0.52) -0.01/0.021  
(-0.01/0.02) 
0.0000 
(0.0222) 
Unadjusted  model (adjusted model) 
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3.6 Discussion 
Overall, within the initial preliminary investigation using both cohorts described 
above, there were no significant associations between CACNA1C risk scores and 
the mood disorder-related traits when assessing the samples as a whole. The 
samples were then stratified by sex based on a priori rationale, and there was 
evidence of a small association between the GPRS and risk of BD for females (but 
not for males). 
 Within ALSPAC, higher CACNA1C GPR scores were associated with a lower 
HCL-28 score in females. This finding is in a direction which is opposite to what 
was anticipated from the existing literature and is difficult to account for (Witt 
et al. 2014; Court et al. 2014; Smith et al. 2015; Hayes et al. 2016). It contrasts 
with the finding in UK Biobank that an increasing risk score was associated with 
greater risk of bipolar status in females (O.R 1.199, 95% CI 1.015/1.406). One 
possibility is that this is related to the different age ranges of the ALSPAC and 
UK Biobank cohorts: perhaps CACNA1C variants have a differential impact on 
mood symptoms across the life course, the variants may be protective at one 
stage and deleterious at another as a result of evolutionary pressures 
(“antagonistic pleiotropy”) (Carter & Nguyen 2011). 
It is also possible that CACNA1C may specifically influence the depressive aspect 
of BD because a significant effect on SMFQ scores was seen in females within the 
ALSPAC cohort. In this analysis there seemed to be an increased risk of greater 
SMFQ scores with an increasing CACNA1C GPR score. It may be that CACNA1C has 
a greater influence on the depressive features of BD relative to the 
hypomanic/manic features; however, it is worth noting that it is unclear why 
this would be the case mechanistically, and no significant associations were 
identified in females (or males) for any of the depression outcome measures in 
UK Biobank. The findings within ALSPAC also contradict the hypothesis that 
CACNA1C variants are implicated in the manic phases of BD. Interestingly, one 
study has found that treatment-resistant bipolar patients administered L-VGCC 
antagonists display improvement of manic symptoms, although there was no 
improvement of depressive symptoms (Kabir et al. 2017). 
 It is important to note that by dividing the ALSPAC sample by sex there 
were fewer observations available for testing which may have resulted in the 
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analyses becoming underpowered to detect true effects (type 2 error), or 
contributed to spurious findings (type 1 error).  To detect small effects at 95% 
power would require a sample size of greater than 1,800; when stratifying by sex 
in ALSPAC a sample of less than 1,600 females remained (Faul et al. 2007).  
Nonetheless, some effects were found for females within both cohorts during the 
preliminary analyses, perhaps suggesting that the CACNA1C locus may have a 
potential sex effect in the context of mood disorders, and particularly for BD. 
Previous studies have also identified a potential sex effect of CACNA1C variants 
where variants were more strongly associated with the phenotypes-of-interest in 
females versus males, although these studies tended to focus solely on single 
variants tested separately (Dao et al. 2010; Strohmaier et al. 2013; Heilbronner 
et al. 2015; Starnawska et al. 2016). Overall, the effects seen in both the 
ALSPAC and UK Biobank cohorts might be considered to provide some preliminary 
evidence for a potential differential effect of CACNA1C variants in females. 
 However, it is important to note that these findings were in fact 
contradictory between the two cohorts (effects were in opposite directions) and 
were based on self-reported data. Clearly before any firm conclusions can be 
drawn these findings require replication. Upon release of the remaining UK 
Biobank genetic data and release of MHQ data for over 157,000 participants, 
replication was possible. Using the lifetime mood disorder variables derived from 
the more extensive MHQ, there was no evidence for associations between 
CACNA1C GPRS and mood disorder outcomes to replicate the preliminary 
findings in UK Biobank.  
 It is of note that there currently are no further, up-to-date, mood-related 
traits in ALSPAC to replicate the significant associations between CACNA1C GPRS 
and hypomania, and depressive state in females within ALSPAC. 
 It has been reported that calcium channel antagonists may have some 
benefit in the mood stabilisation of BD (Bidaud & Lory 2011; Erk et al. 2014b), 
and with weak evidence of a potential sex effect of CACNA1C it is theoretically 
possible that female patients may benefit more from the inclusion of calcium 
channel antagonists than male patients. This is of course a speculative 
suggestion that requires much more detailed future investigation. 
 Furthermore, although some significant effects were found in females, 
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the CACNA1C GPRS explained very little of the variance observed within the 
cohorts (maximum r2 of 0.0347, i.e., 3%). 
Despite the lack of evidence for associations between CACNA1C risk score and 
mood disorder-related traits, there are strengths to this investigation. To my 
knowledge, this is the first application of using a GPRS – generated using 
variation in a single BD candidate risk gene – to investigate the potential 
influence of CACNA1C on mood disorder phenotypes.  
This chapter also demonstrates the evaluation of CACNA1C on relevant mood 
phenotypes in larger samples than existing CACNA1C literature. A strength of 
this chapter is the application of these analyses in two separate cohorts of two 
different age groups. 
3.7 Limitations 
In testing the hypotheses in this way there are limitations. One is the use of self-
reported outcome measures for all analyses carried out; the outcome measure 
may be subject to reporting bias (Ganna & Ingelsson 2015). However, the 
measures of BD and recurrent depression within UK Biobank have proved to be 
useful and reasonably consistent with expected associations within previous 
studies (Smith et al. 2013a). Similarly, for the ALSPAC data, the HCL-32 has been 
widely used to define hypomania (Smith et al. 2015) and the SMFQ has been used 
to measure depressive symptoms (Stochl et al. 2015). 
 A limitation of the investigations in ALSPAC is the lack of statistical 
power. There were a much smaller number of observations in ALSPAC relative to 
UK Biobank for the desired mood phenotypes tested. The ALSPAC analyses may 
therefore be underpowered to detect true associations.  
 When stratifying the samples for sex in ALSPAC, there were an uneven 
number of males and females for the analyses, which could have influenced the 
findings as the female sample could have been better powered to detect effects, 
although the adjusted analysis controlled for this to some extent within the main 
analysis in ALSPAC by adjusting for sex. 
 The analyses within ALPSAC are also unadjusted for potential confounding 
factors such as deprivation and require further correction. It is important to 
note, also, that the results displayed above (both from the ALSPAC and UK 
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Biobank cohorts) have not been corrected for multiple testing and as such can 
only be considered preliminary exploratory findings at best (the observed 
observations did not survive false discovery rate (FDR) correction). 
Also of note is that not all of the SNPs-of-interest were independent of each 
other; some of the chosen SNPs are in high LD with each other (rs1006737 is in 
high LD with rs2007044, rs2159100 and rs1024582, rs4765913 is in high LD with 
rs4765914, rs3819532 is high LD with rs3819534, rs2238070 and rs2238071 with 
the two latter SNPs in high LD with each other, rs2238065 is in high LD with 
rs2238066 and rs2283302, and rs11062247 and rs11062248 (Supplemental Figure 
3.1)) (Dudbridge 2016) which could be confounding the effects reported. As to 
be expected, the LD patterns were consistent between the two cohorts.  
Another limitation of this work is the difficulty in drawing comparisons between 
the two cohorts chosen. UK Biobank is a longitudinal cohort of an older sample 
from different areas of the UK, whereas, ALSPAC is a birth cohort with 
individuals currently now in early adulthood, all of whom were from a specific 
area of the UK. In addition to this, the mood phenotypes tested here have been 
recorded differently between the two cohorts, making it difficult to compare 
findings directly. However, one novel and potentially useful strength of this work 
is that it examined different age groups and as such covers a wide age-range of 
adults. 
Clearly, not all individuals who carry these variants go on to develop 
neuropsychiatric disorders (Yoshimizu et al. 2015).  It is also possible that the 
SNPs associated with greater susceptibility to BD are not causative but rather are 
in linkage disequilibrium with the true risk variants (Heyes et al. 2015). 
Furthermore, the risk SNPs may be incompletely penetrant (Yoshimizu et al. 
2015), consistent with the prevailing view that neuropsychiatric disorders are 
complex polygenic conditions influenced by a diverse combination of genetic, 
epigenetic and environmental factors (Yoshimizu et al. 2015). 
Identifying these causal variants would provide greater understanding of the 
underlying pathophysiology of psychiatric conditions. 
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Finally, the findings above cannot explain the underlying molecular mechanisms 
by which variants in the CACNA1C gene may influence mood phenotypes and, 
hence, provide no insight into the underlying biology of mood disorders.  
3.8 Future Work 
As noted above, the analyses in this chapter are to some extent exploratory.  
This investigation focussed on the CACNA1C risk score in the context of mood 
disorders and mood disorder-related phenotypes. As there was some weak 
evidence of the potential influence of CACNA1C GPRS on these phenotypes, it 
may be of interest to investigate the CACNA1C GPRS in the context of other 
traits known to be associated with mood disorders, such as disrupted circadian 
rhythms. Circadian rhythm disruptions are a common feature of BD (Hayashi et 
al. 2015; Steinan et al. 2015) and the CACNA1C gene is known to have a role in 
circadian rhythm physiology (Shi et al. 2008; Schmutz et al. 2015; McCarthy et 
al. 2016).  
3.9 Conclusions 
The exact impact of CACNA1C genetic variants on mood-related phenotypes in 
generally healthy populations is unclear. However, the potential for an 
increasing CACNA1C risk score influencing BD and/or MDD pathophysiology and 
for sex-specific effects (as seen in other studies) cannot be dismissed; further 
study is required in independent large cohorts. 
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3.10 Supplementary Figures 
 
Supplemental Figure 3.1 LD heat map of selected CACNA1C SNPs-of-interest 
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Supplemental Figure 3.2 Histogram of HCL-28 and SMFQ scores 
Blue line on HCL-28 score graph indicates threshold at which individuals could be designated as 
hypomanic, however, three additional questions are required to assign individual as hypomanic 
(detailed in chapter 2). 
Blue line on SMFQ score graph shows threshold for designating individual as a depressive case for 
the primary depression outcome in ALSPAC (score of 16 or greater). 
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Supplemental Figure 3.3 Histogram of HCL-28 and SMFQ scores separated by sex 
Blue line on HCL-28 score graph indicates threshold at which individuals could be designated as 
hypomanic, however, three additional questions are required to assign individual as hypomanic 
(detailed in chapter 2). 
Blue line on SMFQ score graph shows threshold for designating individual as a depressive case for 
the primary depression outcome in ALSPAC (score of 16 or greater). 
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Supplemental Table 3.1 Summary of HCL-28 and SMFQ scores 
ALSPAC Mean Median Min Max N 
HCL score 14.548 15 0 28 2326 
SMFQ score 2.315 1 0 26 4879 
 
Supplemental Table 3.2 Summary of HCL-28 and SMFQ scores separated by sex 
ALSPAC Mean Median Min Max N 
HCL score  
Female 14.315 15 0 28 1476 
Male 14.952 16 0 28 850 
SMFQ score  
Female 2.331 1 0 26 2447 
Male 2.299 1 0 26 2432 
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Chapter 4 Investigating the effect of genetic 
variants for chronotype preference on mood 
disorder and sleep phenotypes in two 
population cohorts 
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Outline 4.1 Chapter in context of overall study 
 
4.1 Introduction 
The CACNA1C gene locus has been shown to have an association with mood 
disorders including BD and MDD (Bigos et al. 2010; Sklar et al. 2011; Smoller 
2013; Heilbronner et al. 2015; Kabir et al. 2017) and there is increasing evidence 
that altered calcium signalling leading to disruption of second messenger 
systems, possibly as a result of variation at this locus, influences the 
pathophysiology of BD (Harrison 2016). 
Analyses in Chapter 3 did not demonstrate a clear association between CACNA1C 
GPRS and mood disorder phenotypes. It is of note that CACNA1C has been 
robustly associated with BD and related traits, with many of these associations 
being replicated; but the underlying mechanism by which CACNA1C variants 
influence the full range of bipolar phenotypes remains unclear.  
 CACNA1C gene expression is known to both be influenced by circadian 
rhythms and this expression in turn influences circadian rhythmicity (Schmutz et 
al. 2015; McCarthy et al. 2016). There is potential that CACNA1C is involved in 
the pathophysiology of BD through altering circadian rhythms. However, the 
exact influence of circadian rhythmicity genetics on mood disorder phenotypes 
in ALSPAC and UK Biobank is unclear. This chapter aims to investigate potential 
associations between mood disorder-related phenotypes and features of 
circadian rhythmicity, in particular chronotype. 
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4.1.1 Circadian rhythmicity in mood disorders  
Mood disorders are often associated with sleep disturbances (Pagani et al. 2016; 
Dmitrzak-Węglarz et al. 2016; Asaad et al. 2016). Sleep-wake cycle 
abnormalities are observed in all phases of BD, as well as between episodes 
(Baek et al. 2016; Pagani et al. 2016). When compared to healthy controls, 
individuals with BD display a variety of sleep problems including longer sleep 
latency, higher sleep fragmentation and greater sleep disturbances (Geoffroy et 
al. 2014). BD patients appear to be susceptible to sleep-wake cycle disturbances 
and tend to easily shift their circadian phase when sleep-wake cycles are 
disrupted or exposed to inappropriate artificial light; this high sensitivity to 
circadian rhythm phase shifts could be a potential marker of bipolarity (Moon et 
al. 2016). Individuals at risk of developing BD also display sleep and circadian 
rhythm irregularities; these abnormalities can be seen before the onset of the 
disorder and may be considered a modifier of disease course (Bellivier et al. 
2015). 
 Several aspects of sleep profiles and circadian rhythms have been 
investigated in the context of mood disorders, including circadian phase 
preference (chronotype), rest and activity measures and melatonin peak time 
via self-report questionnaires, actigraphy and salivary secretions of melatonin 
and cortisol (Bellivier et al. 2015; Baek et al. 2016; Dmitrzak-Węglarz et al. 
2016). BD patients demonstrate greater daytime dysfunction relative to healthy 
controls (Geoffroy et al. 2014). These circadian rhythm abnormalities are 
associated with disrupted brain function, including impaired cognition and 
emotional processing (Wulff et al. 2010), and have also been suggested to lead 
to deterioration in the mental health of otherwise healthy individuals (Landgraf 
et al. 2014). This may be indicative of bidirectional relationship between an 
individual’s circadian rhythm and their mood and overall cognitive functioning 
(Landgraf et al. 2014). The misalignment between endogenous circadian rhythms 
and an individual’s environment is a common feature for individuals with BD and 
has been associated with both acute manic and depressive relapses (Castro et al. 
2015; Moon et al. 2016). 
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4.1.2 Chronotype 
Chronotype, or diurnal preference, is defined as an individual’s preference for 
wakefulness and activity at a particular time of day (Alloy et al. 2017). 
Individuals are usually classified into three broad chronotypes: morning 
(“larks”), evening  (“owls”) and intermediate (a combination of morning and 
evening) (Berdynaj et al. 2016). Chronotype is considered to be a combination of 
genetics, biological processes and psychosocial processes (Etain et al. 2014; 
Dmitrzak-Węglarz et al. 2016). Diurnal preference is a physiological trait with a 
clear biological basis and has been associated with other endogenous phase 
markers including melatonin secretion, cortisol-awakening response and the 
circadian shift in body temperature (Bellivier et al. 2015). Differences in these 
endogenous phase markers have been reported in individuals with different 
chronotype preferences; for example, evening-types demonstrate a phase delay 
in peak body temperature (N=14) and cortisol levels (N=125), and reduced night 
time melatonin peak levels relative to morning-types (N=170) (Randler & Schaal 
2010; Kerkhof & Van Dongen 1996; Burgess & Fogg 2008) and the diurnal peak in 
physiological functions (including core temperature and melatonin levels) occurs 
earlier in morning than in evening-types (Merikanto et al. 2016; Desanctis 2017).  
There is evidence that an individual’s timing preference for daily activities, their 
chronotype, may be associated to greater risk of adverse health conditions: 
evening chronotypes have an increased risk of sleep problems, hypertension and 
type 2 diabetes, compared to individuals with a morning chronotype (Merikanto 
et al. 2013; Merikanto et al. 2016). 
4.1.3 Potential influence of chronotype on mood 
Chronotype has previously been associated with several mood disorder-related 
phenotypes, including anxiety and depression (Corruble et al. 2014; Dmitrzak-
Węglarz et al. 2016). Certain chronotypes may predispose some individuals to 
mood disorders (Merikanto et al. 2013). Evening-types have been seen to 
associate with depressive symptoms in both depressed patients and healthy 
controls; depressed patients were more likely to be evening-types while healthy 
individuals with a late chronotype were found to have higher depression scores 
and had an increased likelihood of presenting moderate or severe depression 
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symptoms (Chan et al. 2014; Berdynaj et al. 2016; Levandovski et al. 2011; 
Hidalgo et al. 2009). A study of depressed patients demonstrated that individuals 
reporting an evening chronotype had higher non-remission rates than those 
reporting a morning chronotype upon follow-up (O.R 3.36, 95%CI 1.35/8.34). It is 
of note, this study is based on a relatively small sample size of 253 patients with 
a high proportion of females (82.6%) (Chan et al. 2014).  
There is increasing evidence to suggest that chronotype has an involvement in 
the pathophysiology of depression as evening chronotypes reportedly display 
similar negative biases in emotional processing often seen in depressed patients 
even in participants with no history of depression (Berdynaj et al. 2016). 
Individuals with BD also more commonly report an evening chronotype 
preference compared to healthy controls (Baek et al. 2016; Alloy et al. 2017); 
plus eveningness has also been associated with rapid mood cycling and earlier 
age of onset in BD (Bellivier et al. 2015).  
4.1.4 Genome wide association studies of chronotype 
Previous GWAS of BD and MDD have identified several clock genes which have 
core functions in maintaining circadian rhythms (Landgraf et al. 2014; 
MacIukiewicz et al. 2014) and some studies have suggested that variation within 
the clock genes are associated with specific BD clinical subtypes (Moon et al. 
2016). Research involving animal models has demonstrated the link between 
circadian clock genes and brain functions associated with psychiatric illness 
through the manipulation of light-dark cycles and gene knockout experiments 
including deletion of PER1, PER2 and CLOCK genes resulting in hyperactivity, 
greater reward-seeking behaviour, depression-like and mania-like behaviour 
(Landgraf et al. 2014). 
At the time of this analysis, three GWAS were undertaken in different sample 
populations to identify variants which associate with an individual’s likelihood of 
reporting a particular chronotype preference (Jones et al. 2016b; Lane et al. 
2016; Hu et al. 2016). Two of the studies used self-reported chronotype of over 
100,000 individuals from UK Biobank (Lane et al. 2016; Jones et al. 2016b), 
whereas the third used self-reported chronotype responses from 89,000 
participants of 23andMe (Hu et al. 2016). Across the three genome-wide studies, 
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a total of 37 independent SNPs were reported to associate with self-reported 
chronotype. One study exclusively used the 23andMe cohort to investigate self-
reported morningness in over 89,000 individuals and found 15 SNPs associated 
with identifying as “a morning person” (Hu et al. 2016); a further 13 SNPs were 
found to associate with self-reported morningness in UK Biobank in 
approximately 128,000 participants and were replicated within the 23andMe 
cohort (Jones et al. 2016b).  
 Self-reported eveningness was also investigated in UK Biobank (100,000 
participants) and identified 11 SNPs (Lane et al. 2016); the alternate alleles of 
two of those SNPs (rs2050122 and rs10157197) were also found to associate with 
self-reported morningness (Jones et al. 2016b). Both Hu et al. and Lane et al. 
treated chronotype as a binary trait, whereas, Jones et al. used a linear 
chronotype measure for their GWAS which could have provided greater 
statistical power to detect variants. 
 Although both Lane et al. and Jones et al. used UK Biobank participants, 
the exclusion criteria between the two studies were different. Jones et al. 
excluded individuals with any reports of diabetes to allow for downstream 
investigations, whereas, Lane et al. excluded shift workers and those on 
medication for sleep problems which could have  potentially confounding effects 
on circadian rhythmicity (Ferguson et al. 2018). 
Each of the studies reported SNP loci which implicate known circadian genes; 
many other pathways were also implicated including, energy metabolism, 
immune response, nucleotide metabolism, gene expression and light detection. 
The self-reported chronotype was also found to genetically correlate with 
schizophrenia in UK Biobank (Lane et al. 2016; Jones et al. 2016b). 
4.2 Rationale 
Approximately 40% of the population have a distinct morning or evening 
chronotype (Alloy et al. 2017); chronotype preference is reported to correlate 
with many endogenous circadian phase markers including measures of rest and 
activity(Duffy et al. 2001; Etain et al. 2014). As noted above, evening 
chronotypes have been linked to increased risk of mood disorders (often 
demonstrated by significantly lower composite scale of morning scores in mood 
disorder patients (p<0.0001) (Alloy et al. 2017; Baek et al. 2016; Wood et al. 
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2009) and several studies have demonstrated BD patients are more likely to be 
evening-types (Etain et al. 2014). Circadian preference is thought to be 
genetically determined (Etain et al. 2014); however, as yet, genetic variants 
associated with chronotype have not been tested for any association to different 
features of mood disorders. An evening chronotype has been hypothesised to be 
a pre-existing factor for BD (Pagani et al. 2016; Alloy et al. 2017).  
 If genetic loading for a particular chronotype associates with features of 
mood disorder, it may help strengthen evidence of this hypothesis and support 
the suggested requirement for the stabilisation of rest-activity rhythms to be 
included in the management of mood disorders. It is often suggested that the 
treatment of disrupted sleep and circadian rhythm disruptions should be 
combined with typical pharmacotherapy to create a better treatment approach 
for BD and depression (Bellivier et al. 2015); a clear clinical assessment of both a 
range of mood and sleep symptoms may be required in order to more effectively 
manage and treat mood disorders (Chan et al. 2014; Geoffroy et al. 2014). 
Manipulation of sleep has been reported to influence mood symptoms (Baek et 
al. 2016) and individuals with depressive symptoms have described some 
improvement of symptoms after chronotherapeutic interventions (Li et al. 2013).  
4.3 Hypothesis to be tested 
The aim of this investigation is to establish whether, on average, higher 
polygenic loading for both morningness and (separately) eveningness were 
associated with specific mood disorder related phenotypes within two population 
cohorts (ALSPAC and UK Biobank). These phenotypes included: hypomania and 
depressive features (within ALSPAC); and mood instability, neuroticism, lifetime 
BD status, lifetime MDD status and lifetime Generalised Anxiety Disorder (GAD) 
status (within the UK Biobank). The key question was whether individuals who 
were more genetically predisposed to a morning chronotype preference were 
less likely to display mood disorder-related phenotypes? Conversely, were 
individuals with a greater polygenic loading for an evening chronotype 
preference more likely to display these mood phenotypes? 
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4.4 Methods 
4.4.1 ALSPAC 
Participants of ALSPAC who were genotyped were only included in the ALSPAC 
genotype database after meeting particular quality control criteria. Details of 
quality control measures, imputation and phasing described in Chapter 2. Only 
unrelated individuals were included in these analyses in an attempt to prevent 
shared environmental factors influencing associations (Dudbridge 2016); a list of 
unrelated individuals (N=8,197; 96% of the genotyped sample) was provided by 
ALSPAC. Individuals that were not recorded as Caucasian, or those with missing 
ethnic background data (N=1,112; 13.08%), were also removed from analyses 
leaving N=7,390. 
4.4.1.1 Sleep phenotypes 
There is no measure of chronotype within ALSPAC and so the PRS were tested 
against two measures of sleep problems reported at two different ages (age 10 
and age 13). This resulted in four sleep-related variables; these variables were 
generated from mother-answered questionnaires regarding child sleep habits. 
These phenotypes are detailed in Chapter 2.  
As a proxy for disrupted circadian rhythm (and due to the lack of chronotype 
data in ALSPAC), the primary outcome measures for sleep in ALSPAC were the 
categorical variables “Difficulty sleeping-10” and “Difficulty sleeping-13” which 
were tested for their association to chronotype PRS using logistic regression. It is 
of note that due to the small numbers of observations available for individuals 
with both mood outcome and sleep phenotype data for use in phenotypic 
association analysis (Supplemental Table 4.1) individuals that were not of white 
European ancestry were included in this phenotypic analysis. 
4.4.1.2 Hypomania 
To test associations between chronotype PRS and features of BD in ALSPAC 
categorical and continuous measures of hypomania were used. The full details of 
how these measures are generated using HCL-28 can be found in Chapter 2. The 
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categorical definition of hypomania was the primary outcome measure and the 
continuous HCL-28 score was a secondary outcome. 
4.4.1.3 Depressive features 
Depressive symptoms were assessed in the ALSPAC cohort during late childhood 
and adolescence using the SMFQ. This generates an SMFQ score ranging from 0 to 
26 (Wiles et al. 2012), as well as a categorical depression measure based on a 
score of greater than 16. As for hypomania, the categorical SMFQ measure was 
used as the primary outcome measure and the SMFQ score was the secondary 
outcome. Detailed in Chapter 2. 
The primary outcome measures of categorical hypomania and categorical 
depression were tested for association with the chronotype PRS using logistic 
regression assuming an additive risk allelic effect model. The dimensional 
secondary outcome measures (HCL-28 score and SMFQ score) were analysed 
using linear regression. 
4.4.2 UK Biobank cohort 
4.4.2.1 Chronotype phenotype 
Chronotype was derived from the participants’ responses to a question obtained 
from the Morningness-Eveningness questionnaire (Taillard et al. 2003). This 
question is an accepted measure of chronotype and has been reported to explain 
the greatest variance in preference of sleep-wake timings (Taillard et al. 2003). 
Categorical variables were then generated based upon the responses given, 
resulting in the generation of four separate chronotype variables. The primary 
outcome measures used for analysis were the “definite morning” and “definite 
evening” variables with “overall morning” and “overall evening” providing 
secondary outcome measures. The method by which these variables were 
generated is detailed in Chapter 2.   
4.4.2.2 Bipolar Disorder, Depression and Generalised Anxiety Disorder  
A MHQ was developed by a mental health research reference group to collect 
additional mental health phenotype data in UK Biobank and was administered 
during 2016-2017. Lifetime BD, lifetime MDD and lifetime GAD variables were 
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generated for 157,366 UK Biobank participants. Further detail for these variables 
contained in Chapter 2. 
4.4.2.3 Neuroticism 
To define neuroticism a score taken from the 12 item neuroticism scale of the 
EPQ-R-S (Smith et al. 2013a). Individuals were given a score of 0 or 1 for a “no or 
yes” answer, respectively, for each item and given a total neuroticism score 
ranging from 0 to 12. As described in Chapter 2. 
4.4.2.4 Mood instability 
A “mood instability” outcome measure was also obtained from the EPQ-R-S 
questionnaire: participants were asked “Does your mood often go up and down?” 
and given the option to answer “yes”, “no”, “don’t know” or “prefer not to 
answer”. Individuals who selected “don’t know” or “prefer not to answer” were 
coded as missing; this allowed the generation of a categorical mood instability 
variable where those who answered “yes” were designated as cases and 
participants who answered “no” were included as controls. As detailed in 
Chapter 2. 
4.4.2.5 Association analyses 
Most of the association analysis carried out used logistic regression assuming an 
additive allelic effect model (the association analysis using neuroticism score 
used a linear regression). The adjusted analysis included age, sex, 
socioeconomic status (assessed using the Townsend deprivation score), 8 UK 
Biobank genetic principal components, assessment centre and batch as 
covariates. Chronotype preference has been reported to associate with gender 
(Hu et al. 2016) and differences in self-reported chronotype can be seen in the 
sample of the UK Biobank cohort used in these analyses. The association analyses 
were also performed separately for males and females, both unadjusted and 
adjusted, with age, deprivation index, 8 UK Biobank genetic principal 
components, assessment centre and batch included as covariates (Ward et al. 
2017).  
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4.4.2.6 Generating polygenic risk scores 
Weighted PRS were generated for all individuals with genotype data available in 
ALSPAC and UK Biobank using Plink 1.9 (Purcell et al. 2007). To provide 
weighting for the SNPs the log of the odds ratios provided by the chronotype 
GWAS literature were used (15 SNPs from Hu et al., 14 SNPs from Jones et al. 
and 9 SNPs Lane et al.) (Hu et al. 2016; Jones et al. 2016b; Lane et al. 2016). 
PRS methodology is detailed in Chapter 2. Two separate polygenic risk scores 
were generated for each individual; one composed of the genome-wide 
significant SNPs associated with being a “morning person” compared to being an 
“evening person” and a second composed of the genome-wide significant 
variants associated with being an “evening person” compared to being a 
“morning person”. 
 Of the 27 SNPs reported to associate with self-reported morningness by 
two of the GWAS papers, only 25 SNPs were included for analyses as some SNPs 
were not genotyped within ALSPAC or UK Biobank. For previous investigations 
only observations for individuals genotyped at all SNPs-of-interest were used for 
testing, however, as there were approximately only 2500 individuals in ALSPAC 
genotyped for these SNPs-of-interest who also have hypomania data, only 
individuals missing more than 3 of the SNPs-of-interest were excluded. For the 
evening PRS, 11 SNPs were investigated but not all SNPs were found to be 
genotyped in ALSPAC and UK Biobank. In ALSPAC, only 9 SNPs associated with 
self-reported eveningness had been genotyped and only individuals missing 2 or 
more SNPs were excluded. 
 As UK Biobank was used as the initial discovery sample, individuals 
included in the chronotype GWAS were removed from further analyses. Only 
individuals genotyped for all 25 SNPs-of-interest and the 10 eveningness SNPs 
genotyped in UK Biobank were included for the association analyses using the 
morningness PRS and eveningness PRS, respectively.  
 Statistical analyses used are detailed in Chapter 2. Changes in the 
weighted PRS scores are small due to the use of the log of O.R; to provide a 
more comprehensive interpretation of the analyses, the weighted scores were 
standardised to their z values (i.e. per SD). The standard nominal p value 
significance cut-off value of p<0.05 was used for all analyses. 
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4.4.3 Two-Sample Mendelian Randomisation (MR) 
Genetic instruments were selected for morningness and depression using two 
non-overlapping samples were obtained from the summary statistics of Jones et 
al. (2016), PLoS Genetics (Jones et al. 2016b), and Wray et al. (2018), Nature 
Genetics (Wray et al. 2018). Overlapping SNPs between genome-wide significant 
SNPs associated with MDD in Psychiatric Genomics Consortium (PGC) (excluding 
UK Biobank and 23andMe) and all SNPs associated with morningness in UK 
Biobank were identified and tested for overall genetic effect on morningness.  
Overlapping SNPs between genome-wide significant SNPs associated with 
morningess and all SNPs associated with MDD were identified and tested for 
overall genetic effect on MDD. Overall genetic effects were obtained via meta-
analysis of SNP WR, with causal relationships investigated using MREgger and 
IVW. MREgger controls for potential pleiotropy, however, is a more conservative 
method than IVW (Bowden et al. 2016). 
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4.5 Results 
Table 4.1 Demographics of cohorts 
 ALSPAC 
N total = 8,197 
UK Biobank 
N total = 119,953 
Sex  
Female, N (%) 3,525 (48.8) 63,088 (52.6) 
Age  
Mean (SD) 24.497 (0.5) 56.867 (7.93) 
Deprivation (Townsend score)  
Mean (SD) 2.831 (1.33) -1.466 (2.99) 
Range 3 -2.278 
 
As demonstrated in a previous chapter, the two population cohorts capture 
participants of different age groups and so it is unlikely that there is any overlap 
between the samples. The deprivation data in ALSPAC was obtained from the 
maternal socioeconomic status and Townsend score was used in UK Biobank. 
4.5.1 ALSPAC cohort 
The two PRS contain SNPs which were identified to have an association with self-
reported chronotype in UK Biobank; however, it is unclear as to whether these 
SNPs are also associated with sleep phenotypes in ALSPAC. Analyses were carried 
out to explore the potential association between the chronotype risk scores and 
available sleep variables in ALSPAC (Table 4.2). 
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Table 4.2 Logistic regressions of sleep outcome measures and chronotype polygenic risk 
scores 
Phenotype  O.R S.E p value 95% CI r2 
Morningness PRS      
Difficult sleeping-
10 
0.955 
(0.954) 
0.069 
(0.069) 
0.521 
(0.513) 
0.828/1.1 
(0.827/1.099) 
0.000 
(0.004) 
Difficult sleeping-
13 
0.926 
(0.929) 
0.069 
(0.068) 
0.298 
(0.316) 
0.802/1.07 
(0.804/1.073) 
0.001 
(0.003) 
Eveningness PRS      
Difficult sleeping-
10 
1.074 
(1.074) 
0.074 
(0.074) 
0.302 
(0.299) 
0.938/1.229 
(0.938/1.23) 
0.001 
(0.002) 
Difficult sleeping-
13 
0.916 
(0.91) 
0.063 
(0.063) 
0.201 
(0.171) 
0.801/1.048 
(0.796/1.041) 
0.002 
(0.005) 
Unadjusted model (adjusted model) 
 
There were no significant associations when testing the morningness and 
eveningness PRS against several measures of sleep problems during childhood 
(Difficult sleeping-10, assessed age 10) and adolescence in ALSPAC (Difficult 
sleeping-13, assessed age 13) (Table 4.2).  
Disturbed sleep is often associated with mood disorders; however, the 
association between sleep phenotypes and mood-disorder related phenotypes in 
ALPSAC has not yet been investigated. For the depression outcome (age 10-19), 
the categorical sleep phenotypes tested appeared to be significantly associated 
with increased depression risk (Table 4.3). There appears to be no significant 
associations between the primary sleep phenotypes and categorical hypomania 
(age 22-23).  
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Table 4.3 Logistic regressions of sleep measures and primary mood outcome measures in 
ALSPAC 
Phenotype  O.R S.E p value 95% CI r2 
Categorical 
hypomania 
     
Difficult sleeping-10 1.124 
(1.114) 
0.478 
(0.475) 
0.783 
(0.801) 
0.488/2.587 
(0.483/2.569) 
<0.001 
(0.003) 
Difficult sleeping-13 0.682 
(0.336) 
0.252 
(0.294) 
0.3 
(0.212) 
0.33/1.407 
(0.061/1.863) 
0.002 
(0.042) 
Categorical 
depression 
     
Difficult sleeping-10 5.461 
(5.698) 
3.546 
(3.71) 
0.009 
(0.008) 
1.529/19.499 
(1.59/20.416) 
0.008 
(0.01) 
Difficult sleeping-13 13.284 
(13.462) 
14.037 
(14.242) 
0.014 
(0.014) 
1.675/105.377 
(1.692/107.067) 
0.01 
(0.012) 
Unadjusted model (adjusted model) 
 
Logistic regressions were carried out to test for association between an 
increasing chronotype PRS and a designation of “hypomania”. Similar regressions 
were carried out to test for association between chronotype PRS and an 
individual’s depression status. The regressions revealed no significant association 
(at p<0.05) between increased morningness PRS and the primary mood 
phenotype outcome measures (Table 4.4). However, an increasing eveningness 
PRS was found to be associated with a decreased risk of hypomania and this 
remained significant after adjustment for age and sex (Table 4.4). There 
appeared to be no significant association between depression and eveningness 
PRS (Table 4.4).  
  
Chapter 4  79 
Table 4.4 Regressions of primary mood outcome measures and chronotype PRS in ALSPAC 
Phenotype  O.R S.E p value 95% CI r2 
Morningness PRS 
Categorical 
hypomania 
1.10 
(1.113) 
0.091 
(0.092) 
0.234 
(0.196) 
0.939/1.296 
(0.946/1.309) 
0.001 
(0.005) 
Categorical 
depression 
0.982 
(0.99) 
0.194 
(0.195) 
0.925 
(0.959) 
0.666/1.447 
(0.672/1.458) 
0.000 
(0.012) 
Eveningness PRS 
Categorical 
hypomania 
0.842 
(0.839) 
0.066 
(0.066) 
0.029 
(0.027) 
0.721/0.982 
(0.718/0.98) 
0.004 
(0.009) 
Categorical 
depression 
0.869 
(0.871) 
0.157 
(0.159) 
0.439 
(0.449) 
0.61/1.239 
(0.609/1.245) 
0.002 
(0.014) 
Unadjusted model (adjusted model) 
 
Linear regressions were also carried out on the secondary outcome measures; 
this was used to investigate the association between the chronotype risk scores 
and continuous hypomanic and depressive scores obtained from the HCL-32 and 
SMFQ questionnaires, respectively. There were no significant associations with 
the chronotype PRS identified using either of the mood phenotype outcome 
measures (Supplemental Table 4.2). 
Chronotype preference has been reported to associate with sex; with 
morningness shown to be more prevalent in females (Hu et al. 2016); the 
potential association between the chronotype PRS and mood phenotypes was, 
therefore, investigated splitting the sample by sex (Table 4.5). 
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Table 4.5 Regressions of primary mood outcome measures and chronotype PRS in ALSPAC 
split by sex 
Female O.R S.E p value 95% CI r2 
Morningness PRS 
Categorical 
hypomania 
1.101 
(1.101) 
0.118 
(0.118) 
0.369 
(0.369) 
0.893/1.359 
(0.892/1.359) 
0.001 
(0.001) 
Categorical 
depression 
0.918 
(0.915) 
0.309 
(0.31) 
0.8 
(0.793) 
0.475/1.776 
(0.47/1.779) 
0.001 
(0.009) 
Eveningness PRS 
Categorical 
hypomania 
0.928 
(0.923) 
0.092 
(0.092) 
0.448 
(0.421) 
0.764/1.126 
(0.76/1.122) 
0.001 
(0.003) 
Categorical 
depression 
0.957 
(0.96) 
0.255 
(0.261) 
0.868 
(0.88) 
0.567/1.615 
(0.563/1.636) 
0.000 
(0.015) 
 
Male O.R S.E p value 95% CI r2 
Morningness PRS 
Categorical 
hypomania 
1.13 
(1.131) 
0.147 
(0.147) 
0.348 
(0.344) 
0.875/1.458 
(0.877/1.46) 
0.002 
(0.002) 
Categorical 
depression 
1.024 
(1.036) 
0.25 
(0.256) 
0.921 
(0.886) 
0.635/1.651 
(0.639/1.68) 
0.000 
(0.04) 
Eveningness PRS 
Categorical 
hypomania 
0.857 
(0.852) 
0.093 
(0.094) 
0.157 
(0.145) 
0.692/1.061 
(0.687/1.057) 
0.003 
(0.007) 
Categorical 
depression 
0.857 
(0.857) 
0.193 
(0.197) 
0.493 
(0.504) 
0.551/1.333 
(0.547/1.345) 
0.002 
(0.033) 
Unadjusted model (adjusted model) 
 
There were no significant associations between morningness or eveningness PRS 
and the primary mood phenotypes in males or females (Table 4.5). Using the 
continuous hypomania and depression scores as a secondary analysis, a nominally 
significant association was found between greater polygenic loading for 
morningness and greater hypomania score (coefficient 0.309 (standardized),  
p 0.049, Supplemental Table 4.3) which is the reverse of what would be 
expected. No significant associations were identified in males. 
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4.5.2 UK Biobank cohort 
As mentioned previously, over 100,000 participants from the UK Biobank were 
included in the self-report chronotype GWA studies. The individuals included in 
these studies were removed before any analysis using the morningness PRS; this 
resulted in approximately 330,000 observations available for use in further 
analysis (Table 4.6). 
 
 Table 4.6 Summary of mood phenotypes in UK Biobank (N=157,366) 
UK Biobank Cases Controls  
Lifetime BD, N (%) 1,366 (1.43) 94,234 (98.57) 
Lifetime MDD, N (%) 22,671 (28.07) 58,108 (71.93) 
Lifetime GAD, N(%) 6,722 (10.15) 59,473 (89.85) 
Neuroticism, N (%)  121,919 (51.16) 116,380 (48.84) 
Mood Instability, N (%) 129,267 (45.07) 157,524 (54.93) 
 
Within the UK Biobank, individuals who reported a morning chronotype were 
found to have decreased risk of mood disorder-related phenotypes. Whereas, 
self-reported evening chronotype was associated with increased risk of all mood 
disorder phenotypes (Table 4.7). There is clearly a significant association 
between chronotype and mood disorder-related phenotypes in UK Biobank, 
however, it is unclear as to whether this association has a genetic underpinning. 
The derivation of chronotype risk scores can be used to investigate this 
association in the UK Biobank participants not included in the original GWAS 
investigation.  
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Table 4.7 Logistic regressions of mood phenotypes and self-reported chronotype 
Phenotype  O.R S.E p value 95% CI r2 
Morning chronotype (vs. evening)  
Lifetime BD 0.742 0.065 6.6x10-4 0.625/0.881 0.023 
Lifetime MDD 0.63 0.019 1.6x10-54 0.594/0.667 0.046 
Lifetime GAD 0.649 0.03 2.3x10-21 0.594/0.71 0.037 
Mood Instability 0.739 0.011 3.2x10-95 0.718/0.761 0.018 
 Coefficient 
Neuroticism -0.709 0.023 6x10-207 -0.754/-0.664 0.04 
Evening chronotype (vs. morning) 
Lifetime BD 1.348 0.118 6.6x10-4 1.135/1.6 0.023 
Lifetime MDD 1.588 0.047 1.6x10-54 1.498/1.684 0.046 
Lifetime GAD 1.54 0.07 2.3x10-21 1.408/1.683 0.037 
Mood Instability 1.353 0.02 3.2x10-95 1.315/1.392 0.018 
 Coefficient 
Neuroticism 0.709 0.023 6x10-207 0.664/0.754 0.04 
Adjusted model 
 
There was a clear phenotypic association between self-reported chronotype 
preference and mood disorder-related phenotypes.  
 Before testing the chronotype PRS for associations to mood phenotypes, 
regressions – adjusted for age, sex and deprivation – were used to investigate the 
potential association between the chrontype PRS and self-reported chronotype 
preference. Many of the SNPs incorporated in the chronotype PRS were 
discovered by investigating self-chronotype in the UK Biobank sample. Here, the 
chronotype PRS were tested against the self-reported chronotypes of the 
remaining Biobank cohort – after removal of those involved in the GWA studies – 
to ensure these SNPs do indeed associate with self-reported chronotype 
preference. 
The morningness PRS was found to be associated with self-reported morningness; 
both greater definite morningness and overall morningness were significantly 
associated with an increased PRS (Table 4.8). The morningness PRS was also 
found to negatively associate with self-reported eveningness (Supplemental 
Table 4.4). The eveningness PRS appears to be positively associated with self-
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reported eveningness significantly, however, the effect size is relatively small 
(O.R 1.069) (Table 4.8). 
Table 4.8 Logistic regressions of self-reported chronotype and polygenic risk scores 
Phenotype  O.R S.E p value 95% CI r2 
Morningness PRS 
Definite 
morningness 
1.162 0.009 3.8x10-79 1.144/1.180 0.02 
Overall 
morningness 
1.10 0.005 2x10-117 1.091/1.109 0.008 
Eveningness PRS 
Definite 
eveningness 
1.078 0.009 4.4x10-21 1.061/1.095 0.018 
Overall 
eveningness 
1.049 0.004 5.5x10-31 1.04/1.057 0.007 
Adjusted model 
 
The risk scores were then used to investigate the association between genetic 
loading for chronotype and mood-disorder related phenotypes. Regressions were 
carried out to test the morningness and eveningness PRS for associations to 
lifetime BD, lifetime MDD, lifetime GAD, neuroticism and mood instability. The 
logistic regressions were also adjusted for age, sex and townsend score. 
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Table 4.9 Logistic regressions of mood phenotypes and chronotype PRS 
Phenotype  O.R S.E p value 95% CI r2 
Morningness PRS 
Lifetime BD 0.947 
(0.946) 
0.031 
(0.032) 
0.102 
(0.097) 
0.887/1.011 
(0.886/1.01) 
0.000 
(0.018) 
Lifetime MDD 0.988 
(0.988) 
0.009 
(0.01) 
0.218 
(0.2) 
0.97/1.007 
(0.949/1.007) 
0.000 
(0.043) 
Lifetime GAD 0.984 
(0.985) 
0.015 
(0.015) 
0.287 
(0.325) 
0.954/1.014 
(0.955/1.015) 
0.000 
(0.031) 
Mood 
Instability 
0.997 
(0.998) 
0.004 
(0.005) 
0.504 
(0.68) 
0.988/1.006 
(0.989/1.007) 
0.000 
(0.017) 
 Coefficient 
Neuroticism -0.007 
(-0.001) 
0.006 
(0.007) 
0.273 
(0.859) 
-0.019/0.005 
(-0.014/0.012) 
0.000 
(0.038) 
Eveningness PRS 
Lifetime BD 1.069 
(1.069) 
0.03 
(0.03) 
0.019 
(0.02) 
1.011/1.13 
(1.011/1.13) 
0.000 
(0.016) 
Lifetime MDD 1.000 
(0.999) 
0.008 
(0.008) 
0.987 
(0.943) 
0.985/1.016 
(0.983/1.016) 
0.000 
(0.044) 
Lifetime GAD 0.983 
(0.982) 
0.013 
(0.013) 
0.182 
(0.159) 
0.958/1.008 
(0.957/1.007) 
0.000 
(0.033) 
Mood 
Instability 
1.000 
(1.00) 
0.004 
(0.004) 
0.938 
(0.979) 
0.993/1.008 
(0.992/1.007) 
0.000 
(0.016) 
 Coefficient 
Neuroticism -0.003 
(-0.003) 
0.006 
(0.006) 
0.598 
(0.671) 
-0.016/0.009 
(-0.016/0.01) 
0.000 
(0.38) 
Unadjusted model (adjusted model) 
 
The morningness PRS showed no significant association with the mood 
phenotypes tested (p>0.05), however, the eveningness PRS was found to be 
significantly associated with an increased risk of lifetime BD both with and 
without adjustment (O.R 1.069, p 0.019). It is of note that a relatively small 
effect size is seen, therefore, the increase in risk is relatively low (Table 4.9).  
As mentioned previously, associations have been found between chronotype 
preference and sex, with slight differences in self-reported chronotype also seen 
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in the sample of the UK Biobank cohort used in these analyses (56% females 
report a definite morning chronotype). As with the analyses done in ALSPAC, the 
relationship between chronotype PRS and mood phenotypes was investigated 
separately in females and males due to a priori rationale. 
Table 4.10 Logistic regressions of mood phenotypes and chronotype PRS separated by sex 
Female  O.R S.E p value 95% CI r2 
Morningness PRS 
Lifetime BD 0.965 
(0.961) 
0.044 
(0.044) 
0.428 
(0.386) 
0.882/1.054 
(0.879) 
0.000 
(0.016) 
Lifetime MDD 0.984 
(0.981) 
0.012 
(0.012) 
0.166 
(0.116) 
0.961/1.007 
(0.958/1.005) 
0.000 
(0.018) 
Lifetime GAD 0.98 
(0.979 
0.019 
(0.019) 
0.294 
(0.273) 
0.943/1.018 
(0.942/1.017) 
0.000 
(0.018) 
Mood 
Instability 
1.00 
(0.993) 
0.004 
(0.005) 
0.848 
(0.157) 
0.992/1.01 
(0.983/1.003) 
0.000 
(0.018) 
 Coefficient 
Neuroticism -0.018 
(-0.012) 
0.009 
(0.009) 
0.035 
(0.177) 
-0.035/-0.001 
(-0.03/0.006) 
0.000 
(0.013) 
Eveningness PRS 
Lifetime BD 1.086 
(1.087) 
0.042 
(0.042) 
0.034 
(0.031) 
1.006/1.172 
(1.008/1.174) 
0.000 
(0.015) 
Lifetime MDD 0.997 
(0.997) 
0.01 
(0.01) 
0.766 
(0.752) 
0.977/1.017 
(0.958/1.017) 
0.000 
(0.019) 
Lifetime GAD 0.975 
(0.974) 
0.016 
(0.016) 
0.118 
(0.105) 
0.945/1.006 
(0.944/1.005) 
0.000 
(0.02) 
Mood 
Instability 
1.009 
(1.005) 
0.005 
(0.005) 
0.065 
(0.326) 
0.999/1.018 
(0.995/1.015) 
0.000 
(0.018) 
 Coefficient 
Neuroticism 0.014 
(0.012) 
0.008 
(0.009) 
0.109 
(0.19) 
-0.003/0.03 
(-0.006/0.029) 
0.000 
(0.013) 
Unadjusted model (adjusted model) 
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Male O.R S.E p value 95% CI r2 
Morningness PRS 
Lifetime BD 0.928 
(0.929) 
0.045 
(0.0450 
0.122 
(0.133) 
0.843/1.02 
(0.844/1.023) 
0.001 
(0.019) 
Lifetime MDD 0.999 
(1.00) 
0.016 
(0.016) 
0.947 
(0.988) 
0.968/1.031 
(0.968/1.032) 
0.000 
(0.026) 
Lifetime GAD 0.992 
(0.996) 
0.026 
(0.026) 
0.748 
(0.882) 
0.942/1.044 
(0.946/1.049) 
0.000 
(0.021) 
Mood 
Instability 
1.001 
(0.995) 
0.005 
(0.006) 
0.78 
(0.344) 
0.991/1.012 
(0.984/1.006) 
0.000 
(0.013) 
 Coefficient 
Neuroticism 0.009 
(0.012) 
0.009 
(0.01) 
0.328 
(0.217) 
-0.009/0.027 
(-0.007/0.031) 
0.000 
(0.02) 
Eveningness PRS 
Lifetime BD 1.049 
(1.047) 
0.044 
(0.044) 
0.253 
(0.267) 
0.967/1.138 
(0.965/1.136) 
0.000 
(0.017) 
Lifetime MDD 1.005 
(1.004) 
0.014 
(0.014) 
0.722 
(0.76) 
0.978/1.032 
(0.977/1.032) 
0.000 
(0.025) 
Lifetime GAD 0.998 
(0.996) 
0.022 
(0.023) 
0.927 
(0.873) 
0.955/1.043 
(0.953/1.041) 
0.000 
(0.022) 
Mood 
Instability 
0.995 
(0.993) 
0.005 
(0.006) 
0.351 
(0.227) 
0.985/1.005 
(0.982/1.004) 
0.000 
(0.013) 
 Coefficient 
Neuroticism -0.02 
(-0.02) 
0.009 
(0.01) 
0.029 
(0.037) 
-0.038/-0.002 
(-0.038/-0.001) 
0.000 
(0.019) 
Unadjusted model (adjusted model) 
 
When investigating chronotype PRS and mood phenotypes in males there 
appeared to be no significant associations found with the exception of 
neuroticism score. Contrary to the phenotypic associations, greater polygenic 
loading for eveningness was associated with lower neuroticism score in males. 
In females, eveningness PRS was found to be significantly associated with an 
increased risk of lifetime BD and this finding remained significant after 
adjustment. As with the significant association between eveningness PRS and BD 
seen in the whole sample, the effect size seen in females was relatively small 
(namely O.R 0.96-1.09) (Table 4.10). An association was also found between 
Chapter 4  87 
morningness PRS and lower neuroticism score in females, however, this 
association did not remain significant after adjustment for confounders. 
 As there appear to be differences in the PRS findings in males and 
females, the analyses were repeated to establish whether there was an 
interaction between sex and chronotype PRS. When testing for an interaction 
between sex and both the morningness and eveningness PRS, there appeared to 
be no significant associations with BD, MDD, GAD or mood instability. However, 
there was a significant association with decreased neuroticism score when 
investigating the interaction between sex and eveningness PRS  
(coefficient -0.032, p 0.016, Supplemental Table 4.5) which lines up with the 
finding of decreased neuroticism score and evening PRS in males. 
 As the primary sex stratified analyses in ALSPAC showed no significant 
results, and was likely to be underpowered, an interaction test was also likely to 
be underpowered and was not undertaken in ALSPAC. 
4.5.3 Morningness and Depression MR 
Table 4.11 Two sample Mendelian Randomisation 
Two sample MR MREgger/ 
IVW Beta 
MREgger/
IVW S.E 
p value 95% CI igx2 
Depression on morningness  
Slope -0.24 0.029 7.31x10-10 -0.3/-0.18 0.969 
Intercept 0.002 0.001 0.31 -0.001/0.005 0.969 
Morningness on depression  
Slope 0.031 0.013 0.024 0.06/2.27 0.966 
Intercept -0.002 0.0003 2.14x10-8 -0.003/-0.001 0.966 
 
To investigate potential causal relationships between morningness and 
depression, a two sample MR was performed. As relationships between circadian 
rhythms and mood disorders have been hypothesised to be bidirectional (Hidalgo 
et al. 2009), MR was used to test the influence of depression on morningness and 
the effect of morningness on depression (Table 4.11).  There was evidence of 
depression conferring a significantly lower propensity for morningness  
(IVW beta 0.24, IVW p 7.31x10-10). However, when investigating the influence of 
morningness on depression there was evidence of morningness increasing the risk 
of depression (IVW beta 0.03, IVW p 0.024) which is contradictory to the 
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phenotypic analyses above (Table 4.7) and findings from other studies which 
report morningness conferring a reduced risk of depression (Jones et al. 2019). It 
is of note that due to the significant intercept (p 2.14x10-8) this finding may be 
due to pleiotropy in this direction. There may also be bias introduced here by 
weak instruments, the overall genetic effect of morningness on depression using 
meta-analysis of SNP WR was not significant (p 0.71, Supplemental Table 4.6) 
suggesting weak instruments bias in this analysis. 
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4.6 Discussion 
An evening chronotype has been suggested as a pre-existing risk factor for BD 
(Alloy et al. 2017); therefore, it seems logical to hypothesise that polygenic 
loading for morningness may be protective against mood disorders. The aim of 
this study was to investigate potential associations between an individual’s 
chronotype PR scores and mood disorder-related phenotypes within ALSPAC and 
UK Biobank.  
 Within ALSPAC, the chronotype PRS were not associated with sleep 
phenotypes. It is important to note that these associations were tested with 
relatively small sample sizes (N=978) and were likely underpowered to detect 
small effects (Supplemental Table 4.1). The sleep phenotypes tested in ALSPAC 
were associated with the categorical measure of depression with relatively large 
effect sizes; however, the effect sizes seen for the associations between sleep 
phenotypes and mood were relatively small and did not meet nominal statistical 
significance.   
When investigating the association between chronotype PRS and mood the only 
significant finding was the negative association between eveningness PRS and 
binary hypomania (as PRS increased; risk of hypomania decreased). This effect is 
in the opposite direction as to what was expected and as to what was found in 
UK Biobank. This raises the possibility that an increasing eveningness PRS is 
protective against hypomania in adolescence and early adulthood; although, as 
the regressions were potentially underpowered to detect small effects, no 
definitive conclusions can be drawn on this point. 
 In the UK Biobank, the chronotype PRS were significantly associated with 
self-reported chronotype preference; increasing morningness PRS was positively 
associated with morning preference and negatively associated with evening 
preference. The opposite was true for an increasing eveningness PRS (in the 
expected direction).  
Overall, chronotype preference was also significantly associated with all of the 
mood phenotypes of interest; as expected being a “morning person” decreased 
the risk of several mood phenotypes, whereas, being an “evening person” was 
associated with an increased risk of all mood disorder phenotypes. As the 
genetic loading for chronotype was significantly associated with self-reported 
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chronotype preference and the chronotype preference was significantly 
associated with mood disorder phenotypes, there was the potential that the 
chronotype PRS was also associated with these mood phenotypes. However, 
there appeared to be no association to these mood phenotypes when 
investigating the morningness PRS. An increasing eveningness PRS was however 
found to be associated with a small but significant increase in the risk of lifetime 
BD in the UK Biobank sample. 
 Investigating the association between chronotype PRS and mood in 
ALSPAC showed only a significant finding was the negative association between 
eveningness PRS and binary hypomania. This effect is in the opposite direction as 
to what was expected and as to what was found in UK Biobank. This raises the 
intriguing possibility that an increasing eveningness PRS is protective against 
hypomania in adolescence and early adulthood; although, as the regressions 
were underpowered to detect small effects, no definitive conclusions can be 
drawn on this point. 
Upon stratifying this sample by sex, this association between eveningness PRS 
and lifetime BD was seen in females did not reach statistical significance in 
males. The genetic loading for evening preference appears to influence the risk 
of BD and has an effect in females and not males, however, the effect sizes seen 
are small and eveningness PRS seems to have a relatively small effect on the risk 
of BD. The variants associated with eveningness may have some small direct or 
indirect influence on the pathophysiology of BD. When investigated this in 
ALSPAC, a reverse association was seen in females: greater morningness PRS was 
associated with greater hypomania score in females. Again, there is potential 
that chronotype PRS has different effects throughout an individual’s life course. 
Also, as eveningness PRS appears to be protective against neuroticism in males 
and there is evidence of an interaction between sex and eveningness PRS; this 
further suggests a relationship between sex and the underlying genetics of 
chronotype preference. However, these findings are preliminary and in need of 
replication. 
It is still difficult to determine causality; however, there does appear to be a 
significant causal link between chronotype and mood disorders (in this case, 
specifically morningness and depression). Due to the conflicting evidence 
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between the findings of the above MR and recent studies of morningness and 
mood disorders the direction of causality is unclear (Jones et al. 2019). 
4.7 Limitations 
In testing the above hypotheses there are several limitations.  
1. The use of self-reported outcome measures for all analyses carried out; 
the outcome measure may be subject to reporting bias. However, the 
measures of HCL-32 to investigate hypomania (Smith et al. 2015) and the 
SMFQ to measure depressive symptoms (Stochl et al. 2015) in ALSPAC have 
been implemented in previous studies.  The use of the lifetime mood 
disorder variables derived from the MHQ in UK Biobank should reduce this 
self-report bias. 
2. A limitation of the investigations in ALSPAC is a lack of statistical power. 
There were a smaller number of observations in ALSPAC relative to UK 
Biobank for the desired mood and sleep phenotypes. Particularly in the 
case of the sleep phenotype data available in ALSPAC there was a very 
small sample available for analysis. 
3. The UK Biobank sample may also be underpowered to detect small effects 
as individuals with psychiatric and mood disorders appear to be 
underrepresented in this cohort (Fry et al. 2017). 
4. There are also limitations to the MR analysis: there may be biases 
introduced by weak instruments and pleiotropy. These findings require 
replication. Strengthening the genetic instruments used in the analysis 
using more variants associated with depression and chronotype identified 
through GWAS may help to give more evidence of the causal relationships 
between these traits. 
5. It is of note, PRS analyses show only small effects on the traits-of-interest 
and explain very little of the trait variance. A more effective PRS is 
needed to explain a greater proportion of the variance seen. 
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4.8 Future Work 
Upon completion of this analysis, there were more GWAS of chronotype 
preference released which could be used to expand the chronotype risk scores 
used here. The extension of the chronotype PRS may allow the estimations of 
effect on mood disorder to explain more of the phenotypic variance. This may 
also make the PRS more accurate for distinguishing affected individuals in a 
clinical setting. A more extensive PRS could be used to further investigate the 
potential interaction chronotype preference has with sex. 
 However, as many of the GWAS which have been conducted to identify 
variants associated with chronotype include UK Biobank participants it may 
result in confounding of the findings. For future investigations using such risk 
scores would require a separate sample cohort.  
The collection of more participant-reported and objective sleep phenotypes 
measures in ALSPAC could provide a greater understanding of the influence 
these PRS have in young adulthood. 
 Also, there has been strong evidence for the involvement of circadian 
rhythm in mood disorders, such as BD and MDD, and it may be of benefit to 
investigate a variety of circadian phenotypes or sleep symptoms in the context 
of mood disorder related phenotypes to help elucidate a greater understanding 
of the pathophysiology of BD. 
4.9 Conclusions 
This is the first use of a chronotype PRS investigating mood disorders. The 
relationship between mood disorders and circadian behaviours has been widely 
suggested (Merikanto et al. 2013), however, the influence of genetics on this 
relationship has been unclear. These findings strengthen the evidence for the 
relationship between circadian rhythms and mood disorders, and related traits. 
This may help highlight direct or indirect pathways which influence the 
development and pathophysiology of mood disorders. However, these analyses 
are based on a subjective circadian trait and further investigations are required 
to understand the relationships between other circadian rhythm traits and mood 
disorders.  
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4.10 Supplementary Data 
Supplemental Table 4.1 Cross tabulation of observations of ALSPAC mood outcomes and 
sleep phenotypes 
ALSPAC Binary hypomania Binary depression 
Difficult sleeping-10 Yes No Yes No 
Yes 11 134 12 345 
No 13 178 3 471 
Difficult sleeping-13 Yes No Yes* No* 
Yes 12 146 9 313 
No 24 199 1 462 
* excluding individuals of non-white ethnic background resulted in no observations for the desired 
variables. Individuals were not excluded based on ancestry for this phenotypic association test. 
 
Supplemental Table 4.2 Linear regression of chronotype PRS and continuous hypomania 
and depression scores 
Phenotype  Coefficient S.E p value 95% CI r2 
Morningness PRS 
HCL score 0.069 
(0.084) 
0.128 
(0.128) 
0.589 
(0.51) 
-0.182/0.32 
(-0.166/0.335) 
0.000 
(0.003) 
SMFQ score -0.001 
(-0.0003) 
0.042 
(0.042) 
0.975 
(0.995) 
-0.084/0.081 
(-0.083/0.082) 
0.000 
(0.001) 
Eveningness PRS 
HCL score 0.013 
(0.01) 
0.121 
(0.121) 
0.915 
(0.931) 
-0.224/0.25 
(-0.226/0.247) 
0.000 
(0.003) 
SMFQ score -0.046 
(-0.046) 
0.041 
(0.041) 
0.265 
(0.269) 
-0.127/0.035 
(-0.127/0.035) 
0.002 
(0.014) 
Unadjusted model (adjusted model) 
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Supplemental Table 4.3 Linear regression of chronotype PRS and continuous hypomania 
and depression scores split by sex 
Female Coefficient S.E p value 95% CI r2 
Morningness PRS 
HCL score 0.309 
(0.309) 
0.157 
(0.157) 
0.049 
(0.049) 
0.001/0.616 
(0.001/0.616) 
0.003 
(0.003) 
SMFQ score 0.003 
(0.002) 
0.058 
(0.058) 
0.962 
(0.97) 
-0.111/0.116 
(-0.111/0.116) 
0.000 
(0.001) 
Eveningness PRS 
HCL score 0.006 
(0.003) 
0.144 
(0.144) 
0.967 
(0.982) 
-0.276/0.288 
(-0.279/0.285) 
0.000 
(0.000) 
SMFQ score -0.035 
(-0.035) 
0.052 
(0.052) 
0.501 
(0.51) 
-0.138/0.068 
(-0.137/0.068) 
0.000 
(0.001) 
 
Male Coefficient S.E p value 95% CI r2 
Morningness PRS 
HCL score -0.355 
(-0.355) 
0.22 
(0.22) 
0.107 
(0.108) 
-0.787/0.077 
(-0.788/0.078) 
0.003 
(0.003) 
SMFQ score -0.002 
(-0.002) 
0.061 
(0.061) 
0.974 
(0.971) 
-0.121/0.117 
(-0.122/0.117) 
0.000 
(0.000) 
Eveningness PRS 
HCL score -0.099 
(-0.107) 
0.176 
(0.176) 
0.573 
(0.543) 
-0.444/0.246 
(-0.453/0.0.238) 
0.000 
(0.002) 
SMFQ score -0.069 
(-0.071) 
0.055 
(0.055) 
0.215 
(0.2) 
-0.177/0.04 
(-0.18/0.038) 
0.001 
(0.001) 
Unadjusted model (adjusted model) 
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Supplemental Table 4.4 Logistic regressions of self-reported eveningness and morningness 
PRS in UK Biobank 
Phenotype  O.R S.E p value 95% CI r2 
Definite 
eveningness 
0.922 0.007 1.6x10-24 0.908/0.937 0.018 
Overall 
eveningness 
0.949 0.004 4.1x10-37 0.941/0.956 0.071 
Adjusted model 
 
Supplemental Table 4.5 Logistic regression investigating sex interaction with PRS in UK 
Biobank 
 
O.R S.E p value 95% CI r2 
Morningness PRS 
Lifetime BD 1.006 0.056 0.92 0.901/1.122 0.016 
Lifetime MDD 1.007 0.028 0.673 0.974/1.041 0.043 
Lifetime GAD 1.005 0.028 0.861 0.952/1.061 0.033 
Mood Instability 1.002 0.008 0.8 0.987/1.017 0.017 
 Coefficient  
Neuroticism 0.024 0.013 0.07 -0.002/0.05 0.038 
Eveningness PRS 
Lifetime BD 0.96 0.053 0.466 0.861/1.071 0.016 
Lifetime MDD 1.003 0.017 0.881 0.97/1.036 0.043 
Lifetime GAD 1.016 0.028 0.567 0.963/1.071 0.033 
Mood Instability 0.988 0.008 0.112 0.973/1.003 0.017 
 Coefficient  
Neuroticism -0.032 0.013 0.016 -0.057/-0.006 0.038 
Adjusted model 
 
Supplemental Table 4.6 Two sample MR overall genetic effects using meta-analysed SNP 
WR 
Overall genetic effects  Log odds S.E p value p chi 
Depression to morningness -0.224 0.014 3.01x10-54 1.1x10-4 
Morningness to depression -0.009 0.025 0.709 1 
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Chapter 5 The potential influence of CACNA1C 
GPRS on circadian rhythm phenotypes 
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Outline 5.1 Chapter in context of overall study 
 
5.1 Introduction 
As described in Chapter 3, there have been multiple SNPs within the CACNA1C 
loci found to have an association with several psychiatric conditions including 
BD, schizophrenia and MDD. CACNA1C has been identified as a risk locus by both 
GWAS and subsequent meta-analyses (Bigos et al. 2010; Sklar et al. 2011; 
Smoller 2013; Heilbronner et al. 2015; Kabir et al. 2017). However, it is still 
unclear as to the exact mechanism by which CACNA1C genetic variants influence 
the pathophysiology of BD.  
 The CACNA1C gene is known to have a role in circadian rhythm (Schmutz 
et al. 2015; McCarthy et al. 2016) and disruptions of circadian rhythm are 
frequently reported in BD (Hayashi et al. 2015; Steinan et al. 2015). In Chapter 
3, CACNA1C GPRS were used to investigate the potential associations between 
CACNA1C risk variants and mood disorders phenotypes. Upon replication, there 
was little evidence for an association between the GPRS and mood disorders, 
particularly in UK Biobank. However, it is possible that CACNA1C may be 
exacting influence on mood disorders through disrupted circadian rhythms. As 
demonstrated in Chapter 4, there is phenotypic association between chronotype 
(a subjective measure of circadian rhythmicity and rest-activity preference) and 
mood disorder-related traits in both ALSPAC and UK Biobank. The aim of this 
chapter is to determine whether there is an association between CACNA1C GPRS 
and circadian rhythm phenotypes, specifically chronotype preference and 
relative amplitude (an objective measure of rest-activity cycles). 
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5.1.1 CACNA1C in circadian rhythms 
The CACNA1C gene function is influenced by the circadian clock, as well as 
having a role in rhythmic calcium signalling (Schmutz et al. 2015; McCarthy et al. 
2016). The Cav1.2 protein is expressed rhythmically, with its peak occurring late 
at night, and contributes to the induction of clock genes. Knockout of the Cav1.2 
channels in mouse models has shown a role in circadian clock resetting. The 
influx of calcium ions via the Cav1.2 channels activate second messenger systems 
leading to the transcription of circadian clock genes (Schmutz et al. 2015). 
Greater detail on the functions of the Cav1.2 channel and influence of the 
CACNA1C gene is reported in Chapter 3. 
 CACNA1C polymorphic variants associated with psychiatric and mood 
disorders have been reported to associate with increased sleep latency in both 
children and adults; sleep latency refers to the time taken to transition from 
wakefulness to sleep (Kantojarvi et al. 2017); and it has been suggested that 
CACNA1C partially modulates the electrophysiology of sleep (Kantojarvi et al. 
2017). 
5.1.2 Circadian rhythms in mood disorders 
As described in chapters 1 and 4, disrupted circadian rhythmicity are commonly 
observed in mood disorders, including higher sleep disturbances, longer 
circadian phase and greater evening chronotype preference compared to healthy 
individuals (Pagani et al. 2016; Dmitrzak-Węglarz et al. 2016; Asaad et al. 2016). 
Individuals with, or at risk of, mood disorders (particularly BD) appear to be 
more susceptible to disruptions of circadian rhythmicity and sleep-wake cycle 
disturbances when compared to healthy controls (Geoffroy et al. 2014; Moon et 
al. 2016). Chronotype has been reported to associate with mood disorders and 
mood-related traits, in a previous chapter and in several other studies, with 
evening chronotype reported more frequently than in healthy controls (Corruble 
et al. 2014; Dmitrzak-Węglarz et al. 2016; Pagani et al. 2016; Chan et al. 2014; 
Berdynaj et al. 2016; Hidalgo et al. 2009; Baek et al. 2016; Alloy et al. 2017). In 
a recent study, within the UK Biobank, objective measures of rest-activity 
rhythmicity from accelerometer data were derived (mainly RA) (Lyall et al. 
2018). It was found that low RA, a measure showing little average difference 
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between an individual’s rest and activity over the course of a week, was 
associated with several mood disorder phenotypes (Lyall et al. 2018). 
5.2 Rationale 
As disruptions of sleep homeostasis and circadian rhythm systems are frequently 
associated with mood disorders, it is logical to hypothesise that CACNA1C may 
influence BD and MDD through its circadian effects. There are subjective 
measures of sleep phenotypes available in ALPSAC which could be used to 
investigate this. Also, chronotype and RA are measures of sleep-wake preference 
and rest-activity, respectively, in UK Biobank and may reflect altered sleep 
homeostasis and circadian rhythmicity. If CACNA1C risk scores show associations 
with these phenotypes, which have already been linked to mood disorders 
(Corruble et al. 2014; Dmitrzak-Węglarz et al. 2016; Pagani et al. 2016; Chan et 
al. 2014; Berdynaj et al. 2016; Hidalgo et al. 2009; Baek et al. 2016; Alloy et al. 
2017; Lyall et al. 2018), it may be beneficial to consider an individual’s 
CACNA1C genotype when developing treatment interventions. Breast and ovarian 
cancer risk and treatment is often informed by BRCA1/BRCA2 genotyping (Tung 
& Garber 2018), a more extensive genotyping of CACNA1C could eventually be 
used in a similar way to inform mood disorder treatment. 
5.3 Hypothesis to be tested 
The aim of this chapter is to investigate whether a higher genetic loading for 
CACNA1C risk variants is associated with both subjective and objective measures 
of circadian rhythmicity within ALSPAC and UK Biobank. These findings could, 
potentially, strengthen the evidence of CACNA1C’s involvement in sleep 
homeostasis and circadian rhythmicity; as well as highlight a possible pathway by 
which variation in the CACNA1C gene could be influencing mood disorder 
pathophysiology. 
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5.4 Methods 
A weighted GPRS was generated for all individuals with genotype data available 
in ALSPAC and UK Biobank using Plink 1.9 (Purcell et al. 2007); CACNA1C SNP 
weightings were obtained from several BD GWAS and meta-analyses (chapter 
3)(Kloiber et al. 2012; Green et al. 2013; Fiorentino et al. 2014; Heilbronner et 
al. 2015). Chapters 2 and 3 describe CACNA1C GPRS/PRS methodology. Weighted 
scores were standardised to z values (i.e. per SD). Statistical analysis described 
in Chapter 2.  
5.4.1 ALSPAC 
Participants of ALSPAC who were genotyped were only included in the ALSPAC 
genotype database after meeting particular quality control criteria. Details of 
quality control measures, imputation and phasing described in Chapter 2. Only 
unrelated individuals were included in these analyses in an attempt to prevent 
shared environmental factors influencing associations (Dudbridge 2016); a list of 
unrelated individuals (N=8,197; 96% of the genotyped sample) was provided by 
ALSPAC. Individuals that were not recorded as Caucasian, or those with missing 
ethnic background data (N=1,112; 13.08%), were also removed from analyses 
leaving N=7,390. 
5.4.1.1 Sleep phenotypes 
There is no measure of chronotype within ALSPAC and so the CACNA1C GPRS was 
tested against four measures of sleep problems reported at two different ages. 
This resulted in four sleep-related variables; these variables were generated 
from mother-answered questionnaires regarding child sleep habits. These 
phenotypes are detailed in Chapter 2.  
The primary outcome measures for sleep in ALSPAC were the categorical 
variables “Difficulty sleeping-10” and “Difficulty sleeping-13” (ALSPAC variable 
kv7034 and tb7034, respectively) which were tested for their association to 
CACNA1C GPRS using logistic regression. Secondary outcome measures were also 
tested (“Difficulty sleeping-scale” (tb5538) and “Worried sleep” (tb6555)) using 
linear regression. 
Chapter 5  101 
5.4.2 UK Biobank cohort 
Before any analyses were undertaken with UK Biobank data individuals were 
removed from the initial cohort of N=152,000 based upon several quality control 
criteria, including relatedness, ancestry (Non-Caucasian individuals), gender 
mismatch and quality control failure in the UK BiLEVE study. Chapter 2 describes 
the quality control and exclusion criteria. This left N=119,953 (78.9% of the 
cohort). As with the analyses undertaken in Chapter 3, individuals missing 
genotype information for any of the 15 chosen SNPs were also excluded from 
analyses leaving N=95,073. 
5.4.2.1 Chronotype phenotype 
As described in Chapter 2, chronotype was derived from the participants’ 
responses to a question obtained from the Morningness-Eveningness 
questionnaire (Taillard et al. 2003). This question is an accepted measure of 
chronotype and has been reported to explain the greatest variance in preference 
of sleep-wake timings (Taillard et al. 2003). Categorical variables were then 
generated based upon the responses given, resulting in the generation of four 
separate chronotype variables. The primary outcome measures used for analysis 
were the “definite morning” and “definite evening” variables with “overall 
morning” and “overall evening” providing secondary outcome measures.  
5.4.2.2 Relative amplitude phenotype 
Accelerometer data were obtained from 103,720 UK Biobank participants. This 
data underwent extensive pre-processing and exclusion criteria in order to 
derive a RA variable. RA is defined as the relative difference between the most 
active continuous 10-hour period and the least active continuous 5-hour period 
in an average 24-hour period; or each individual, the RA data point was the 
mean RA value across seven days. RA ranges from 0 to 1, with higher values 
indicating greater distinction between activity levels during the most and least 
active periods of the day. 
 Chapters 2 and 6 detail the pre-processing, exclusions and generation of 
the RA variable. 
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5.5 Results 
5.5.1 ALSPAC 
It is unclear as to whether CACNA1C has any influence on sleep features. Logistic 
regression was used to test the associations between CACNA1C GPRS and subject 
sleep phenotypes in ALSPAC. 
Table 5.1 Logistic regressions of sleep outcome measures and CACNA1C GPRS 
Phenotype  O.R S.E p value 95% CI r2 
Difficult sleeping-
10 
1.055 
(1.054) 
0.07 
(0.07) 
0.423 
(0.428) 
0.926/1.202 
(0.925/1.201) 
0.001 
(0.002) 
Difficult sleeping-
13 
0.997 
(0.999) 
0.066 
(0.066) 
0.964 
(0.984) 
0.876/1.135 
(0.877/1.137) 
0.000 
(0.001) 
Unadjusted model (adjusted model) 
 
There were no associations found between the GPRS and difficulty sleeping 
(Table 5.1). Compared to the GPRS analyses undertaken in Chapter 3 there are 
far fewer observations available for this analyses (N= 978, maximum sample size 
in above analysis) and is therefore likely to be underpowered. 
Consistent with the analyses undertaken in Chapter 3, the sample was stratified 
by sex in order to investigate a potential sex effect between CACNA1C GPRS and 
sleep phenotypes. The above regressions were repeated separately in females 
and males. 
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Table 5.2 Logistic regressions of sleep outcome measures and CACNA1C GPRS 
Phenotype  O.R S.E p value 95% CI r2 
Female      
Difficult sleeping-
10 
0.996 
(0.997) 
0.086 
(0.086) 
0.964 
(0.971) 
0.84/1.181 
(0.841/1.182) 
0.000 
(0.000) 
Difficult sleeping-
13 
0.983 
(0.981) 
0.084 
(0.083) 
0.837 
(0.818) 
0.832/1.161 
(0.83/1.159) 
0.000 
(0.001) 
Male      
Difficult sleeping-
10 
1.139 
(1.143) 
0.119 
(0.119) 
0.21 
(0.201) 
0.929/1.397 
(0.932/1.402) 
0.003 
(0.004) 
Difficult sleeping-
13 
1.019 
(1.027) 
0.107 
(0.108) 
0.855 
(0.798) 
0.83/1.251 
(0.836/1.263) 
0.000 
(0.001) 
Unadjusted model (adjusted model) 
 
No evidence of associations was identified in females or males. However, the 
analyses including only males appears to show a greater (still small) effect on 
difficultly sleeping at age 10 and explain a slightly higher proportion of variance 
than in females (Table 5.2). This association is not significant, although it is of 
note that only 428 males had both genotype and sleep phenotype data; it is 
likely this analysis is underpowered and there could be a potential link between 
CACNA1C GPRS and sleep phenotypes in young males. Of course this is 
speculation based on these preliminary findings. 
5.5.2 UK Biobank 
To investigate the effect of CACNA1C GPRS on chronotype preference logistic 
regression assuming an additive allelic model was used. The analyses were also 
adjusted for confounders for age, sex, deprivation, principal component and 
other quality control measures. “Definite morning” and “definite evening” were 
the primary outcome measures for this analysis. The regressions yielded no 
significant effects on the primary or secondary measurement outcomes using the 
standardized GPRS (Table 5.3).  
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Table 5.3 CACNA1C GPRS vs chronotype 
Outcome O.R S.E p value 95% CI r2 
Definite 
morning 
1.005 
(1.003) 
0.013 
(0.013) 
0.695 
(0.797) 
0.98/1.03 
(0.978/1.029) 
<0.0001 
(0.0205) 
Definite 
evening 
0.995 
(0.997) 
0.013 
(0.129) 
0.695 
(0.797) 
0.97/1.02 
(0.972/1.022) 
<0.0001 
(0.0205) 
Overall 
morning 
1.005 
(1.004) 
0.007 
(0.007) 
0.474 
(0.533) 
0.991/1.019 
(0.991/1.018) 
<0.0001 
(0.008) 
Overall 
evening 
0.995 
(0.996) 
0.007 
(0.007) 
0.474 
(0.533) 
0.982/1.009 
(0.982/1.009) 
<0.0001 
(0.008) 
Unadjusted model (adjusted model) 
 
As above, the regressions were also conducted in females and males separately. 
Table 5.4 CACNA1C GPRS vs chronotype after splitting sample by sex 
Outcome O.R  S.E p value 95% CI r2 
Female      
Definite 
morning 
0.989 
(0.989) 
0.017 
(0.018) 
0.527 
(0.532) 
0.956/1.024 
(0.955/1.024) 
<0.0001 
(0.0185) 
Definite 
evening 
1.011 
(1.011) 
0.018 
(0.018) 
0.527 
(0.532) 
0.977/1.047 
(0.977/1.047) 
<0.0001 
(0.0185) 
Overall 
morning 
1.002 
(1.002) 
0.009 
(0.009) 
0.859 
(0.838) 
0.983/1.02 
(0.984/1.021) 
<0.0001 
(0.007) 
Overall 
evening 
0.998 
(0.998) 
0.009 
(0.009) 
0.859 
(0.838) 
0.98/1.017 
(0.98/1.017) 
<0.0001 
(0.007) 
Male      
Definite 
morning 
1.021 
(1.02) 
0.019 
(0.019) 
0.256 
(0.289) 
0.985/1.059 
(0.983/1.059) 
0.0001 
(0.0233) 
Definite 
evening 
0.979 
(0.98) 
0.018 
(0.018) 
0.256 
(0.289) 
0.944/1.015 
(0.945/1.017) 
0.0001 
(0.0233) 
Overall 
morning 
1.008 
(1.007) 
0.01 
(0.01) 
0.404 
(0.469) 
0.989/1.029 
(0.987/1.028) 
<0.0001 
(0.0097) 
Overall 
evening 
0.992 
(0.993) 
0.01 
(0.01) 
0.404 
(0.469) 
0.972/1.011 
(0.973/1.013) 
<0.0001 
(0.0097) 
Unadjusted model (adjusted model) 
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When stratifying the sample by sex there were no associations found between an 
increasing GPRS and a specific chronotype preference. There appeared to be a 
greater effect in males who reported a definite chronotype, however, this 
finding was not significant (Table 5.4). 
The above analyses are based on self-reported and subjective circadian 
measures. As described previously, objective measures of rest-activity cycles has 
been derived from UK Biobank accelerometer data. Linear regressions were 
conducted to determine whether there is an association between CACNA1C GPRS 
and the objective rest-activity measure RA. 
Table 5.5 Linear regression of RA and CACNA1C GPRS 
Outcome Beta S.E p value 95% CI r2 
RA -0.001 
(-0.001) 
0.018 
(0.018) 
0.973 
(0.978) 
-0.036/0.035 
(-0.036/0.035) 
0.000 
(0.000) 
Unadjusted model (adjusted model) 
There was no association found between CACNA1C GPRS and RA (Table 5.5). 
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5.6 Discussion 
There are multiple lines of evidence to support the hypothesis of altered calcium 
signalling and the CACNA1C genotype in BD (Harrison 2016). However, it is still 
unclear as to the exact mechanism by which CACNA1C genetic variants influence 
the pathophysiology of BD. It has been suggested that CACNA1C may directly or 
indirectly affect the underlying mechanisms of BD by disrupting circadian 
rhythms (Kantojarvi et al. 2017; Schmutz et al. 2015; McCarthy et al. 2016). 
The relationship between the CACNA1C gene and peripheral features of the 
circadian clock, such as chronotype and RA, are currently not understood. 
However, the above preliminary analyses did not find evidence of associations 
between CACNA1C GPRS, subjective, and objective measures of circadian 
rhythmicity. 
 Therefore, further investigation is required to understand the potential 
mechanisms of CACNA1C in BD in the context of circadian rhythmicity.  
5.7 Limitations 
There appears to be no studies which have combined CACNA1C SNPs in this way; 
therefore, the usefulness of the GPRS generated here has not been validated and 
could be lacking by limiting the collection of SNPs to only those reported as 
genome-wide significant. Theoretically, a more extensive CACNA1C GPRS may be 
more accurate for detecting potential associations with circadian measures. Due 
to the small sample size of individuals with both genotype and sleep phenotype 
data in ALSPAC the analyses was underpowered. As described in Chapter 3 and 4, 
compared to UK Biobank there are much smaller sample sizes available in 
ALSPAC for the outcomes-of-interest. 
A limitation of this study was the subjective circadian measures used. In the 
case of ALSPAC, the sleep phenotypes available were based on mother-reported 
questionnaires and may not align with the child’s experience. Also, chronotype is 
based upon the self-reported responses to a single question in the UK Biobank 
(Ganna & Ingelsson 2015). However, this is an accepted measure of chronotype 
and has been reported to explain the greatest variance of sleep-wake preference 
(Taillard et al. 2003).  
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It is important to note, also, that the results displayed above have not been 
corrected for multiple testing and after applying multiple testing, again, no 
associations were found. 
As described in Chapter 3, the CACNA1C GPRS did not consist of completely 
independent SNPs which could have affected the findings (Williams & Haines 
2011).  
5.8 Future work  
With the release of more recent psychiatric GWAS there is potential to generate 
a more extensive CACNA1C GPRS which could be more effective for investigating 
the link between this candidate gene and mood disorders. A more robust GPRS 
may also be of use in determining whether there is an association between 
CACNA1C and circadian rhythmicity.  
 Chapter 4 reported significant associations between chronotype 
preference and mood disorders. As mentioned in the previous chapter these 
associations were based on subjective measures of circadian rhythmicity, further 
study is required to understand the underlying genetic architecture of objective 
circadian traits, of particular interest is RA. 
5.9 Conclusion 
Overall, there was no evidence of associations between CACNA1C GPRS and 
measures of circadian rhythmicity. The influence of CACNA1C on the underlying 
pathophysiology of mood disorders currently remains unclear. 
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Chapter 6 Genome-wide association study of 
circadian rest-activity rhythmicity in over 77,000 
UK Biobank participants 
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This chapter appears in a published format at Ferguson et al. (2018), 
EBioMedicine, doi: https://doi.org/10.1016/j.ebiom.2018.08.004 (Ferguson et 
al. 2018) 
 
Outline 6.1 Chapter in context of overall study 
 
6.1 Introduction 
In chapter 4, the influences of chronotype PRS were investigated for associations 
with several mood disorder-related phenotypes of hypomania, depressive 
features, lifetime BD, lifetime MDD, mood instability and neuroticism. Increased 
PRS for evening chronotype positively associated with BD, MDD, mood instability 
and neuroticism. As chronotype is a subjective measure, investigating a PRS of 
an objectively measured circadian rhythmicity parameter is preferable. To date 
there are no large GWAS of objective circadian rhythmicity measures in humans, 
the largest GWAS using objective measures of sleep parameters obtained from 
actigraph data consisted of 956 participants from the LIFE Adult Study (Spada et 
al. 2016). Therefore, this chapter focusses on the first large-scale GWAS of 
relative amplitude, an objective measure of rest-activity rhythm, in over 77,000 
individuals from UK Biobank. 
6.1.1 Circadian rhythms  
Circadian rhythms are variations in physiology and behaviour that recur 
approximately every 24 hours (McClung 2007). They include rhythms of body 
temperature, hormone release, activity, concentration, mood, eating and 
sleeping. 
 Circadian rhythmicity plays a fundamental role in homeostasis and in the 
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maintenance of physical and mental wellbeing (Reppert & Weaver 2001; 
Merikanto et al. 2017). Circadian disruption is associated with a range of adverse 
health outcomes, including cardiovascular disease, obesity, diabetes and some 
cancers (Reutrakul & Knutson 2015; Wulff et al. 2010; Sigurdardottir 2012), as 
well as increased risk for MDD and BD (Burton et al. 2013; Bullock & Murray 
2014; Ng et al. 2015). 
Circadian rhythmicity is co-ordinated centrally by the suprachiasmatic nucleus 
(SCN) in the anterior hypothalamus (Reppert & Weaver 2001) and is regulated by 
both exogenous environmental stimuli (“zeitgebers”) and by genetic factors 
(Charrier et al. 2017). The circadian clock can be further classified into the 
central clock and peripheral clocks (Mohawk et al. 2012).  
 The central clock refers to the autoregulatory transcription/translational 
feedback loops that maintain cell-cycle function (Koike et al. 2012). The SCN 
acts as the main regulator of central circadian oscillators which rhythmically 
alter gene expression to sustain many biological processes, involving several core 
circadian clock genes (Mohawk et al. 2012). However, circadian oscillators are 
expressed differentially and independently in different tissues referred to as the 
peripheral clock (Mohawk et al. 2012; Albrecht 2012). As well as being subject to 
central oscillators of the circadian clock, cells also contain their own intrinsic 
clock with peripheral oscillators (Mohawk et al. 2012). There is little overlap in 
the expression of genes under circadian control between tissues (Mohawk et al. 
2012; Albrecht 2012), suggesting a need for specific spatial and temporal 
controls to function efficiently (Mohawk et al. 2012; Albrecht 2012).  
 As noted above, several core genes involved in regulating the central 
circadian clock have been identified, however, communication between the 
SCN, central and peripheral circadian clocks is not yet well understood (Albrecht 
2012). Given the complexity required to synchronise the central and peripheral 
clocks, and to regulate the mechanisms required to create differential spatial 
and temporal gene expression, the control of circadian rhythms is likely to be 
polygenic, with many regulatory genes and pathways still to be identified (Zhang 
et al. 2009; Merikanto et al. 2017; Albrecht 2012; Mohawk et al. 2012). 
 
To date, the most commonly used measure of circadian phenotypes in humans 
has been subjectively-reported chronotype, defined as an individual’s 
preference for morning or evening wakefulness and activity (Alloy et al. 2017). 
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As noted above, evening chronotype is more likely to be associated with adverse 
health outcomes (Corruble et al. 2014; Dmitrzak-Węglarz et al. 2016; Merikanto 
et al. 2017; Goel et al. 2014). Recently, GWAS of chronotype, self-reported 
sleep duration, and accelerometer-derived sleep traits have identified several 
independent genetic loci previously implicated in the regulation of circadian 
function (including PER2, PER3, RSG16, AK5, FBXL13), in addition to novel 
associated genetic loci (Hu et al. 2016; Jones et al. 2016b; Lane et al. 2016; 
Jones et al. 2018; Dashti et al. 2018; Jones et al. 2019). 
 
6.1.2 Circadian rhythmicity in mood disorders  
Several aspects of circadian rhythms and sleep profiles have been investigated 
within mood disorders, including chronotype and rest/activity measures (Burton 
et al. 2013). Disruption of circadian rhythmicity, assessed from both subjective 
questionnaires and actigraph data, is associated with mood disorders, as well as 
daytime dysfunction, and impaired cognitive and emotional processing (Geoffroy 
et al. 2014; Wulff et al. 2010). Previous chapters have explored sleep 
disturbances, rest-activity circadian rhythmicity disruption and chronotype in 
relation to mood disorder-related traits, both phenotypically and genetically. 
Most of these analyses were based on variables generated from subjectively-
reported data (chronotype). 
6.2 Rationale 
Chronotype, as a subjective measure, is vulnerable to response bias. It may also 
have inconsistent associations with more objective measures of circadian 
rhythmicity (Taillard et al. 2003). In a recent study within the UK Biobank 
cohort, objective measures of rest-activity rhythmicity from accelerometer data 
were derived and it was found that low RA, an objective measure of an 
individual’s rest-activity rhythmicity, was associated with several mood disorder 
phenotypes (Lyall et al. 2018). This chapter will build on that study by 
conducting a GWAS of the rest-activity measure low RA. 
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6.3 Hypothesis to be tested 
The aim of this investigation was to conduct a GWAS of low RA in UK Biobank to 
provide data regarding genetic architecture underlying disrupted rest-activity 
circadian rhythmicity. A secondary GWAS of continuous RA was also undertaken 
to provide a more complete understanding of the genetics of rest-activity cycles. 
Further, the findings of the primary GWAS were used to assess the degree of 
genetic correlation between low RA and several psychiatric phenotypes, 
including attention deficit hyperactivity disorder (ADHD), BD, MDD, mood 
instability, post-traumatic stress disorder (PTSD), schizophrenia, anxiety and 
insomnia.  
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6.4 Methods 
6.4.1 Participants and ethical approval 
Information on participants’ recruitment to UK Biobank is detailed in Chapter 2. 
Here, the data from 91,448 participants who provided genetic and 
accelerometer data that passed quality control (details below) and who had 
available data on all covariates included within fully and/or partially adjusted 
models were used in the GWAS.  
6.4.2 Accelerometry data collection and pre-processing 
In 2013, 240 000 UK Biobank participants were invited to wear an accelerometer 
for seven days as part of a physical activity monitoring investigation; with 
103,720 (43%) accepted and returned the accelerometer to UK Biobank after use 
(Doherty et al. 2017). Raw activity intensity data were combined into five 
second epochs (Supplemental Figure 6.1).  Further details on data pre-processing 
are found in Chapter 2 and are available from UK Biobank at 
http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=131600 (Doherty et al. 2017).  
6.4.3 Circadian rest-activity rhythmicity (relative amplitude, RA)  
From the summary five second epoch data, a measure of RA was calculated using 
Clocklab Version 6 (Actimetrics) by Dr. Cathy Wyse (Wyse et al. 2018, 
unpublished). This accelerometer-derived activity measure has demonstrated 
reliability and validity (Sadeh 2011). RA is used commonly as a non-parametric 
measure of rest-activity rhythm amplitude. It is defined as the relative 
difference between the most active continuous 10-hour period (M10) and the 
least active continuous 5-hour period (L5) in an average 24-hour period (Van 
Someren et al. 1996):  
𝑅𝐴 =
(M10 − L5)
(M10 + L5)
 
M10 is the mean activity during the continuous 10 hour period containing 
maximum activity in each 24 hour recording period (midnight to midnight). L5 is 
the mean activity for the corresponding 5 hour period containing the minimum 
activity within the same recording period. For each individual, the RA data point 
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was the mean RA value across all included 24-hour periods (seven days). RA 
ranges from 0 to 1, with higher values indicating greater distinction between 
activity levels during the most and least active periods of the day.  
Exclusion criteria detailed in Chapter 2. In the current sample (N=91,870), mean 
RA was 0.87 (Standard deviation (SD) 0.06; range 0.121-0.997), similar to 
previously reported values in healthy populations (Bullock & Murray 2014), 
however, the distribution of RA values was negatively skewed (Supplemental 
Figure 6.2). 
6.4.4 Genotyping and imputation 
Full details of the genotyping and imputation methods used by UK Biobank have 
been described in Chapter 2. 
6.4.5 Primary GWAS of low RA  
Our primary GWAS was a study of cases of low RA defined as a “pathological 
tail” of mean RA greater than two standard deviations below the overall mean 
RA, with the remaining participants classified as controls (Supplemental Figure 
6.2) (Lyall et al. 2018). Before proceeding with genetic analyses, further 
exclusions were applied to the data. Individuals were removed according to UK 
Biobank genomic analysis exclusions, failure of quality control, gender 
mismatch, sex chromosome aneuploidy, ethnicity (not Caucasian), lack of 
accelerometry data, plus the other accelerometry exclusions as noted above. For 
related individuals (first cousins or closer), a single individual was randomly 
selected from each pair of related individuals for inclusion in the analysis. After 
these (and the accelerometry-based) exclusions, 71,500 individuals were 
available for GWAS. Data were further refined by removing SNPs with an 
imputation score of <0.8, minor allele frequency of <0.01 and Hardy-Weinberg 
equilibrium p<1x10-6, resulting in 7,969,123 variants. 
The primary association analysis was conducted using logistic regression in PLINK 
(Purcell et al. 2007); an additive allelic effects model was used with sex, age, 
genotyping array, and the first 8 genetic principal components as covariates. For 
the GWAS, genome-wide significance was set at p<5x10-8.   
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6.4.6 Secondary GWAS of RA as a continuous trait 
The BOLT-LMM method allows the inclusion of related individuals within GWAS. 
This method requires less restrictive assumptions compared with standard GWAS, 
as used above, by using a mixture of two Gaussian priors and is a generalisation 
of a standard mixed model. This mixed model accounts for both relatedness and 
population stratification, resulting in greater power compared to principal 
component analysis (Loh et al. 2015). After exclusions, 77,440 individuals were 
available for this GWAS. As above, genome-wide significance was less than 
p<5x10-8. Note that due to the imbalance between cases and controls available 
for low RA as a dichotomous measure, it was not appropriate to use a BOLT-LMM 
approach for the primary GWAS (Loh et al. 2015). 
6.4.7 eQTL analysis 
The lead SNP from each locus, identified by GWAS, was assessed for the 
possibility of eQTLs. This genotype-specific gene expression was assessed using 
the GTEx portal (GTEx Consortium 2013). The portal was also used to investigate 
tissue-specific expression for the implicated genes (GTEx Consortium 2013). 
6.4.8 Gene-based analysis  
The summary statistics from both the primary and secondary GWAS analyses 
were uploaded to the FUMA web application for gene-based analyses (Watanabe 
et al. 2017). Gene-based analyses were carried out based on the MAGMA method 
using all genetic associations within the summary statistics (Watanabe et al. 
2017; de Leeuw et al. 2015). For these analyses genome-wide significance was 
set at p<5x10-5. 
6.4.9 Genetic correlations between low RA and psychiatric 
phenotypes 
LDSR was applied to the GWAS summary statistics to provide an estimate of SNP 
heritability (h2SNP) (Bulik-Sullivan et al. 2015; Zheng et al. 2017). LDSR was also 
used to investigate genetic correlations between low RA and anxiety, ADHD, BD, 
MDD, mood instability, PTSD, schizophrenia and insomnia. The LD scores for 
these disorders were obtained using the summary statistics from the Psychiatric 
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Genomics Consortium, the CNCR-Complex Trait Genomics group, and from UK 
Biobank. ADHD, BD, MDD, schizophrenia and insomnia were analysed using LD 
Hub (Zheng et al. 2017). 
Methods also detailed in Ferguson et al., 2018. 
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6.5 Results 
6.5.1 GWAS of low RA 
The primary analysis was a case-control GWAS of low RA. The GWAS data showed 
only a slight deviation in test statistics compared to the null (λGC 1.016, Figure 
6.1); this deviation may be due to the polygenic architecture of low relative 
amplitude. The h2SNP accounted for less than 1% of the population variance in 
low RA (h2SNP 0.0067, S.E 0.0054). The Manhattan plot for low RA GWAS is 
presented in Figure 6.1. Two independent genomic loci on chromosomes 1 and 
22 were associated with low RA at genome-wide significance, including three 
SNPs (Supplemental Table 6.2 Genome-wide significant loci associated with low 
RA).  These SNPs highlighted two candidate gene loci: Neurofascin (NFASC) on 
chromosome 1 and Solute Carrier Family 25 Member 17 (SLC25A17) on 
chromosome 22 (Figure 6.2). As each of these SNPs is an intronic variant, the 
exact effect of each polymorphism is unclear.  
 
Figure 6.1 SNP Manhattan plot and QQ plot (inset) of low RA GWAS (N=2700 cases verses 
N=68,300 controls)  
Red line of Manhattan plot represents genome-wide significance (p<5×10−8).  
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Figure 6.2 Regional plots of NFASC and SLC25A17 
Regional plots of SNPs produced by FUMA (Watanabe et al. 2017). 
 
6.5.2 GWAS of continuous RA 
As a secondary analysis, a GWAS of a continuous measure of RA using a BOLT-
LMM model was performed. The BOLT-LMM GWAS showed a slight deviation in 
the test statistics compared to the null (λGC 1.054, Figure 6.3), again consistent 
with a polygenic architecture for RA. The h2SNP for RA as a continuous measure 
accounted for greater than 8% of the population variance (h2SNP 0.085,  
S.E 0.00035). This estimate is much higher compared to that found for low RA 
(RA=8.5%, low RA=0.67%) which may be a result of the less restrictive BOLT-LMM 
method used for the continuous RA GWAS. Five SNPs, all localised to one locus 
on chromosome 2, were associated with continuous RA at genome-wide 
significance (Supplemental Table 6.3 Genome-wide significant loci associated 
with continuous RA using BOLT-LMM). These SNPs highlight the Meis Homeobox 1 
(MEIS1) gene. Again, as noted above, these are intronic SNPs and their exact 
effects are not known. 
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Figure 6.3 SNP Manhattan plot and QQ plot (inset) of continuous RA GWAS (N=77,440) 
Red line of Manhattan plot represents genome-wide significance (p<5×10−8). 
6.5.3 Gene-based analysis of RA 
Gene-based analyses of both low RA and continuous RA were undertaken. The 
gene-based analysis of low RA identified two genes significantly associated with 
low RA: Forkhead Box J1 (FOXJ1) on chromosome 17 and Zinc Finger FYVE-type 
Containing 21 (ZFYVE21) on chromosome 14 (Figure 6.4). The gene set analysis 
of continuous RA identified three genes: Copine 4 (CPNE4) and Chromosome 3 
open reading frame 62 (C3orf62) on chromosome 3, and Renalase (RNLS) on 
chromosome 10 (Figure 6.5).  
 
 
Figure 6.4 Low RA gene-based analysis 
Chapter 6  120 
 
 
Figure 6.5 Continuous RA gene-based analysis 
Red line represents genome-wide significance (p<5x10-8). 
 
6.5.4 eQTL analysis 
The lead SNPs from both GWAS were assessed for potential eQTLs. Only the lead 
SNP found on chromosome 22 (rs9611417) was associated with the expression of 
a nearby gene. Being heterozygous at rs9611417 was associated with lower 
expression of RANGAP1 gene in oesophageal mucosa in comparison to rs9611417 
C allele homozygotes (beta -0.43, p 7.2x10-5, Figure 6.6). Information on the 
influence of G homozygotes was not available. 
 
Figure 6.6 eQTLs of rs9611417 box plot 
Homo Ref: rs9611417 CC, Het: rs9611417 CG, Homo Alt: rs9611417 GG. Obtained from GTex 
portal.(GTEx Consortium 2013) 
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6.5.5 Genetic correlation between low RA and psychiatric 
phenotypes 
There were no significant genetic correlations identified between low RA and 
ADHD, anxiety, BD, MDD, mood instability, PTSD and schizophrenia. There was 
weak evidence of genetic correlation between low RA and insomnia (rg 0.90,  
S.E 0.42, p 0.033), suggesting that the biology underlying low RA may be 
associated with the regulation of sleep (Table 6.1) but this finding did not 
survive FDR correction.  
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Table 6.1 Genetic correlations between low relative amplitude and ADHD, anxiety, BD, MDD, 
mood instability, PTSD, schizophrenia and insomnia 
Phenotype rg S.E z p value p FDR corrected 
ADHD 0.35 0.45 0.77 0.44 0.93 
Anxiety -0.004 0.42 -0.01 0.99 1.00 
BD -0.06 0.18 -0.34 0.73 1.00 
MDD 0.005 0.25 0.02 0.99 1.00 
Mood Instability -0.16 0.27 -0.58 0.56 0.94 
PTSD 0.74 0.62 1.19 0.23 0.71 
Schizophrenia 0.15 0.14 1.14 0.25 0.71 
Insomnia 0.90 0.42 2.13 0.03 0.28 
ADHD: meta-analysis of Children’s Hospital of Philadelphia, International Multicenter ADHD 
Genetics Project (phase I and II) and Pfizer funded study from University of California, Los 
Angeles, Washington University and Massachusetts General Hospital (N=5,414) (Neale et al. 
2010). 
Anxiety: Anxiety NeuroGenetics Study Consortium (N=18,000) (Otowa et al. 2016). 
BD: Psychiatric Genomics Consortium – BD working group (N=63,766) (Sklar et al. 2011). 
MDD: Meta-analysis of Psychiatric Genomics Consortium 29, deCODE, Generation Scotland, 
Genetic Epidemiology Research on Aging, iPSYCH, UK Biobank and 23andMe (N=480,359) (Wray 
et al. 2018). 
Mood Instability: UK Biobank (N=113,968) (Ward et al. 2017). 
PTSD: Psychiatric Genomics Consortium – PTSD working group (N=20,070) (Duncan et al. 2018). 
Schizophrenia: Psychiatric Genomics Consortium – Schizophrenia working group (N=150,064) 
(Schizophrenia Working Group of the Psychiatric Genomics Consortium et al. 2014). 
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6.6 Discussion 
The primary GWAS of low RA identified three genome-wide significant SNPs 
within two independent loci; the two NFASC SNPs highlighted were found to be 
in relatively high LD (r2 0.66-1.00) in many populations (Ensembl 2018c) and are 
potentially tagging a single underlying functional variant influencing low RA. The 
secondary GWAS of RA as a continuous measure identified five genome-wide 
significant SNPs at a single locus, within the MEIS1 gene on chromosome 2. 
Again, the SNPs identified are in medium to high LD with each other  
(r2 0.39-1.00) in many populations, including UK Biobank (Supplemental Figure 
6.4) (Ensembl 2018b). 
6.6.1 Genes of interest 
One of the genes highlighted by GWAS was NFASC (Figure 6.2), a gene encoding 
the neurofascin protein (Taylor et al. 2017). Neurofascin is an L1 family 
immunoglobulin cell adhesion molecule that interacts with several proteins to 
anchor voltage-gated Na+ channels to the intracellular skeleton in neurons.  It is 
involved in neurite outgrowth and organization of axon initial segments (AIS) 
during early development (Taylor et al. 2017). These AIS complexes (Figure 6.7, 
comprising neurofascin, ankyrin G (encoded by ANK3), gliomedin and betaIV 
spectrin) are important for the generation of action potentials and for the 
maintenance of neuronal integrity (Thaxton et al. 2010; Leterrier et al. 2015).  
 
 
Figure 6.7 Diagram of AIS displaying neurofascin protein interacting with Na+ channels 
(Leterrier et al. 2015) 
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Polymorphisms in ANK3 have been found to be associated with BD through 
several case-control GWAS (Ferreira et al. 2008; Sklar et al. 2011). The direct 
binding of neurofascin to ankyrin G at the AIS therefore represents a potentially 
important biological link between circadian rhythmicity and BD. Interestingly, 
variants in the NFASC gene have previously been found to have a suggestive 
significant association (p<5x10-5) with increased daytime sleep (napping) in UK 
Biobank (Lane et al. 2017). The NFASC SNPs identified by the low RA GWAS were 
intronic variants and the NFASC transcript undergoes extensive alternative 
splicing with not all variants being functionally categorised (Taylor et al. 2017). 
The precise influence these variants have on the NFASC gene is currently 
unclear.  
One of the genome-wide significant SNPs from the primary GWAS is located 
within SLC25A17. This gene encodes a peroxisomal solute carrier membrane 
protein that transports several cofactors from the cytosol to the peroxisomal 
matrix (Agrimi et al. 2012). Variants of this gene have previously been 
associated with autism spectrum disorder, schizophrenia (The Autism Spectrum 
Disorders Working Group of The Psychiatric Genomics Consortium 2017), and 
more recently with BD (Stahl et al. 2017) and morning chronotype preference to 
suggestive significance (Lane et al. 2016; Jones et al. 2016b). The SLC25A17 
gene is also involved in adrenomyeloneuropathy (Van Veldhoven 2010), an 
inherited condition in which long chain fatty acids accumulate in the CNS 
disrupting several brain functions (Moser et al. 1999). 
The SNP identified in the GWAS of low RA (rs9611417) was associated with lower 
expression of RANGAP1, a GTPase activator protein involved in nuclear transport 
(Bischoff et al. 1995). RANGAP1 is 439kb downstream of rs9611417 and shows 
relatively high expression in the brain (Supplemental Figure 6.3); this gene has 
been found to be suggestively associated (p<5x10-5) with several sleep traits in 
UK Biobank, including short sleep duration, frequent insomnia symptoms and 
excess daytime sleepiness (Lane et al. 2017). 
The GWAS of RA as a continuous measure highlighted SNPs within the MEIS1 
gene. This gene encodes a homeobox transcription factor (TF) protein crucial for 
the normal development of several tissues, including the CNS (Wang et al. 2014; 
Xiong et al. 2009). The MEIS1 gene has been reported to have significant 
associations with insomnia and suggestive significant associations with sleep 
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duration and excessive daytime sleepiness in UK Biobank (Lane et al. 2017). This 
gene is also associated with myeloid leukaemia (Wang et al. 2014) and restless 
leg syndrome 7 (RLS 7) (Wang et al. 2014; Xiong et al. 2009). Restless leg 
syndromes are neurological sleep-wake disorders characterised by involuntary 
muscle movement during rest periods, resulting in sleep deprivation and 
insomnia (Xiong et al. 2009). This is perhaps further evidence of the potential 
role of the MEIS1 gene in rest-activity cycles.  
6.6.2 Gene-based analyses 
The gene-based analysis of low RA identified two genes: FOXJ1 on chromosome 
17, and ZFYVE21 on chromosome 14. FOXJ1 encodes a forkhead TF protein which 
has a role in cell differentiation in respiratory, reproductive, immune, and CNS 
tissues. It is required for the formation of cilia (Jacquet et al. 2011). In mouse 
models, FOXJ1 was reported to be important for neurogenesis within the 
forebrain and olfactory bulb (Jacquet et al. 2011). 
The ZFYVE21 gene encodes the zinc-finger FYVE-type containing 21 protein, 
involved in cell migration and adhesion (Nagano et al. 2011). There is relatively 
little characterisation of the function of this protein and gene such that the 
potential involvement of this gene in the brain and circadian function is unclear. 
For the continuous measure of RA, three genes were identified in the gene-based 
analysis: CPNE4 and C3orf62 (chromosome 3); and RNLS on (chromosome 10). 
The CPNE4 gene encodes a calcium-dependent phospholipid binding protein 
involved in membrane trafficking and may be involved in intracellular calcium-
mediated processes (Tomsig & Creutz 2002). Deletion of this gene has been 
associated with earlier age-of-onset of Alzheimer’s disease (Szigeti et al. 2013), 
and has been associated at genome-wide significance with sleep traits in UK 
Biobank, including frequent insomnia and daytime sleep (Lane et al. 2017). 
Currently, the C3orf62 gene is an uncharacterised protein coding gene that has 
not been functionally annotated (Ensembl 2018a). 
RNLS encodes a flavin adenine dinucleotide-dependent amine oxidase, known as 
Renalase, an enzyme hormone secreted from the kidney into the bloodstream 
(Xu et al. 2005). Renalase is involved in mediating cardiac function and blood 
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pressure by influencing heart rate and has been associated with hypertension, 
chronic kidney failure and type 1 diabetes prediction (Xu et al. 2005; Lv et al. 
2016; Frohnert et al. 2018; Desir 2008). It is perhaps worth noting that disrupted 
circadian rhythmicity has been associated with both diabetes and hypertension 
in several studies (Merikanto et al. 2013; Merikanto et al. 2016; Reutrakul & 
Knutson 2015), and that RNLS has been associated with both treatment outcome 
and episode recurrence in BD, as well as showing suggestive significant 
associations with frequent insomnia symptoms (Fabbri & Serretti 2016; Lane et 
al. 2017).  
There was no evidence of genetic correlation between low RA and any of the 
psychiatric disorders or mood traits tested. A suggestive genetic correlation was 
identified between low RA and sleep traits, specifically insomnia; however, this 
did not remain significant after correcting for multiple testing. The GWAS of low 
RA is still preliminary and is limited by the small case sample size; it could have 
been underpowered to detect a large proportion of variants influencing low RA. 
More extensive low RA GWAS may be required to effectively assess genetic 
correlations to psychiatric disorders and mood traits. 
6.7 Limitations 
There are several limitations to the design used to test the above hypothesis: 
1. UK Biobank may not be representative of the general UK population (Fry 
et al. 2017), with a possible under-representation of individuals with 
disrupted rest-activity cycles (i.e. those with low RA) resulting in a 
relatively small sample size of low RA cases. It is likely that the case-
control GWAS of low RA was underpowered to detect variants which have 
only small or moderate effects on RA. Much larger case sample sizes are 
required to detect variants (Dunn et al. 2015). 
2. The use of the LDSC package for estimating SNP heritability in low RA 
cases (1.2 million SNPs rather than 9 million SNPs assessed by the BOLT-
LMM approach) could have resulted in an underestimation of trait 
heritability. Also, with the relatively small sample size of low RA cases, 
our analyses may be underpowered resulting in a lower estimate of SNP 
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heritability than expected (for example, compared to chronotype) (Jones 
et al. 2016b). Previous investigations of accelerometer-based phenotypes 
using selected clinical samples (such as BD) reported higher heritability 
estimates (h2>0.30) (Pagani et al. 2016). The use of a non-clinical, general 
population cohort with potential under-representation of psychiatric 
disorders may have resulted in a SNP heritability estimate that is lower 
than might be expected. 
3. Circadian rhythms are subject to influence from both biological factors 
and environmental stimuli. It is a potential limitation of this investigation 
that the analyses were not adjusted for potential non-genetic confounders 
operating during the accelerometry data collection period, such as 
medical illness, medication status, chronic pain, transmeridian air travel, 
obesity and irregular work patterns. The accelerometers were worn for 7 
days which may not fully represent rhythmicity, particularly in working 
participants where weekend rhythms might differ substantially from 
weekday rhythms. Further studies are required to investigate the possible 
interaction between RA and environmental factors; future investigations 
may also benefit from the inclusion of other measures of RA variability to 
adjust for intra- and inter-individual activity levels. There are limitations 
to accelerometers also; they are not valid for measuring some physical 
activities, including cycling and resistance force activities. It is also 
difficult to extrapolate accelerometry data as individuals typically 
perform activities for a shorter time period than when not wearing the 
accelerometer (de Almeida Mendes et al. 2018). 
6.8 Future work 
The direct influence that genes-of-interest highlighted here have on circadian 
rhythmicity and mood disorders is unclear. Further studies are required to 
elucidate their function with respect to depression and BD. The identification of 
genes with putative biological links to, or associated with, mood disorders does 
however suggest a link between circadian rhythmicity and mood disorders. This 
merits further investigation, for example, with polygenic risk scores. The 
following chapter will investigate the associations between low RA polygenic risk 
scores and mood disorder phenotypes.  
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 The results of this investigation are preliminary and require replication. 
Accelerometery data from large cohorts such as 23andMe may help to strengthen 
the findings of the above GWAS. If accelerometery data was collected in a 
cohort such as ALSPAC, this would provide data on rest-activity data and, by 
extension, information on individuals’ circadian rhythmicity at an earlier age 
which may highlight variants and pathways involved in the development of mood 
disorders and related traits. 
6.9 Conclusions 
Overall, these findings contribute new knowledge on the genetic architecture of 
circadian rhythmicity. Several of the genetic variants are located within or close 
to genes which may have a role in the pathophysiology of mood disorders. These 
findings provide novel genetic variants to investigate in the context of mood 
disorders and potentially strengthen the evidence for the relationship between 
disrupted circadian rhythmicity and psychiatric traits and conditions. 
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6.10 Supplemental  
 
Supplemental Figure 6.1 Representative actograms of high RA and low RA 
 
 
Supplemental Figure 6.2 Relative amplitude histogram indicating (N=2,987 Cases and 
N=80,352 Controls) 
Red line represents mean value of RA. Blue line is two standard deviations from the mean, 
designating cases for use in the primary GWAS. These numbers indicate all (Caucasian) 
individuals available for GWAS before genetic exclusions and QC were applied. 
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Supplemental Figure 6.3 Tissue specific expression of RANGAP1 
 
Obtained from GTex portal.(GTEx Consortium 2013) 
 
 
Supplemental Figure 6.4 LD heat map of continuous RA GWAS significant SNPs (within 
MEIS1 gene) 
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Supplemental Table 6.1 Demographics of UK Biobank participants included in 
accelerometer data subset 
 Low RA cases Controls Test statistic p value 
Age at baseline, years   3.15 <0.0001 
Mean(SD) 55.94(0.15) 56.39(0.03)   
Median(IQR) 57(50-64) 58(52-65)   
Age at accelerometry, years    2.92 <0.0001 
Mean(SD) 61.69(0.15) 62.11(0.03)   
Median(IQR) 62(56-69) 63(57-69)   
Sex   -18.18 <0.0001 
Female 1,187(39.78) 45,405(56.57)   
Male 1,797(60.22) 34,857(43.43)   
Townsend deprivation score   -21.1 <0.0001 
Mean(SD) -0.84(0.06) -1.91(0.01)   
 
 
Supplemental Table 6.2 Genome-wide significant loci associated with low RA 
SNP Chr Position A1/A2 MAF Beta p value Nearby gene 
rs147964682 1 204,896,804 G/C 0.012 0.584 3.179x10-9 NFASC 
rs146042826 1 204,904,528 A/G 0.013 0.568 6.17x10-9 NFASC 
rs9611417 22 41,202,227 G/C 0.012 0.5616 4.753x10-8 SLC25A17 
A1: reference allele  
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Supplemental Table 6.3 Genome-wide significant loci associated with continuous RA using 
BOLT-LMM 
SNP Chr Position A1/A2 Info Beta p value Nearby gene 
rs113851554 2 66,750,564 G/T 0.93 0.0048 6.10x10-11 MEIS1 
2:66782432_AC_A 2 66,782,432 AC/A 0.92 0.0048 9.80x10-10 MEIS1 
rs11679120 2 66,785,180 G/A 0.93 0.0045 2.10x10-8 MEIS1 
rs115087496 2 66,793,725 G/C 0.92 0.0047 2.90x10-9 MEIS1 
rs142412330 2 66,802,493 T/TCTC 0.93 -0.0036 6.80x10-10 MEIS1 
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Supplemental Table 6.4 Suggestive significant loci associated with low RA 
SNP Chr Position A1/A2 Info Beta p value Nearby gene 
rs11715894 3 53,040,459 A/T 0.421 0.138 1.16x10-6 SFMBT1 
rs560770640 3 53,044,907 G/T 0.42 0.136 1.52x10-6 SFMBT1 
rs578200280 3 53,068,709 C/T 0.421 0.136 1.67x10-6 SFMBT1 
rs151079563 3 53,194,321 T/C 0.447 0.145 4.01x10-7 PRKCD 
rs190135744 4 32,918,842 C/T 0.054 0.285 2.71x10-7 intergenic 
rs9277979 6 33,294,098 T/C 0.177 0.167 1.91x10-6 DAXX 
rs546882114 6 33,308,438 T/C 0.181 0.169 1.95x10-6 intergenic 
rs372171356 6 33,295,111 G/A 0.177 0.164 3.10x10-6 DAXX 
rs76775274 7 91,713,047 C/T 0.011 0.521 1.75x10-6 AKAP9 
rs117704951 7 91,876,485 T/A 0.011 0.514 1.92x10-6 ANKIB1 
rs146314842 7 97,662,316 T/G 0.03 -0.459 9.71x10-6 intergenic 
rs289055 13 68,464,763 G/A 0.364 0.134 3.44x10-6 intergenic 
rs289056 13 68,476,397 T/C 0.366 0.132 4.74x10-6 OR7E111P 
rs2094932 13 68,482,537 G/A 0.363 0.13 8.42x10-6 intergenic 
rs556389482 17 74,166,151 A/G 0.268 0.16 4.57x10-7 RNF157 
rs562449594 17 74,171,132 G/A 0.264 0.152 9.40x10-7 RNF157 
rs754706 17 74,150,113 C/T 0.264 0.151 1.03x10-6 RNF157 
rs547968601 17 74,171,356 A/G 0.264 0.151 1.05x10-6 RNF157 
rs1868822 17 74,149,524 C/T 0.264 0.151 1.06x10-6 RNF157 
rs9277979 6 33,294,098 T/C 0.177 0.167 1.91x10-6 DAXX 
rs546882114 6 33,308,438 T/C 0.181 0.169 1.95x10-6 intergenic 
rs372171356 6 33,295,111 G/A 0.177 0.164 3.10x10-6 DAXX 
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Supplemental Table 6.5 Suggestive significant loci associated with continuous RA 
SNP Chr Position A1/A2 Info Beta p value Nearby gene 
rs10194961 2 106,304,263 T/A 0.338 0.002 2.80x10-7 intergenic 
rs115291000 2 149,409,639 G/A 0.958 0.004 2.90x10-6 EPC2 
rs11686221 2 107,263,240 C/T 0.988 0.006 4.70x10-6 intergenic 
rs139169199 2 141,262,927 C/CA 0.96 0.004 1.10x10-5 LRP1B 
rs11693221 2 66,799,986 C/T 0.953 0.004 1.00x10-7 MEIS1 
rs142704867 5 151,700,577 T/C 0.964 0.004 4.40x10-7 intergenic 
rs79593753 5 151,777,074 C/T 0.974 0.005 3.20x10-6 NMUR2 
rs11538104 5 133,727,052 T/G 0.989 0.007 3.30x10-6 UBE2B 
rs36072161 5 133,729,345 T/A 0.989 0.007 4.10x10-6 intergenic 
rs3842139 6 34,665,678 C/CAA 0.264 -0.002 4.10x10-7 intergenic 
rs12194155 6 18,557,377 G/T 0.94 -0.003 2.00x10-6 MIR548A1HG 
rs12215669 6 18,561,460 C/T 0.94 -0.003 2.10x10-6 MIR548A1HG 
rs115595252 7 110,014,522 T/A 0.991 0.008 3.90x10-6 intergenic 
rs7809370 7 93,708,083 A/G 0.63 0.001 4.80x10-6 intergenic 
rs11139851 9 85,493,040 C/G 0.852 0.002 6.00x10-7 intergenic 
rs142398474 11 18,669,128 C/T 0.982 0.006 1.90x10-7 intergenic 
rs7951433 11 86,084,878 C/A 0.986 0.007 6.10x10-7 intergenic 
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Outline 7.1 Chapter in context of overall study 
 
7.1 Introduction 
In a previous chapter, a GWAS of RA, an objective measure of rest-activity cycles 
and circadian health, was conducted (Ferguson et al. 2018). This chapter builds 
on the findings of this work by assessing, within both UK Biobank and ALSPAC, 
how PRS for low RA associates with both mood disorders and sleep phenotypes. 
7.1.1 Circadian rhythms in mood disorders 
Chapters 4-6 have highlighted that disrupted circadian rhythmicity is associated 
with a range of adverse health outcomes, including cardiovascular disease, 
obesity, diabetes and some cancers (Reutrakul & Knutson 2015; Wulff et al. 
2010; Sigurdardottir 2012), as well as increased risk for MDD and BD (Burton et 
al. 2013; Bullock & Murray 2014; Ng et al. 2015). Many studies have found an 
association between mood disorders, psychiatric traits and disruption of 
circadian rhythmicity (Baek et al. 2016; Pagani et al. 2016; Geoffroy et al. 2014; 
Bellivier et al. 2015). In UK Biobank, low RA (reflective of greater circadian 
disruption) was associated with increased risk of BD, MDD, mood instability and 
neuroticism, as well as, subjective measures of wellbeing. Individuals with low 
RA were also more likely to have lower health satisfaction scores, lower 
subjective happiness and greater subjective loneliness (Lyall et al. 2018).  
As described in Chapter 6, there are layers of complexity within the circadian 
clock; many biological processes under circadian control which require both 
synchronization and spatial-temporal control. Disrupted rest-activity cycles, i.e., 
low RA, could be influenced by alterations in any one of these multiple layers of 
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complexity within the circadian control system. Although there have been major 
advances in understanding the molecular substrates of the circadian clock, there 
is still much to be discovered in this area.  
In Chapter 6, a primary GWAS of low RA in UK Biobank identified three SNPs of 
genome-wide significance (p<5x10-8) as well as many SNPs of suggestive 
significance (p<5x10-5) but there was little to no genetic correlation found 
between low RA, sleep traits and psychiatric phenotypes (as reported in Chapter 
6) (Ferguson et al. 2018). However, as genetic correlations can be limited by the 
design, power and results of GWAS investigations (in the sense that some GWAS 
methodologies are more restrictive and underestimate heritability or may be 
underpowered due to smaller sample size) some associations may have been 
missed (Loh et al. 2015). The epidemiological data suggests that low RA may be 
genetically correlated with mood disorders and related traits, as well as with 
subjective sleep features.  
 Understanding how low RA affects these traits should provide a greater 
understanding of the underlying pathophysiology of mood disorders and could 
provide a novel target for treatment or management of the disorders. In this 
chapter, these potential associations will be tested in both UK Biobank and 
ALSPAC using low RA PRS. This approach allows for the assessment of the 
possible link between genetic loading for low RA and these traits-of-interest in a 
wide age-range of adults, as there may be a differential affect at younger versus 
older ages. 
7.2 Rationale 
Low RA has previously been, phenotypically, associated with mood disorder-
related outcomes in UK Biobank (Lyall et al. 2018). However, it was unclear 
whether genetic loading for low RA associates with mood disorders, mood-
related traits and sleep-related traits in UK Biobank and ALSPAC. The advantage 
of investigating the potential associations in both UK Biobank and ALSPAC is the 
possibility of replicating associations. However, it is reasonable to suggest that 
the differences in factors such as age, lifestyles, life experience and 
socioeconomic status between the two cohorts could highlight potential external 
influences on the effects driven by low RA PRS. 
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There appear to be no studies using PRS of objective circadian measures in this 
way. The following analyses may provide a greater understanding of the 
underlying mechanisms of mood-disorders and related traits.  
7.3 Hypothesis to be tested 
The aim of this investigation was to determine whether higher genetic loading 
(based on a minimum of 21 SNPs) for low RA was associated with mood disorder-
related outcomes and features of disrupted sleep.  
 Within a group of UK Biobank participants who were not part of the 
primary GWAS study (141,000 individuals), the association between increased 
PRS for low RA and mood trait phenotypes (specifically BD, MDD, GAD, mood 
instability and neuroticism) was tested. I also tested the association between 
low RA PRS and self-reported chronotype. 
Within ALSPAC, low RA PRS was tested for association with hypomania, 
depression and subjective measures of disturbed sleep. 
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7.4 Methods 
7.4.1 Genotyping and imputation 
Descriptions of the genotyping, imputation and phasing methods used in UK 
Biobank and ALSPAC are detailed in Chapter 2. 
7.4.2 Bipolar Disorder, Depression and Generalised Anxiety 
Disorder  
A MHQ was developed by a UK Biobank mental health research reference group 
to collect additional mental health phenotype data and was administered during 
2016-2017. Lifetime BD, lifetime MDD and lifetime GAD variables were generated 
for 157,366 UK Biobank participants. Further details for these variables have 
been described in Chapter 2. 
7.4.3 Neuroticism 
To define neuroticism a score taken from the 12 item neuroticism scale of the 
EPQ-R-S (Eysenck et al. 1985). Individuals were given a score of 0 or 1 for a “no 
or yes” answer, respectively, for each item and given a total neuroticism score 
ranging from 0 to 12. As described in Chapter 2. 
7.4.4 Mood instability 
As described in Chapter 2, a “mood instability” outcome measure was also 
obtained from the EPQ-R-S questionnaire: participants were asked “Does your 
mood often go up and down?” and given the option to answer “yes”, “no”, 
“don’t know” or “prefer not to answer”. Individuals who selected “don’t know” 
or “prefer not to answer” were coded as missing; this allowed the generation of 
a categorical mood instability variable where those who answered “yes” were 
designated as cases and participants who answered “no” were included as 
controls.  
7.4.5 Chronotype phenotype in UK Biobank 
Chronotype was derived from the participants’ responses to a question obtained 
from the Morningness-Eveningness questionnaire. Categorical variables were 
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then generated based upon the responses given, resulting in the generation of 
four separate chronotype variables. The primary outcome measures used for 
analysis were the “definite morning” and “definite evening” variables with 
“overall morning” and “overall evening” providing secondary outcome measures. 
The method by which these variables were generated is detailed in Chapters 2 
and 4.   
7.4.6 Hypomania 
To test associations between low RA PRS and features of BD in ALSPAC 
categorical and continuous measures of hypomania were used. The full details of 
how these measures are generated using HCL-28 can be found in Chapter 2. The 
categorical definition of hypomania was the primary outcome measure and the 
continuous HCL-28 score was a secondary outcome. 
7.4.7 Depressive features 
Depressive symptoms were assessed in the ALSPAC cohort during late childhood 
and adolescence using the SMFQ. This generates an SMFQ score ranging from 0 to 
26 (Wiles et al. 2012), as well as a categorical depression measure (binary 
depression) based on a score of greater than 16. The categorical SMFQ measure 
was used as the primary outcome measure and the SMFQ score was the 
secondary outcome.  
7.4.8 Sleep phenotypes in ALSPAC 
There is no measure of chronotype within ALSPAC therefore the low RA PRS was 
tested against four measures of sleep problems reported at two different ages 
(age 10 and age 13). This resulted in four sleep-related variables; these variables 
were generated from mother-answered questionnaires regarding child sleep 
habits. These phenotypes are detailed in Chapter 2 and Chapter 4.  
The primary outcome measures for sleep in ALSPAC were the categorical 
variables “Difficulty sleeping-10” and “Difficulty sleeping-13” which were tested 
for their association to low RA PRS using logistic regression. Secondary outcome 
measures were also tested (“Difficulty sleeping-scale” and “Worried sleep”) 
using linear regression.  
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7.4.9 Association between PRS for low RA and mood disorder 
phenotypes in UK Biobank 
Associations between higher PRS for low RA and psychiatric diagnoses were 
examined in up to 76,018 Caucasian individuals who had completed the MHQ and 
who were not included in the primary low RA GWAS, described in Chapter 6. 
Similarly, associations between low RA PRS and mood instability/neuroticism 
were examined in between 91,248 and 140,504 individuals (depending on the 
dependent variable) not included in the low RA GWAS. PRS including SNPs at 6 
different significance thresholds (p<5x10-8, p<5x10-5, p<0·01, p<0·05, p<0·1, 
p<0·5) were divided into quartiles, with the exception of p<5x10-8 which was 
divided into tertiles as there were only three scores generated for participants 
at this threshold. The top and bottom quantiles were compared in logistic 
regression models that were adjusted for age, sex, Townsend deprivation index 
(Townsend 1987), genotype array and the first 8 genetic principal components. 
FDR correction was applied which is less conservative than Bonferroni correction 
(Pike 2011; Benjamini & Hochberg 1995).  
7.4.10 Association between PRS for low RA and mood 
disorder phenotypes in ALSPAC 
Associations between higher PRS for hypomania and depression were examined 
in up to 2,500 Caucasian individuals. PRS were generated at 5 SNP significance 
thresholds, using variants identified by the low RA GWAS undertaken in UK 
Biobank, and divided into quantiles, as above. Due to the small number of SNPs 
used to generate a PRS for genome-wide significant SNPs, there was insufficient 
genotype data available in ALSPAC to generate scores for this threshold. The top 
vs. bottom quantiles were contrasted in regression models that were adjusted 
for sex and deprivation. As in previous chapters, ALSPAC analysis was not 
adjusted for age due to participants being of similar age (25-27 years old). 
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7.5 Results 
7.5.1 Association between PRS for low RA and mood disorder 
phenotypes in UK Biobank 
The findings of analyses assessing the association between low RA PRS and 
several mood disorder-related phenotypes are presented in Table 7.1. Positive 
associations were identified between increased PRS and (increased risk of) mood 
instability at all PRS thresholds (these associations met significance with 
p<0.05), with the exception of genome-wide significance threshold (p<5x10-8). 
For MDD, small positive associations were found for the low RA PRS at the top 
three significance thresholds (O.R 1·02-1·03), which remained significant after 
FDR correction (p 0·025-0·05). A positive association with neuroticism was found 
for the highest threshold (p 0·004, FDR adjusted p 0·021). However, other 
associations between the remaining PRS thresholds and neuroticism score were 
not significant (Ferguson et al. 2018). 
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Table 7.1 Associations between low RA PRS and mood disorder phenotypes 
PRS p 
threshold 
Outcome(Cases/Controls) O.R (95% CI) p 
uncorrected 
p FDR 
corrected 
p<5x10-8 BD 
(406/37,699) 
0·99 (0·92,1·06) 0·748 0·785 
p<5x10-5 1·05 (0·98, 1·12) 0·206 0·746 
p<0·01 1·03 (0·96, 1·11) 0·355 0·746 
p<0·05 1·04 (0·96, 1·12) 0·309 0·746 
p<0·1 1·02 (0·94, 1·10) 0·617 0·785 
p<0·5 1·02 (0·93, 1·11) 0·754 0·785 
p<5x10-8 MDD 
(9,543/24,317) 
1·00 (0·99, 1·02) 0·812 0·805 
p<5x10-5 1·00 (0·98, 1·02) 0·966 0·805 
p<0·01 1·01 (0·99, 1·03) 0·395 0·494 
p<0·05 1·02 (1·00, 1·04) 0·03 0·050 
p<0·1 1·03 (1·01, 1·05) 0·005 0·025 
p<0·5 1·03 (1·00, 1·05) 0·021 0·050 
p<5x10-8 GAD 
(2,587/23,564) 
0·97 (0·95, 1·00) 0·092 0·300 
p<5x10-5 0·98 (0·96, 1·01) 0·274 0·548 
p<0·01 0·99 (0·97, 1·02) 0·729 0·729 
p<0·05 1·01 (0·98, 1·04) 0·475 0·713 
p<0·1 1·03 (0·99, 1·06) 0·1 0·300 
p<0·5 1·01 (0·97, 1·04) 0·699 0·729 
p<5x10-8 Mood Instability 
(78,710/91,248) 
1·00 (0·99, 1·01) 0·913 0·940 
p<5x10-5 1·01 (1·00, 1·02) 0·019 0·0096 
p<0·01 1·01 (1·01, 1·02) 9·5x10-5 2·2x10-4 
p<0·05 1·02 (1·01, 1·02) 3·6x10-6 9·6x10-5 
p<0·1 1·01 (1·01, 1·02) 8·3x10-5 5·9x10-4 
p<0·5 1·02 (1·01, 1·03) 1·2x10-6 1·5x10-5 
PRS p 
threshold 
Outcome (N) Beta (95% CI) p 
uncorrected 
p FDR 
corrected 
p<5x10-8 Neuroticism score 
(140,504) 
-0·004 (-0·02, 0·007) 0·456 0·399 
p<5x10-5 0·01 (-0·003, 0·02) 0·124 0·134 
p<0·01 0·01 (-0·002, 0·02) 0·098 0·134 
p<0·05 0·01 (-0·005, 0·03) 0·059 0·134 
p<0·1 0·01 (-0·003, 0·02) 0·128 0·134 
p<0·5 0·02 (0·007, 0·04) 0·004 0·021 
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7.5.2 Association between PRS for low RA and mood disorder 
phenotypes in ALSPAC 
The PRS for low RA was tested for any association with hypomanic and 
depressive symptoms in ALSPAC (Table 7.2). There were no significant 
associations found between low RA and the primary mood-related trait measures 
in ALSPAC. There was a nominally significant association between low RA and 
SMFQ score at two significance thresholds, however, these associations did not 
survive correction. 
Table 7.2 Associations between low RA PRS and mood disorder-related traits in ALSPAC 
PRS p 
threshold 
Outcome 
 
O.R (95% CI) p 
uncorrected 
p FDR 
corrected 
p<5x10-5 Binary Hypomania 
(age 22-23) 
0·98 (0·84,1·14) 0·793 0.991 
p<0·01 0·99 (0·81,1·22) 0·970 0.991 
p<0·05 0.98 (0·81, 1·20) 0·872 0.991 
p<0·1 1.08 (0·89, 1·32) 0·424 0.991 
p<0·5 1·00 (0·82, 1·22) 0·991 0.991 
p<5x10-5 Binary Depression 
(age 10-19) 
 
1·16 (0·94, 1·43) 0·173 0.286 
p<0·01 1·22 (0·94, 1·59) 0·129 0.286 
p<0·05 1·19 (0·45, 1·57) 0·229 0.286 
p<0·1 1·27 (0.97, 1·68) 0·087 0.286 
p<0·5 1·14 (0.86, 1·51) 0·355 0.355 
PRS p 
threshold 
Outcome Beta (95% CI) p 
uncorrected 
p FDR 
corrected 
p<5x10-5 HCL score 
(age 22-23) 
0·05 (-0·21, 0·31) 0·720 0.720 
p<0·01 0·20 (-0·16, 0·57) 0·274 0.567 
p<0·05 0·17 (-0·18, 0·53) 0·340 0.567 
p<0·1 0·31 (-0·05, 0·66) 0·089 0.445 
p<0·5 0·13 (-0·22, 0·49) 0·46 0.575 
p<5x10-5 SMFQ score 
(age 10-19) 
0·02 (-0·02, 0·007) 0·647 0.647 
p<0·01 0·09 (-0·003, 0·02) 0·079 0.132 
p<0·05 0·11 (-0·002, 0·02) 0·031 0.108 
p<0·1 0·10 (-0·005, 0·03) 0·043 0.108 
p<0·5 0·03 (-0·003, 0·02) 0·512 0.640 
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7.5.3 Association between PRS for low RA and chronotype in UK 
Biobank 
It was unclear as to whether the polygenic loading for low RA would show any 
association to more subjective circadian/sleep phenotypes. These analyses could 
be a partial indication of how low RA aligns with other circadian traits. In 
chapter 4, the influences of different chronotypes on both physical and mental 
health were discussed in depth; the earlier chapter reported the association 
between evening chronotype and mood disorder-related phenotypes. 
As expected, the genetic loading for low RA was found to be associated with 
decreased self-reported morningness and increased eveningness at several PRS 
significance thresholds (Table 7.3). 
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Table 7.3 Associations between low RA PRS and self-reported chronotype in UK Biobank 
PRS p 
threshold 
Outcome O.R (95% CI) p 
uncorrected 
p FDR 
corrected 
p<5x10-8 Definite morning 
 
0·99 (0·98, 1.01) 0·610 0.610 
p<5x10-5 0.98 (0·96, 1.00) 0·057 0.068 
p<0·01 0.96 (0·94, 0.97) 1.1x10-4 1.65x10-4 
p<0·05 0.96 (0·94, 0.97) 6.5x10-7 1.76x10-6 
p<0·1 0.95 (0·94, 0.97) 2.2x10-8 1.32x10-7 
p<0·5 0.96 (0·94, 0.97) 8.8x10-7 1.76x10-6 
p<5x10-8 Definite evening 
 
1·01 (0·99, 1·03) 0·610 0.610 
p<5x10-5 1·02 (1.00, 1·04) 0·057 0.068 
p<0·01 1·04 (1.02, 1·06) 1.1x10-4 1.65x10-4 
p<0·05 1·05 (1·03, 1·06) 6.5x10-7 1.76x10-6 
p<0·1 1·05 (1·03, 1·07) 2.2x10-8 1.32x10-7 
p<0·5 1·05 (1·03, 1·06) 8.8x10-7 1.76x10-6 
p<5x10-8 Overall morning 
 
1.00 (0·99, 1·00) 0·700 0.840 
p<5x10-5 1.00 (0·99, 1·01) 0·860 0.860 
p<0·01 0·99 (0·98, 1·00) 0·0054 0.0081 
p<0·05 0.98 (0·97, 0.99) 3.4x10-5 6.8x10-5 
p<0·1 0.98 (0·97, 0.99) 3x10-6 9x10-6 
p<0·5 0.98 (0·97, 0.99) 8.9x10-7 5.34x10-6 
p<5x10-8 Overall evening 
 
1·00 (0·99, 1·01) 0·700 0.840 
p<5x10-5 1·00 (0·99, 1·01) 0·860 0.860 
p<0·01 1·01 (1·01, 1·02) 0·0054 0.0081 
p<0·05 1·02 (1·01, 1·03) 3.4x10-5 6.8x10-5 
p<0·1 1·02 (1·01, 1·03) 3x10-6 9x10-6 
p<0·5 1·02 (1·01, 1·03) 8.9x10-7 5.34x10-6 
 
7.5.4 Association between PRS for low RA and sleep phenotypes 
in ALSPAC 
As there was a positive finding between low RA and chronotype in UK Biobank, it 
was of interest to assess for an association between low RA and sleep 
phenotypes in ALSPAC. However, there were no significant findings using the 
primary or secondary sleep phenotype data in ALSPAC (Table 7.4). There were 
relatively few individuals with both sufficient genotype data for low RA PRS and 
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sleep phenotype data. Therefore, the analysis may have been underpowered to 
detect effects of low RA PRS in the ALSPAC cohort. 
Table 7.4 Associations between low RA PRS and mother-reported sleep traits in ALSPAC 
PRS p 
threshold 
Outcome O.R (95% CI) p 
uncorrected 
p FDR 
corrected 
p<5x10-5 Difficulty sleeping-10 
 
0·91 (0·79,1·05) 0·202 0.960 
p<0·01 0·94 (0·78,1·13) 0·506 0.960 
p<0·05 0.97 (0·80, 1·17) 0·757 0.960 
p<0·1 1.00 (0·82, 1·21) 0·960 0.960 
p<0·5 1·03 (0·85, 1·24) 0·770 0.960 
p<5x10-5 Difficulty sleeping-13 
 
0.88 (0·76, 1·02) 0·093 0.465 
p<0·01 0.89 (0·74, 1·08) 0·237 0.505 
p<0·05 1·01 (0·83, 1·23) 0·906 0.906 
p<0·1 1·02 (0.83, 1·25) 0·860 0.906 
p<0·5 0.90 (0.76, 1·10) 0·303 0.505 
PRS p 
threshold 
Outcome Beta (95% CI) p 
uncorrected 
p FDR 
corrected 
p<5x10-5 Difficulty sleeping-
score 
 
-0·03 (-0·06, 0·01) 0·134 0.335 
p<0·01 -0·04 (-0.09, 0·01) 0·072 0.335 
p<0·05 -0·03 (-0·08, 0·02) 0·273 0.455 
p<0·1 -0·01 (-0·06, 0·04) 0·623 0.740 
p<0·5 -0·01 (-0·05, 0·04) 0·740 0.740 
p<5x10-5 Worried sleep 
 
0·02 (-0·04, 0·01) 0·149 0.745 
p<0·01 0·09 (-0·04, 0·02) 0·560 0.970 
p<0·05 0·11 (-0·02, 0·03) 0·756 0.970 
p<0·1 0·10 (-0·03, 0·03) 0·961 0.970 
p<0·5 0·03 (-0·03, 0·03) 0·970 0.970 
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7.6 Discussion 
As noted previously (Chapter 6), there was little evidence of genetic correlation 
between low RA and psychiatric phenotypes (Ferguson et al. 2018). This is 
perhaps surprising given the cross-sectional, observational associations in the 
literature on circadian rhythmicity and mood disorders, although a lack of 
genetic correlation in the case of exposure/outcome associations could imply 
direct causality – rather than shared genetic architecture. Many features of 
circadian rhythmicity have been associated with BD and depression, including 
low RA and circadian phase preference (chronotype) (Lyall et al. 2018; Baek et 
al. 2016; Dmitrzak-Węglarz et al. 2016). Also, core circadian clock genes have 
been associated with both BD and depression, with altered circadian biology 
suggested to be a vulnerability marker for mood disorders (Partonen 2012; Etain 
et al. 2011; Liberman et al. 2018; Geoffroy et al. 2014; McCarthy et al. 2013; 
Ferguson et al. 2018).  
 However, as described in Chapter 6 and above, genetic correlations may 
be limited by the design of both the preliminary GWAS of low RA and GWAS of 
traits-of-interest. There is also potential that the genetic overlap between 
circadian rhythms and mood disorders are due to the variants underlying 
circadian rhythmicity traits other than RA. The GWAS were also unable to detect 
rare variants (occurring in less than 1% of the population); some of the genetic 
overlap could be due to rare variants with moderate effects (Manolio et al. 
2009).  
It has been suggested that the treatment of disrupted circadian rhythmicity 
could be used in combination with current pharmaceutical therapies to develop 
more effective treatments for mood disorders (Bellivier et al. 2015). Therefore, 
a more complete understanding of circadian rhythmicity in the context of mood 
disorders is important clinically (Ferguson et al. 2018). 
Within the UK Biobank cohort lower RA has been associated with prevalent 
adverse mental health (Lyall et al. 2018). In the current study, some evidence 
was found for an association between greater polygenic risk for low RA and both 
MDD and neuroticism (in independent sub-samples of the cohort). Across several 
PRS thresholds, there was a more robust association between increasing PRS for 
low RA and the phenotype of mood instability. Mood instability is a common 
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symptom that cuts across several psychiatric disorders and, as potential RDoC 
trait, may be a more useful phenotype than categorical diagnoses for 
understanding underlying biology (Broome et al. 2015; Insel 2014). This also 
demonstrates a possible direct link between genetic loading for circadian 
disruption and the subjective experience of dysregulated or unstable mood. For 
this reason, the observed association is of interest and merits further 
investigation (Ferguson et al. 2018).  
 As relapse occurs often in mood disorders (Hofmann et al. 2012) it may in 
future be useful to monitor rest-activity cycles, for example, of individuals with 
known higher PRS, to potentially pre-emptively treat or manage incipient mood 
disorder relapses. Again, more complete investigations into these relationships 
are required, as the mood instability phenotype used here was based on a self-
reported subjective measure that may be influenced by response bias (Ferguson 
et al. 2018). 
 The few significant associations found between PRS and lifetime BD and 
MDD could be partially due to the possible under-representation of individuals 
with psychiatric disorders in UK Biobank; UK Biobank may not be fully 
representative of the general UK population (Fry et al. 2017). 
The association between low RA PRS and chronotype also appears to strengthen 
the evidence for the involvement of genetic variants associated with low RA in 
circadian rhythms. It should be noted however that the risk scores showed 
relatively small effects on the traits of interest and overall explain only a small 
proportion of the variance within the traits.  
When testing the PRS for low RA in ALSPAC there were no significant associations 
identified with most of the mood trait phenotypes tested with the exception of 
weak associations between low RA PRS and depression score. These analyses may 
have been underpowered because of the relatively small sample size and there is 
some uncertainty about the validity of self-reported mood phenotypes, such that 
a potential influence of genetic loading for low RA on hypomania and depression 
cannot be completely dismissed. The small sample size also means that outlying 
or unrepresentative participants are more prominent, leading to potential type-1 
error and spurious findings. 
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There were no associations found between the low RA PRS and sleep outcomes in 
ALSPAC and, as above, the small sample size available is an obvious limitation. 
Another limitation of ALSPAC is the reliance on self-report and mother-reported 
variables which could be influenced by response biases. The collection of 
objective measures of sleep and circadian function in ALSPAC, similar to those 
used in UK Biobank, would be useful in the longer-term. 
It is possible that genetic variants affecting circadian rhythmicity may have an 
unknown developmental-specific effect on how mood disorder-related traits 
manifest in adolescence and adulthood; although as there is currently no way to 
verify this using data which is currently available. There are also limitations to 
this PRS analysis, as only 3 genome-wide significant SNPs were included for the 
most stringent PRS threshold the analysis is likely to be underpowered; the lack 
of associations found between mood phenotypes and genome-wide PRS threshold 
could be in part due to this lack of statistical power. 
 These preliminary results add some support to disrupted circadian 
rhythmicity as a potential endophenotype of mood disorders; which could 
eventually be a target for treatment. Several studies have demonstrated clear 
differences in motor activity between mood disorder patients and healthy 
controls (Scott et al. 2017). Investigations of actigraph data have reported 
differences distinguishing MDD and BD patients however it is of note that these 
studies were limited by relatively small sample sizes (Scott et al. 2017). 
Nevertheless, the potential of activity monitoring as a diagnostic tool or for the 
observation of treatment response could be beneficial to patients with greater 
genetic loading for circadian disruption.  
7.7 Future work  
The current analyses are not adjusted for environmental factors which may 
influence circadian rest-activity cycles, such as, medication status, irregular 
work patterns and chronic pain status. Further study is required to look at the 
potential interaction between genetic variants (risk scores) and environmental 
factors, and how they associate with psychiatric phenotypes.  
 As described in Chapter 6, further study is required to gain a better 
understanding of the genetic architecture of circadian rhythmicity. Larger GWAS 
could provide many more variants for inclusion in PRS which then may be more 
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effective at assessing the associations between circadian rhythmicity and mood 
disorders.  
 The above PRS analyses require replication in cohorts, such as 23andMe 
and All of Us, which may be more representative of the general population.   
7.8 Conclusions 
Overall, the findings above contribute new knowledge on how the underlying 
genetics of circadian rhythmicity (namely, the rest-activity cycle measure of 
relative amplitude) overlaps with mood disorder phenotypes, particularly mood 
instability.  
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8.1 Overview of main findings 
Mood disorders are highly prevalent and are a leading cause of disability. They 
comprise many different features and how these features impact on 
pathophysiology is currently not well-understood. Specifically, disrupted 
circadian rhythmicity (for example, disrupted daily activity and altered sleep 
patterns) is a core feature of mood disorders but the relationship between 
circadian function and mood disorders is unclear. This thesis aimed to contribute 
new knowledge on the genetic architecture of mood disorders and circadian 
rhythms. 
This thesis has attempted to understand this relationship from a genetic 
perspective, with a focus on polygenic risk scores. 
In Chapter 3, as an exploratory analysis, GPRS was used to investigate the 
influence of the BD candidate risk gene CACNA1C on mood disorder-related 
traits in UK Biobank and in ALSPAC. There were no clear associations identified 
in either cohort. However, when investigating the samples separately by sex 
there appeared to be a weak association between CACNA1C and BD traits in 
females within both cohorts (although according to the MHQ-defined outcomes 
available for some UK Biobank participants there were no associations). 
In Chapter 4, I investigated the relationship between circadian function and 
mood disorders more directly. Associations were found between chronotype PRS 
and mood disorder-related traits suggesting a potential link between diurnal 
preference and mood disorders. A limitation of using PRS for chronotype is the 
fact that it is based on a self-reported, subjective measure which can be subject 
to reporting bias. 
In Chapter 4, an exploratory MR analysis was used to investigate the potential 
causal relationship between chronotype and depression. Depression was found to 
be causative for eveningness (as expected) however morningness was found to 
have a causative effect on depression. This was contradictory to the phenotypic 
study undertaken in UK Biobank which reported that greater morningness PRS 
was associated with decreased risk of depression and may suggest a degree of 
reverse causality in the observational correlations. This finding also did not align 
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with another MR study of chronotype and depression which reported that 
morningness SNPs were associated with decreased depression risk (Jones et al. 
2019). The findings of both that study and my analysis may indicate a 
bidirectional relationship (Landgraf et al. 2014). Clearly, further investigation is 
required to establish the true directions of this relationship. 
As CACNA1C has been reported to be involved in circadian function (Schmutz et 
al. 2015; McCarthy et al. 2016), this GPRS was also tested for associations with 
both chronotype preference (morningness and eveningness) and RA (a marker of 
circadian rhythmicity). It is possible that previously-identified associations 
between CACNA1C and mood disorders were occurring via the gene’s influence 
of circadian function. There were no associations between the CACNA1C GPRS 
and both subjective and objective measures of circadian rhythmicity within 
ALSPAC and UK Biobank, as described within Chapter 5. 
At the time of the chronotype-focussed study there were no large-scale GWAS of 
objective circadian parameters available from which to generate PRS of 
circadian dysfunction but with the release of the UK Biobank accelerometer data 
I was able to conduct a GWAS using RA, a derived objective rest-activity 
measure that is less likely to be affected by response bias compared to 
subjective methods. The case-control GWAS of low RA identified three variants 
associated with low RA and a secondary GWAS of continuous RA identified 
several variants associated with RA. As detailed in Chapter 6, the variants 
associated with low RA highlighted a potential biological link between rest-
activity cycles and a replicated BD candidate risk gene (ANK3) and SLC25A17 was 
associated with BD in a recent GWAS (Stahl et al. 2017). 
When investigating low RA PRS in Chapter 7, a significant association was only 
found between greater PRS for disrupted rest-activity cycles (low RA) and mood 
instability. However, the chronotype PRS has greater statistical power to detect 
associations as the variants were identified in GWAS using larger sample sizes 
with a better balance of case and controls (evening chronotype vs morning 
chronotype) relative to the GWAS of low RA. This highlights the requirement of a 
larger sample with accelerometer data as well as a greater balance of 
individuals with low RA and higher RA than the GWAS undertaken in Chapter 6; 
with this type of sample cohort more variants associated with disrupted rest-
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activity cycles could be identified and improved PRS generated to better explore 
the link between mood disorders and disrupted circadian rhythmicity. 
8.2 Contribution to the literature 
1. The lack of evidence for an association between CACNA1C GPRS and mood 
traits in ALSPAC and UK Biobank suggests that focussing on single 
candidate risk gene is ineffective for evaluating mood disorder risk in the 
general population.  
2. With the emergence of large population cohorts, including UK Biobank and 
23andMe, which have information on self-reported subjective circadian 
measures, several GWAS of chronotype preference have now been 
published (Lane et al. 2016; Jones et al. 2016b; Hu et al. 2016). This 
allowed for one of the first assessments using morningness and 
eveningness PRS to study the relationship between chronotype preference 
and mood disorders at a genetic level. This analysis identified an 
association between greater eveningness PRS and BD.  
3. The underlying genetic architecture of circadian rhythmicity is complex 
and not well understood. However, as mentioned above, with the release 
of UK Biobank accelerometer data the largest GWAS of an objective 
circadian measure (RA) was undertaken. This GWAS highlighted a variant 
within the NFASC gene; as described in chapter 6, neurofascin (the 
protein product of the NFASC gene) physically interacts with ankyrin G. 
The gene which encodes this product (ANK3) is a replicated BD candidate 
risk gene (Ferreira et al. 2008; Sklar et al. 2011). The NFASC had not been 
implicated in mood disorders previously, however, this finding suggests its 
potential involvement in the pathophysiology of BD. The SLC25A17 gene 
which was also identified in the GWAS of low RA has reported to be 
associated with BD in a recent GWAS (Stahl et al. 2017). 
The associations identified in this thesis provide new knowledge of the potential 
biology underlying the pathophysiology of mood disorders and provide some 
support for a biological relationship between disrupted circadian function and 
mood disorders. 
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8.3 Implications 
As reported in Chapters 4 and 7, PRS of circadian features were associated with 
features of mood disorders including mood instability, hypomania and BD. In the 
future, using circadian PRS alongside clinical data may help to provide a better 
understanding of the specific aspects of an individual’s mood disorder and 
potentially predict their likely clinical presentations.  
If PRS can be further developed to explain a greater proportion of the variance 
seen it may be more directly clinically applicable (Dudbridge 2013). Using a 
circadian PRS could potentially indicate how patients may respond to different 
treatments or management strategies and therefore treat BD and MDD with 
greater efficiency than is seen with current treatments. For example, 
schizophrenia PRS has been shown to predict psychotic symptoms in BD 
(Hamshere et al. 2011); applying circadian PRS in this way may be able to 
predict specific features of BD or MDD. 
In the future PRS may be clinically useful; more research is required to establish 
how these PRS associate with mood traits in clinical populations. Further work is 
also required to understand the potential influence PRS could have on treatment 
response, for example because the most effective dose of pharmaceutical 
treatments could be dependent on the patient’s genotype. Genes found to 
associate with depression have shown to be potential targets for existing drugs, 
hence, genotyping could be useful to develop the most appropriate treatment 
for an individual (Howard et al. 2019).  
 Potentially developing tailored genotyping arrays to identify an 
individual’s polygenic loading for risk variants and calculating several risk scores 
for example, BD, MDD, low RA and chronotype PRS could provide clinicians with 
useful information. A larger risk score containing multiple PRS may have better 
ability to predict an individual’s risk (discussed in more detail in section 8.5.4 
below) (Krapohl et al. 2018).  
 Understanding a patient’s specific risk scores may allow for the design of 
personalised treatment plans. Using an individual’s genotype to predict risk and 
provide the appropriate treatment has been successfully included in clinical 
practice for treating cancer patients, particularly breast and ovarian cancer 
(Tung & Garber 2018).  
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There is increasing evidence of the involvement of circadian dysfunction in the 
pathophysiology of mood disorders. A composite assessment of circadian rhythm, 
including polygenic risk scores, rest-activity measures, sleep quality and 
chronotype measures may be beneficial to inform more individual-based 
treatment and management strategies which could help to maintain remission 
and reduce relapse in mood disorders (Dong et al. 2019). 
One of the main considerations in psychiatric research is how findings could 
eventually be applied to inform faster and more efficient diagnoses and provide 
information for the development of effective treatments.  
 An example is the identification of objective biomarkers which could not 
only identify individuals with psychiatric conditions but also aid in distinguishing 
disorders. These biomarkers could also be potential biological targets for 
treatments (Phillips & Kupfer 2013; Ruderfer et al. 2014). 
 The variants included in PRS which associate with mood disorders could 
highlight genes whose products could be viable targets for future treatments. A 
recent study demonstrated it may be possible to identify new treatment targets 
by investigating the genes implicated by variants associated with MDD. The study 
used findings from the latest PGC GWAS to integrate gene expression 
information and drug-target networks to indicate which genes are likely to be 
affected by a chosen treatment (Gaspar et al. 2019). Although this study 
highlighted several potentially targetable genes which were enriched in MDD the 
results require further investigation and replication. In the future this could be a 
useful method for identifying novel treatment targets from GWAS data (Gaspar 
et al. 2019). 
Integration of many different diagnostic tools which encompass lifestyle 
assessments, clinical presentation and biological measures could be a better 
representation of an individual’s specific pathophysiology (Phillips & Kupfer 
2013; Ruderfer et al. 2014); for example, accelerometer, genotype and 
chronotype data could be integrated with other clinical assessments to improve 
diagnoses and allow for more personalised treatment. 
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8.4 Limitations 
8.4.1 Limitations: polygenic scores 
A strength of this thesis is the use of novel PRS to investigate the relationship 
between circadian genetics and mood disorders. However, this is also a potential 
limitation. As this is the first use of these PRS they have not been externally 
validated (although the PRS found associations in both UK Biobank and ALSPAC).  
It is of note that the PRS used had only a small effect on the mood phenotypes 
tested. Replication of the findings of this study and a PRS which has a greater 
effect on mood phenotypes may be required before any definitive conclusions 
can be drawn.  Currently, PRS may be more useful for associations tests, as they 
have been used in this thesis, than for predicting disease (Dudbridge 2013). 
Using a less conservative PRS could improve the accuracy of predicting 
individuals at risk, however the PRS should not be so extensive as to include 
uninformative variants that are identified by GWAS at higher p-values (Stocker 
et al. 2018). For example, studies have found that including SNPs with GWAS p 
value of <0.01 in PRS demonstrated better distinction between healthy controls 
and Alzheimer patients than more conservative p value thresholds (Stocker et al. 
2018). Current GWAS do not have large enough case sample sizes to identify 
more risk variants, therefore PRS could also be further expanded by undertaking 
GWAS using increased case sample sizes (Dudbridge 2013). With replication, 
further findings of GWAS and less conservative p value thresholds PRS could be 
expanded to increase predictive accuracy and clinical utility (Stocker et al. 
2018; Dudbridge 2013). 
As detailed in Chapters 4-7, there are limitations to both the subjective and 
objective circadian measures used in the chronotype and low RA PRS analyses, 
and the GWAS of low RA. The derived RA measure – although exposed to various 
QC measures – was not adjusted for some potentially confounding variables 
(described in Chapter 6). However, it should also be noted that over-adjusting 
for confounding factors could result in false negatives and variants influencing 
RA may have been missed (Aschard et al. 2015). 
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8.4.2 Limitations: cohorts used 
The mood phenotypes investigated in ALSPAC and UK Biobank are based on self-
report or structured interviews which could be sensitive to responder bias and 
are a limitation to this study as the outcomes could be under- or over-
representative of the true incidences of mood disorders (Ganna & Ingelsson 
2015). Being able to make use of formal diagnoses of BD and MDD to investigate 
the relationships between the PRS and mood disorder would have been 
desirable.  
 In the case of ALSPAC, primary and secondary care data has been 
collected on a subset of participants; however these data are still being 
processed by ALSPAC and were not available for use by researchers during the 
course of this study (http://www.bristol.ac.uk/alspac/researchers/our-
data/linkage/).  
 There is currently no primary care data in UK Biobank available to 
researchers, however, standardised primary care data with information on 
participants diagnoses, treatments etc. should be available in the near future 
(https://www.ukbiobank.ac.uk/wp-content/uploads/2018/12/Primary-Care-
Data.pdf). Unfortunately, this standardised primary health care data was not 
available during the time frame of this thesis.  
With the available data it is not possible to reliably separate individuals in UK 
Biobank with different clinical subtypes of BD. Even though there are potential 
biases and limitations for clinically-defined subtypes of BD (as described in 
Chapter 1), discrepancies in clinical presentations may indicate differences in 
the biological underpinnings between the subtypes. There is evidence to support 
genetic differences between BDI and BDII, BDI has a relatively strong genetic 
correlation with schizophrenia, whereas BDII is more strongly correlated with 
MDD (Stahl et al. 2017). The BD outcomes used for the analyses in this thesis 
could not be separated into different BD classifications. It is possible more 
subtle associations between PRS and specific BD subtypes could be lost. 
As the mental health data in both ALSPAC and UK Biobank are cross-sectional, 
there are limitations to the conclusions that can be drawn. Cross-sectional data 
is taken from certain time points and so does not account for possible changes 
over time: the data may not be representative of the true incidences of the 
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phenotypes-of-interest. Cross-sectional data also make causal inferences 
difficult (Bowen & Wiersema 1999). The cohorts represent samples of two 
different age groups (adolescent/young adult and older adult/elderly) and the 
results obtained in this thesis have sometimes been in opposing directions when 
comparing ALSPAC and UK Biobank. It is possible there are some differential 
effects of the PRS at different developmental stages. However, as there was 
little longitudinal data it is difficult to investigate how the influence of PRS may 
change over an individual’s life course. 
UK Biobank is not representative of the general UK population. Of the 
approximate 9.2 million UK residents invited to join the cohort there was only a 
5.5% response rate; those who volunteered to join were more likely to be 
female, older, better educated, living in less socio-economically deprived areas 
and with fewer health conditions compared to the general population (Fry et al. 
2017).  
 Also, as the ALSPAC cohort participants were recruited from a relatively 
small area of the UK it may not be representative of the wider population. 
Therefore, the findings from UK Biobank and ALSPAC may not be generalisable. 
8.5 Possible future work 
8.5.1 Replication of findings 
The GWAS of RA and low RA detailed in Chapter 6 were the first large-scale 
investigations of the genetics of rest-activity rhythmicity. These results 
therefore must be considered preliminary and require replication. As there was 
an uneven proportion of cases compared to controls in the low RA GWAS, a 
replication GWAS could be undertaken in UK Biobank if more participants could 
be recruited for accelerometer data collection in the future. If a better balance 
of cases and controls could be obtained, a less conservative GWAS method could 
be used (such as BOLT-LMM which was used for the GWAS of RA); also, a greater 
number of cases would increase power to detect variants of low effect. 
 A replication GWAS of low RA able to identify a greater number of 
associated variants would also allow for an investigation of the potential causal 
relationship (and the direction of the causality) between low RA and mood 
disorders. This could serve as a preliminary study into the causal relationship 
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between circadian disruption and mood disorders. 
 Also, with the release of more up-to-date GWAS of BD and other mood 
disorders this causal relationship could be investigated in more disorders; 
depression was used to investigate causal relationships as it has relatively 
current GWAS findings compared to BD. 
 As mentioned above, there is currently no primary care data available in 
ALSPAC or UK Biobank, however these data are reportedly available for use soon. 
It would be of interest to test the associations between the PRS used in the 
previous chapters and primary-care diagnosed cases of BD and MDD in these 
cohorts. 
There are several cohorts that contain both genetic data and a variety of 
phenotypic information, including self-report and clinical psychiatric measures, 
for example 23andMe and Generation Scotland (Eriksson et al. 2010; Smith et al. 
2013b). A replication study could be undertaken to investigate the association 
between the risk scores generated in this thesis and the self-reported mood 
phenotypes available in these cohorts. 
 Some population cohorts, such as deCODE (Balkau 2000), also contain both 
genetic data and phenotypic information obtained from electronic health 
records. The benefit of these cohorts is the linked data and variety of 
phenotypic information available which could provide replication cohorts for 
testing the PRS used in this thesis. 
 In order to investigate how the PRS may influence the development of 
mood disorders, consistent mental health data collected at different stages of 
life is required. An example of a longitudinal cohort with both mental health and 
genotype data is Add Health (National Longitudinal Study of Adolescent to Adult 
Health); PRS could be tested for their associations to self-report mood outcomes 
at various ages to investigate the potential developmental influences of PRS 
(Evans & Erickson 2019). 
 However, these cohorts do not include the extensive phenotyping of 
objective circadian measures required to replicate the analyses detailed in 
Chapters 6 and 7. 
Also, with the use of growing emergence of “mobile health data”, there is 
potential to apply information on both the subjective and objective measures 
generated by these accessible technologies and software to large cohorts to 
Chapter 8  162 
further explore the relationship between circadian function and mood disorders 
(Merikangas et al. 2019). Developing cohorts, for example All of Us 
(https://allofus.nih.gov/), advertise a wide variety of data which links basic 
lifestyle/demographics, genotype data, self-reported health, electronic health 
records and mobile health data. It would be of interest to investigate circadian 
measures derived from this mobile health data in the context of psychiatric and 
mood disorders. 
8.5.2 Investigating within clinical samples 
The analyses undertaken in this thesis focussed on birth and population cohorts 
which could be under-representative of individuals with psychiatric conditions. 
Future analyses could be applied to clinical populations to investigate the 
applicability of circadian PRS for predicting mood disorder risk. Hypothetically, 
applying the chronotype or circadian PRS to clinical subsets may be useful for 
investigating treatment responses. There is recent evidence of chronotype 
preference and circadian preference associating with lithium response in BD 
patients on lithium monotherapy (N=193) (McCarthy et al. 2018b). Non-
responding patients were more likely to report an evening chronotype compared 
to patients responding to lithium. A subset of patients included in this study 
donated fibroblasts which allowed for the investigation internal circadian rhythm 
measures. Lithium non-responders also displayed greater circadian 
dysregulation, such as longer circadian period, than lithium responders 
(McCarthy et al. 2018b). There is potential that using circadian PRS may predict 
patient response to lithium before subjecting patients to the treatment. 
Providing appropriate treatment to patients could improve patient QOL and 
reduce morbidity (Phillips & Kupfer 2013; Bauer et al. 2018). 
PRS may also be useful in determining which patients may benefit most from 
psychosocial or lifestyle interventions. Individuals with high polygenic loading for 
circadian dysfunction could potentially benefit from treatment interventions 
focussed on establishing better circadian rhythmicity. Interpersonal and social 
rhythm therapy (IPSRT) was designed specifically for BD patients based on the 
hypothesis of circadian disruption and abnormal sleep-wake cycles are involved 
in the symptomology of BD (Frank et al. 2000). IPSRT is a psychotherapy, to be 
implemented in conjunction with medication, using various behavioural 
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techniques to aid patients in dealing with interpersonal changes and regiment 
their daily routines. There is some epidemiological evidence that mood disorder 
patients benefit from strict, rhythmic schedules; however, it is worth noting that 
this evidence is based on relatively small-scale studies (Frank et al. 2000). 
By investigating circadian PRS within a clinical population it may also be possible 
to focus on specific characteristics of mood disorders to establish whether the 
PRS would be useful in predicting a patient’s clinical presentation. For example, 
does greater polygenic loading for circadian disruption associate with greater 
risk of patient relapse or poorer prognosis? 
8.5.3 Gene-environment interactions 
Mood disorders are known to have both genetic and environmental inputs 
(Yoshimizu et al. 2015; Wray et al. 2018), however, the relationships between 
these risk factors are currently unclear. As this thesis describes one of the few 
incidences of using circadian measure PRS it is also unknown at present how the 
potential interactions between these risk scores and environmental risk factors 
influence the risk of mood disorders. Some environmental exposures may be 
more detrimental to patients with greater polygenic loading for circadian 
dysfunction. Therefore, patients with both high risk scores and exposure to 
specific environments or life events could have more severe presentations than 
patients with high risk scores but no exposure to the environmental risks. 
8.5.4 Combining PRS 
The associations identified between the PRS and mood phenotypes have 
relatively small effects on the phenotypes and more work is needed to further 
develop the PRS in order to explain a greater proportion of the trait variance. 
With development the PRS could have a more effective clinical application than 
as they stand currently (Dudbridge 2013). It would be of interest to generate a 
combined risk score which contains both variants associated with BD or MDD and 
variants associated with circadian disruptions.  
 A recent study has demonstrated that using a risk score composed of 
multiple PRS is able to give better prediction of phenotypic variation compared 
to a single PRS. A multiple PRS approach could be useful in providing individual-
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specific estimates of risk (Krapohl et al. 2018). This method suggests that even 
risk scores of traits which are only slightly genetically related could be combined 
to increase predictive power. The combined power of multiple PRS obtained 
from many discovery GWAS could explain a greater proportion of trait variance 
(Krapohl et al. 2018). An expanded risk score may explain more of the 
phenotypic variance seen in complex disorders and could be more efficient at 
predicting individuals at risk of developing mood disorders. 
It is theoretically possible that using several risk scores (i.e. using RA, 
chronotype, BD and MDD PRS in conjunction) to determine an individual’s 
susceptibility to mood disorders, potential disease prognosis or treatment 
response could improve patient outcomes (Hamshere et al. 2011).  
8.6 Conclusions 
The literature on mood disorder genetics has historically suffered from low 
quality, small sample size data. This thesis made use of relatively large high-
quality datasets and identified several associations which strengthen the theory 
of a relationship between circadian function and the risk of mood disorders. This 
study was able to use new PRS to identify links between both subjective and 
objective circadian measures, and mood disorder-related phenotypes, and also 
identified genetic variation associated with disrupted rest-activity cycles in the 
first large-scale GWAS of an objective circadian measure. However, these 
findings require replication.  
In conclusion, this thesis has provided new and supporting evidence of the 
genetic relationship between circadian function and mood disorders and argues 
for further research to develop a greater understanding of how these 
relationships influence the development of mood disorders and how they may 
inform the development of novel treatment targets. 
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During the course of this PhD thesis I was also involved in producing the 
following publications, each of these publications was important for the progress 
of this thesis: 
• Strawbridge. R.J. et al. 2019. Identification of novel genome-wide 
associations for suicidality in UK Biobank, genetic correlation with 
psychiatric disorders and polygenic association with completed suicide. 
EBioMedicine, 41, pp.517-525. 
• Ward. J. et al. 2018. Polygenic risk scores for major depressive disorder 
and neuroticism as predictors of antidepressant response: Meta-analysis of 
three treatment cohorts. PLoS One, 13(9). 
• Strawbridge. R.J. et al. 2018. Genetics of self-reported risk-taking 
behaviour, trans-ethnic consistency and relevance to brain gene 
expression. Translational Psychiatry, 8(1), pp.178. 
• Ferguson. A. et al. 2018. Genome-wide association study of circadian 
rhythmicity in 71,500 UK Biobank participants and polygenic association 
with mood instability. EBioMedicine, 35, pp.279-287 
• Lyall. L.M. et al. 2018, Association of disrupted circadian rhythmicity with 
mood disorders, subjective wellbeing, and cognitive function: a cross-
sectional study of 91,105 participants from the UK Biobank. Lancet 
Psychiatry, 5(6), pp.507-514. 
• Strawbridge. R.J. et al. 2018. Genome-wide analysis of self-reported risk-
taking behaviour and cross-disorder genetic correlations in the UK Biobank 
cohort. Translational Psychiatry, 8(1), pp.39. 
• Lyall. L.M. et al. 2018. Seasonality of depressive symptoms in women but 
not men: A cross-sectional study in the UK Biobank cohort. Journal of 
Affective Disorders, 229, pp.296-305. 
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• Ward. J. et al. 2017, Genome-wide analysis in UK Biobank identifies four 
loci associated with mood instability and genetic correlation with major 
depressive disorder, anxiety disorder and schizophrenia. Translational 
Psychiatry, 7(11), pp.1264. 
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